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Abstract
Treatment decision-making in head and neck oncology is gaining complexity by the in-
creasing evidence pointing towards more individualized and selective treatment options.
Therefore, decision making in multidisciplinary teams is becoming the key point in the clin-
ical pathways. Clinical decision-support systems based on Bayesian networks can support
complex decision-making processes by providing mathematically correct and transparent
advises.
In the last three decades, different clinical applications of Bayesian networks have been
proposed. Because appropriate data for model learning and testing is often unobtainable,
expert modeling is required. To decrease the modeling and validation effort, networks usu-
ally represent small or highly simplified decision structures. However, especially systems
for supporting multidisciplinary treatment decisions may only gain a user’s confidence if
the systems’ results are comprehensive and comprehensible. Challenges in developing such
systems relate to knowledge engineering, model validation, system interaction, clinical im-
plementation and standardization. These challenges are well-known, however, they are not
or only partially addressed by the developers.
The aim of this thesis is to contribute to the development of and interaction with Bayesian
network-based clinical decision support system, specifically for multidisciplinary treatment
decisions. The challenges were encountered and addressed in close collaboration with the
University Hospital Leipzig. An exemplary disease of laryngeal cancer was selected to
develop concepts, methods and tools with and for clinicians.
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Since the report To Err is Human of the Institute of Medicine in 2000 [88], computer-aided
clinical decisions are considered to be essential for a significant improvement of patient
safety. First diagnostic clinical decision support system (CDSS) were developed in the
1970’ with The Internist and MYCIN, and became more popular, widely accepted, and,
today, clinically desired since computers are faster, user interfaces are more intuitive and
systems provide high quality suggestions. When CDSSs support clinicians with the right
information at the right time they have the potential to ”[...] change the way medicine has
been taught and practiced” (Berner, 2009).
However, most CDSS projects fail to become clinically integrated because of an initially
insufficient strategy regarding their development, clinical adoption and maintenance as well
as disregarded user requirements. Especially for complex treatment decisions, a CDSS de-
velopment and acceptance may be hampered due to the less verifiable nature of decisions.
1.1 Motivation
This work is motivated and supported by the Digital Patient and Process Model (DP2M)
Project at the Innovation Center Computer Assisted Surgery (ICCAS) in Leipzig, Germany.
DP2M aims to develop a computer system that supports clinicians in finding the best ther-
apy decisions for patients with complex diseases. In case of complex diseases, patients
require individually tailored treatment decisions in order to reach the qualitatively best
possible outcomes or simply to survive. Therefore, multidisciplinary teams of clinicians
are required to collect, study and discuss extensive sets of patient data in order to find the
best treatment options by mutual consent. CDSSs have the potential to support difficult
decision-making tasks. For the basis of a CDSS, the Bayesian networks selected by DP2M
provide a transparent, human-understandable and customizable knowledge representation
and decision reasoning. Laryngeal cancer has been selected as the first exemplary disease,
and meetings of multidisciplinary expert teams as the starting therapy decision support en-
vironment. This project collaborates closely with the Head and Neck Department at the
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University Hospital in Leipzig, Germany.
First clinical decision support systems, by means of diagnostic or treatment decision sup-
port, were developed more than 40 years ago. Various support systems were developed
but never reached a clinical integration. Single clinically integrated systems of pioneering
institutions exist, but they are still neither established nor widespread. Major issues for
failing systems are 1) developments without clinical involvement, 2) a lack of their adop-
tion to technical and personnel environments in hospitals, and 3) missing development and
integration strategies beforehand. The technological evolution of decision support systems
occurs slowly, because 4) researchers usually focus on machine learning systems but the
required data is often rare or unobtainable, and 5) the development of the machine intel-
ligence of systems is rarely described in the literature; specifically, they lack of regulated
procedures for modeling, validation and maintenance.
My work focuses on development and integration strategies for therapy decision support
systems using Bayesian networks. Specifically for the use of Bayesian networks in the
clinical domain, I focus on methods for expert modeling. Parts of the presented strategies
were realized prototypically and evaluated. The clinical part of this work was realized in
cooperation with the clinician Dr. Matthaeus Stoehr.
1.2 Objective
The main objective of this dissertation is to contribute to the methodology of Clinical De-
cision Support System development. Specifically, I focus on building a Therapy Decision
Support System that is based on Bayesian networks. Contributions are mainly presented
in context of the support of multidisciplinary therapy decisions for patients with laryngeal
cancer.
A further aim of this thesis is to define a strategy that includes methods, systems and tools
as well as users involved in developing, validating, maintaining and interacting with ther-
apy decision models that are based on Bayesian networks. From this strategy, the focus
lies mainly in 1) the knowledge representation of complex multidisciplinary treatment de-
cisions, 2) the knowledge engineering for building these complex Bayesian networks when
adequate data is unavailable, and partially on 3) the visualization for user-model interac-
tion. The knowledge engineering of Bayesian networks includes graphical and probabilis-
tic modeling as well as model validation. A visualization is presented in context of an
expert-based treatment analysis.
1.3 Method
A Therapy Decision Support System based on Bayesian networks is the given primary
objective. First, an analysis of the clinical workflows was conducted to identify situations
of decision-making, the participants and their environments.
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A concept for a Therapy Decision Support System that is based on Bayesian networks
was defined. Further conceptions extended the existing Bayesian network methodologies
of building complex models, knowledge engineering, and graphical user interfaces. A
conceptualized model structure enables modeling multidisciplinary therapy decisions and
was applied to laryngeal cancer. A concept for knowledge engineering reduces the role of
knowledge engineers (usually computer scientists) by a clinically adopted modeling sys-
tem, which enables domain experts in autonomous modeling and validation. A visualiza-
tion concept focuses on the requirements in context of the users and environments.
Concepts were exemplary implemented and validated or evaluated. The model of laryn-
geal cancer was validated in teamwork between a knowledge engineer and a domain expert,
and using a dataset that is relatively small compared to the model size. From the knowledge
engineering concept, two tools for autonomous and collaborative modeling were imple-
mented and validated by clinicians; one for graph- and the second for probabilistic mod-
eling. Additionally, a usability study was conducted for the probabilistic modeling tool.
From the visualization concept, a visualization tool was developed to support analyses of
complex patient-specific models, and finally evaluated by a group of clinicians.
1.4 Thesis Outline
This thesis is separated into three parts, firstly, presenting a basic consideration, secondly,
the development of a therapy decision support system using Bayesian networks, and finally,
an overall conclusion.
Developing a therapy decision support system using Bayesian networks requires a basic
consideration over various clinical and technical disciplines. Therefore, Part I introduces
the exemplary disease of laryngeal cancer, the clinical process of making treatment deci-
sions, best practice in developing clinical decision support systems, and the methodologies
of and tools for Bayesian networks.
Part II presents concepts, extended methodologies and new tools for the development
and interaction with therapy decision support systems. The presented work has mainly been
published in different proceedings and journals, and will be cited in the specific chapters.
The last part of thesis, Part III appraises the presented work by its applicability and
impact, and discusses future work intentions.

Chapter 2
Tumor Board Decision for Larynx
Cancer Patients
2.1 Laryngeal Cancer
This section introduces the epidemiology, anatomy, pathology, and basic therapy forms
regarding laryngeal cancer as a primary tumor.
2.1.1 Epidemiology
Laryngeal cancer has a worldwide annual incidence of approximately 157,000 cases [56].
In Germany, the annual incidence reaches approximately 3,600 cases, which amounts to
25%-30% of all head and neck cancer cases [78, 136]. The five-year survival rate is about
47%. Over the last years, a slight increase of survival is observed through earlier diag-
noses and optimized integrated treatment approaches [22]. Since survival increases, more
attention is paid to patients’ quality of life and enhancement of functional outcomes [57].
Based on an in-house study from 2012 to 2015, the University Hospital Leipzig has
an annual incidence of approximately 60 new laryngeal cancer cases and nearly 20 recur-
rences.
2.1.2 Anatomy and Physiology
The larynx is an organ in the neck area of the body. It describes the closure mechanism
between the trachea and the esophagus and enables the separation between airway and
digestive tract [156]. It is involved in breathing, swallowing and sound production.
In detail, the larynx area is subdivided into five anatomic areas, see Figure 2.1: the glot-
tis, supraglottis (area above the glottis), and subglottis (area under the glottis), paraglottic
space, and pre-epiglottic space. The larynx consists of nine cartilages and 17 muscles. The
main component of the mechanism is the glottis, which includes the vocal folds with a pair
of arytenoid cartilages, and the respiratory and phonatory muscles enabling the swallowing
7
8 Chapter 2. Tumor Board Decision for Larynx Cancer Patients
Figure 2.1: Gray’s [65] sketches of the laryngeal area representing a) a larynx surface, b)
a coronal section of the larynx, and c) lymph nodes surrounding the larynx (highlighted by
blue color).
and phonation (for pitch and volume). The most important role for survival is to protect the
lungs from foreign objects by coughing and other reflexive actions.
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2.1.3 Cancer and Diagnostic
In general, cancer describes an abnormal cell growth, which transforms local organ struc-
tures and impairs the organ’s functions [6]. With its growing, cancer cells spread to the
lymph nodes surrounding the larynx, and through the lymph channels or the bloodstream
to potentially all other organs. The original cancer is called primary tumor, while cancer
cells that migrated to other tissues and formed descendeant tumors are called metastases.
A primary tumor of laryngeal cancer can be located in all five laryngeal areas. First
metastases usually appear in locoregional lymph nodes. Distant metastases mainly oc-
cur in the lung, liver and bone through the bloodstream. Symptoms come from laryngeal
dysfunctions: problems with swallowing or change of the phonation as well as swollen
lymph nodes. For a patient, to provide accurate diagnostics, usually, a number of diagnos-
tic methods are evaluated, each with advantages and disadvantages. Diagnostic standard
examinations of the larynx area are performed by clinical examination, endoscopy, palpi-
tation, pan-endoscopy, ultrasound, medical imaging techniques (e.g., computer tomogra-
phy, magnetic resonance imaging and positron emission tomography) or histopathology.
Stroboscopy gives information about the vocal folds’ functionalities. Panendoscopy un-
der general anesthesia allows a direct view on the cancer surface, and is usually combined
with a biopsy (tissue removal). Medical imaging techniques give an insight about the or-
gan structures and metabolic processes, but findings may be difficult to differentiate from
other anomalies. Histopathology is mandatory for verification of the diagnosis from a tis-
sue biopsy, however, correct histological assessment depends on the available biopsy, that
is analyzed by the pathologist.
2.1.4 Therapy Decision of Laryngeal Cancer
Clinical treatment guidelines for oncology, such as from the National Comprehensive Can-
cer Network (NCCN) on head and neck cancers [116] recommend the treatment of laryn-
geal cancer based on the TNM staging system [17]. The TNM staging system provides
an objective method for evaluating the patient’s disease status and for correlating with the
prognosis. TNM staging determines the cancer stage for the primary tumor (T-state), the
surrounding lymph nodes (N-state) and metastases (M-State). Each of the three parameters
is assigned a range of possible values:
• T ∈ {Tx, T0, T is, T1, T2, T3, T4},
• N ∈ {Nx,N0, N1, N2, N3}, and
• M ∈ {M0,M1}.
In general, the T-state relates to the number and type of infiltrated tissue, and vocal fold
functionality; the N-state relates to the number and localization of infiltrated nodes; and
the M-state with its two states describes the existence of metastases. In Appendix A, these
values are presented in more details.
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The diagnostic evaluation and staging prior to treatment typically merges into a clinical
TNM staging (cTNM) and a (histo)pathological TNM staging (pTNM). A cTNM com-
bines data from physical examination, endoscopy and diagnostic imaging. A pTNM is
stated from (histo)pathological examination. In direct comparison between the cTNM and
pTNM, the pTNM is considered to be more reliable. However, the correct diagnosis relies
on the histopathological report and consequently depends on the quality of the specimen.
Therefore, a correct TNM staging depends on the availability and correctness of the exam-
ination results and their individual quality.
Finally, for laryngeal cancer there exist three basic treatment options: surgery, radia-
tion therapy and chemo therapy. However, each treatment can be combined with the other
in various orders. The best combination of treatments depends on the individual patient
characteristics including the TNM staging, tumor resectability, comorbidities, general con-
dition, potential risk factors and quality of life, and in the near future also genetic factors.
2.2 Best Practice of Clinical Judgment
The best practice in clinical decision-making is known as evidence-based medicine (EBM)
[67], which combines 1) the best available external clinical evidences from systematic re-
search, 2) individual clinical expertise, and 3) patient values and preferences [140, 112], see
Figure 2.2. EBM aims to adjust a population-based ”average” patient from external random
clinical trails to a specific patient case [55, 140, 149]. However, EBM becomes difficult
for complex patient cases, particularly when finding best decisions depends on mentally
processing large amounts of information by a multidisciplinary team. Experts may under-
estimate or miss certain information, which potentially leads to suboptimal decisions.
Figure 2.2: A representation of EBM, which is based on three factors: 1) randomized
controlled trials, 2) clinical experiences, and 3) patient values and preferences.
In general, external clinical evidences are usually based on randomized controlled tri-
als from basic medical research. Researchers aim for identifying therapies that increase
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the patient survival and quality of life, and decrease unnecessary procedures and costs
[86, 140]. Best evidences are collected in clinical protocols, called guidelines. Clinicians
are advised to follow regularly updated guidelines to provide the best available patient
care [165]. However, even excellent evidences are limited to 1) populations, 2) predefined
sets of parameters, and 3) the number of studied patient characteristics [48]. Furthermore,
patient-specific values or preferences may disagree with guideline recommendations, but
they are crucial for any clinical decision [140]. Therefore, clinical knowledge and experi-
ence is essential to tailor guideline recommendations and preferences to a specific patient
case, also known as clinical judgment [140, 149].
Specifically to find the best treatment options for complex patient cases (e.g., with rare
or multiple diseases, or unusual health conditions), clinical judgment requires the exper-
tise of a multidisciplinary team. The increasing number of available examination methods
(e.g., physical examinations, imaging, and histology) and treatment options (e.g., surgeon,
radiation therapist and system therapist) theoretically allows for a patient-specific diagnosis
and an individually tailored treatment. However, an optimal EBM by a multidisciplinary
expert team may become impossible due to 1) the large amount of information with 2) a
less verifiable nature that is 3) mentally processed and, therefore, difficult to 4) communi-
cate, 5) understand, and 6) reproduce [55, 84]. In detail, complex patient cases may require
treatment combinations that are neither covered by guidelines nor well experienced by
clinicians. Clinical decisions (including deviations) are partially subjective and, therefore,
may be difficult for others to understand and reproduce [84]. For instance, a clear under-
standing of complex thought processes is necessary to be reproducible as regards insurance
providers’ management of costs and treatment errors. Furthermore, wrong decisions are
also costly by means of losing both the patients’ trust in health care systems as well as the
satisfaction of patients and clinicians [88]. Finally, it seems to be a paradox that clinicians
are advised to follow guidelines being responsible for any deviation, but complex patient
cases require deviations [55].
2.3 Head and Neck Tumor Board
For complex diseases, such as laryngeal cancer, clinical judgment based on EBM is per-
formed by experts at a multidisciplinary cancer conference meeting, also known as multi-
disciplinary cancer meeting or tumor board [131]. A tumor board is a regular meeting for
prospectively reviewing and discussing patients’ diagnostic aspects and treatment options.
Tumor board decisions require a collaborative decision-making and treatment planning,
where the core team members share their knowledge and make collective recommenda-
tions for patient management.
In detail, an expert team studies, discusses and intuitively selects relevant examination
results to build a mental model of a patient’s situation, and finally, to agree in principle
in an unanimous consensus on a single or a combination of treatment options. Figure
2.3 presents a head and neck tumor board at Leipzig University Hospital. In this figure,
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individual mental models are exemplary visualized above the clinicians’ heads. Clinical
examination methods are more or less error-prone for various reasons, e.g., because of
technical inaccuracy or difficult examination conditions. Therefore, usually more than one
examination method is conducted to substantiate or exclude a specific pathology. Attending
experts are from various domains, specialized in a subset of examination methods and
therapy procedures of usually one body area. Each method and procedure brings its own
complexity. A specialization in combination with an expert’s background knowledge and
experiences can be described as the expert’s viewpoint. Finally, the scope of a mental
patient model and, therefore, the quality of decisions depends on the clinicians’ ability to
gain and combine the other viewpoints.
Figure 2.3: A head and neck tumor board at University Hospital Leipzig with experts from
multiple disciplines. The complexity of decision-making is exemplary represented by a
visualization of decision models above the experts’ heads. Models vary depending on an
expert’s viewpoint, all representing the same patient.
2.3.1 Aims of a Tumor Board
Patkar et al. [131] review studies of tumor boards from 1975 to 2010. First tumor boards
started in the 1960s, but since the 1980s in the United States the goal of tumor boards
shifted from previously pure education to an improving patient care. Many European coun-
tries and Australia followed this trend in the late 1990s. Summarized, the major aims are:
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2.3-A1 to share information among participating physicians to increase the quality of
care for patients,
2.3-A2 that patient management is evidence-based,
2.3-A3 that all patients receive timely diagnosis, and
2.3-A4 that there is a continuity of patient care.
Furthermore, a tumor board is an opportunity for:
2.3-A5 education and learning for its members and trainee doctors, and
2.3-A6 for identifying patients for research trails.
Most of the presented studies from the last decades show that tumor boards can increase
the quality of a patient outcome significantly. In that regard, Abraham et al. [1] emphasize
an increase of a guideline-recommended care.
On the other hand, a beneficial patient care strongly depends on the quality of a tumor
board [18, 85, 13, 95]. This quality can be defined by two components:
2.3-C1 the structural and functional components of a tumor board, and
2.3-C2 the participants’ experiences, level of competence, and discussion culture.
Finally, the authors agree that CDSS could support the decision-making process and
should provide a total transparency (who has decided what and when). Furthermore, Patkar
et al. and Blayney recommend research in the field of CDSS with focus on:
2.3-S1 electronic patient records (EPRs) to assist in structural and administrative as-
pects of the tumor board, such as data collection, preparation, presentation,
consistent documentation,
2.3-S2 the exploration of a “virtual” or telemedicine tumor board, and
2.3-S3 CDSS supporting patient-centered, evidence-based decision-making.
To meet the demands of the list items 2.3-A1 to 2.3-A6 and to provide high quality tu-
mor boards, the German Cancer Society (DKG) determines requirements for cancer center
certifications. Requirements for tumor boards are:
2.3-R1 presentation of 95% of all primary patients,
2.3-R2 attendance of a multidisciplinary team (required are specialists for diagnosis,
surgery, radio oncology, oncology, radiology and pathology),
2.3-R3 gathering and handing all patient-related information to participants before
the board,
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2.3-R4 providing patient-specific medical images (pathology and radiology),
2.3-R5 obligatory decision of the tumor board, and
2.3-R6 tumor board documentation, including therapy deviations and therapy changes
at the will of the patient.
2.3.2 Head and Neck TPU at Leipzig University Hospital
The University Hospital Leipzig is a registered oncological center for head and neck tu-
mors. In a close cooperation with the ENT Department of the University Hospital Leipzig,
the ICCAS focuses on support systems for cancer treatment decisions. To increase the tu-
mor board quality and the clinical workflow, a therapy planning unit (TPU) was developed
and integrated into the head and neck tumor board at Leipzig University Hospital. The
TPU consists of a meeting room concept with an IT infrastructure and a clinical informa-
tion system named oncoflow [15, 107].
In more detail, Meier’s oncoflow [107] is a centralized and structured information
source during an entire oncological head and neck treatment workflow. A workflow is sepa-
rated into six steps: (1) patient consulting, (2) examinations (e.g., panendoscopy), (3) tumor
board to determine a therapy option, (4) treatment procedure, (5) tumor board debriefing,
and (6) a five-year follow-up. In each of these steps, patient-specific information develop
or change. Oncoflow gathers these patient-specific information automatically from various
clinical systems. Furthermore, oncoflow provides assistant functionalities and web-based
graphical user interfaces (GUIs) supporting physicians and surgeons in their daily work.
Functionalities include documentation of first consultation results, panendoscopy reports,
the creation of tumor board invitations with patient cases, and tumor board protocols. GUIs
are developed specifically for tablets, physician workplaces, and tumor board monitors.
Altogether, oncoflow builds a basis for the clinical integration of CDSSs (list item 2.3-
S3). In this context, an exemplary information exchange between oncoflow and a separate
radiation therapy decision support system (TDSS) is described. The communication from
oncoflow to the radiation TDSS is intended after workflow activity step for (4) the initial
therapy, and back from the CDSS to oncoflow for (5) the following tumor board. The steps
of (4) and (5) can repeat depending on the therapy success. Meier states the possibility
of integrating a TDSS into oncoflow following an appropriate IT architecture (see Section
3.4).
A good patient care needs a high-quality tumor board. The referenced authors recom-
mend the research in the fields EPR, virtual tumor board, and CDSS presented by the list
items 2.3-S1 to 2.3-S2. EPRs (2.3-S1) are already well explored, integrated in the daily
clinical workflow, and in Germany required by the DKG (in particular, list items 2.3-R3 to
2.3-R6). The positive development of EPRs is substantial for the development of CDSSs to
support evidence-based decision-making (2.3-S3). CDSSs are only developed at the level
of research work and are usually used by hospitals involved in the research (see Chapter 3:
Development of a Clinical Decision Support System).
Chapter 3
Development of a Clinical Decision
Support System
Introduction
CDSSs aim for improving clinical decision-making and patient safety [88]. They can im-
prove patient care by ”providing the right information to the right person at the right point
in workflow in the right intervention format through the right channel” [126].
CDSSs may support decisions passively, e.g., by error recognitions using computer-
ized physician order entry (CPOE) and monitoring a patient situation, or actively, e.g., by
providing alerts in unusual or dangerous situations, recommending medications, and sup-
porting physicians to find optimal decisions. Active decision support systems that require
a rethinking and reorganizing of decisions and health care plans from clinicians (e.g., sup-
port for diagnostic and treatment decisions) are more likely to fail their acceptance [154].
In such cases, clinicians ignore or overwrite the decisions of a system and, finally, stop
using it.
Once a CDSS is built, its clinical acceptance depends on an appropriate integration, by
means of both its technical adaption to existing clinical systems, specifically to the local
electronic health record (EHR), as well as user-friendly interfaces. Well developed and
clinically integrated, CDSSs can minimize errors, promote patient safety, save time and,
finally, decrease the costs of care [88]. A successful CDSS development and clinical inte-
gration requires to reach one of these expected benefits without impairing the remaining,
or at least to increase the cost-benefit ratio [88]
The work of Berner et al. [12] reviews CDSSs to investigate their impact and effective-
ness on clinical decision-making and points out various challenges. Challenges concern
technical issues, such as data integration, system development, issues around the vocabu-
lary, system output and maintenance, as well as organizational and personal issues, such
as vendors, developers and users, and, finally, legal and ethical issues. To address all these
topics in advance is considered to be highly relevant for a successful CDSS development
and its clinical implementation.
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First, the following section presents a basic introduction to the most common machine
intelligence methods that can build the provide of a CDSS, secondly, related work focusing
on Bayesian network (BN)-based CDSS, thirdly, best practice techniques and experiences
of CDSSs developments, and, finally, a conceptual information and communication tech-
nology (ICT) architecture for the clinical integration of a CDSS.
3.1 Machine Intelligence in CDSSs
CDSSs are capable to support clinicians in making complex decisions by reasoning over a
large set of information entities and present their results in a human-understandable way.
A CDSS’s reasoning requires one or more machine-intelligent methods. Machine intel-
ligence (or artificial intelligence) describes the methodology of using computer programs
to simulate human decision-making [145, 110]. Each method has competitive advantages
with respect to the others being suitable for a subset of applications. Their development
is usually costly in time and resources and, therefore, their requirements should be re-
gressively specified beforehand [12]. Two types of machine-intelligent systems have to be
distinguished: non-knowledge-based systems and knowledge-based systems.
3.1.1 Non-knowledge-based System
Non-knowledge-based systems use machine learning methods to learn and reason highly
complex decisions directly and quickly from datasets [152]. The methods learn unsuper-
vised or supervised.
In unsupervised learning, the dataset consists of information without specific knowl-
edge about their relations. The learning aims to detect similarities in the data and build
patterns or clusters. Therefore, this kind of learning is applied for knowledge discovery,
such as clustering, statistical distributions, and filtering.
In supervised learning, the dataset requires samples consisting of input information and
desired output. A system learns sample after sample by 1) creating a network between the
input and output variables (the ”black box”), 2) computing an output based on the sample’s
input information, 3) comparing its output results to the desired output, and 4) only in case
of mismatches between the outputs the system autonomously adjusts the structure to receive
an output with the least discrepancies. Typically, applications for this type of learning are
classification and regression analysis.
Either way of learning, non-knowledge-based systems have two disadvantages regard-
ing a required dataset and a hidden network structure. First, their training dataset needs
to be significantly large compared to the number of its variables, and in a high quality
[89, 141]. Second, only the input (e.g., the patient data) and the output (the decisions)
are human-understandable. The system’s reasoning in between the input and output is not
human-understandable and, therefore, called a ”black box”. In other words, one may gain
the main decision factors of a non-knowledge-based system, but must trust in its correct
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data interpretation and reasoning [75].
However, non-knowledge-based methods will become even more valuable for CDSS
with the fast growing trend of life tracking to analyze the so-called ”big data” [129]. For
this purpose, promising methods are artificial neural networks (ANNs) [45] and genetic
networks [27]. An ANN is inspired by the human brain with a set of fully interconnected
nodes (representing neurons with axons and dendrites) and weights for the connections.
Given a set of patient information, nodes get activated and send signals to activate con-
nected nodes conditional on the weights. The network ends when reaching one or more
output information. A genetic network is inspired by Darwin’s theory of evolution by
natural selection. In this context, information represent genes, while a set of information
represents chromosomes. Given a dataset and a desired output, 1) the network selects the
”fittest” and 2) randomly selects subsets of information to 3) create new offspring sets.
Finally, the network repeats the steps for the offspring until reaching an offspring that fits
to the expected threshold with an acceptable threshold. The most popular non-knowledge-
based application became IBM’s Watson, which uses ANNs (or more specifically, deep
learning) [89].
3.1.2 Knowledge-based System
In contrast, a knowledge-based system requires the construction of decision models, the
knowledge base. Specifically, the system consists of (1) an input interface, (2) a knowledge
base, (3) a reasoning (inference) engine, and an output interface [152].
The heart of such a system is the knowledge base, which comprises the essential medi-
cal knowledge of relevant variables, their relation, and influences. Various types of knowledge-
based methods exist to encode medical knowledge. For instance, knowledge can be en-
coded by IF-THEN-ELSE rules or graphs with probabilistic association. The input inter-
face provides patient data for the reasoning. Based on the knowledge base and the patient
information, a reasoning engine uses algorithms to compute an output (e.g., differential di-
agnosis or therapy suggestions). Knowledge-based methods and inference algorithms are
strongly related to each other. Usually, for every method several algorithms exist, which
vary in their computation time and precision. Finally, an output interface is required to
allow the user (or machine) to receive the system’s inferred information after computation.
Decision models can be 1) automatically learned from data using machine learning
methods, 2) manually constructed from expert knowledge, or 3) a combination of learn-
ing and expert modeling (see Section 4.3). Furthermore, both the knowledge base and its
reasoning are human-understandable. However, a decision model can quickly reach an un-
computable complexity and, therefore, special modeling techniques may need to be applied
for simplification (see Section 4.2).
For decision support, exemplary knowledge-based methodologies are Arden Syntax,
decision trees, Markov random fields, and Bayesian networks.
Arden Syntax is a language to represent and share medical knowledge between health
care systems [77, 159]. Knowledge is encapsulated by a set of independent modules, specif-
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ically medical logic modules. Basically, each module describes an individual decision of
lowest level using IF-THEN-ELSE rules and fuzzy thresholds. A single module can be
combined to larger decision support structures enabling error-entry recognition and com-
plex alerts. A medical logic module is simple to understand and update, while comprehen-
sive module components may become difficult to overview. Furthermore, Arden Syntax is
unsuitable to represent probabilistic information [105].
In contrast, more intuitive to understand and interpret are graphical decision models,
specifically decision trees [108]. A decision tree encodes knowledge in a tree-like graph
with nodes representing sequential tests of single attributes and, specifically leafs repre-
senting decisions. To find the best fit for a patient case, the tree is studied top-down by
answering the questions at the nodes until reaching leafs. Additionally, the connection be-
tween the nodes can have chances and costs, so that each path from a root node to a leaf
can have a utility value.
Markov random fields and Bayesian networks are both probabilistic graphical models
[91]. Both networks represent knowledge by a graph consisting of variables and dependen-
cies in between directly related variables as well as probabilistic parameters quantifying
influences between the directly dependent variables. Markov random fields encode knowl-
edge by an undirected cyclic graph and probabilistic weights for each dependency, while
Bayesian networks encode knowledge by an acyclic graph with conditional probabilities
for each variable. Both types of models may also be easy to understand but require some
introduction.
However, Arden Syntax, decision trees and Markov random fields cannot describe
causal knowledge and conditional independencies, which may be crucial for represent-
ing complex decisions human-understandable. Therefore, Bayesian networks seem to be
the most suitable knowledge-based network developing clinical decision support systems.
Finally, each knowledge-based system requires the development of a knowledge base,
which is at the same time its disadvantage and advantage [139]. Its development can be
very time-consuming and is usually customized to a desired diagnostic question which the
developer had in mind and, therefore, becomes useless for other decision developments. On
the other hand, a knowledge-based system is transparent, human-readable and adjustable.
3.2 Impact of BN-based CDSS
Publication reviews from the last three decades demonstrate an increasing presence and
value of BN approaches for CDSS. The value of BNs has also been substantiated by several
comparisons to other machine learning approaches.
Kourou et al. [92] studied PubMed publication of five years between 2010 and 2014
and received more than 650 articles regarding machine learning techniques for cancer pre-
diction. For the last three decades, ANN and DT have been used at most, but since a decade
the trend slightly changes to Support Vector Machine and BN approaches. Particularly for
BN-based CDSS, Jiang et al. [81] conducted a MEDLINE search of publications of the last
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two decades between 1993 and 2012. While they counted less than 300 publications be-
tween 1993 and 2002, between 2003 and 2012 they counted more than 1600 publications.
These numbers confirm the value of BNs in medicine that was also expected by recognized
AI-scientists in 2001 at an international BN workshop [106].
Furthermore, during the last three decades, researchers compared BN approaches to
several other well-known machine learning methods. BNs performed comparably strong,
but they pointed out that BNs’ human-readable and customizable knowledge base has cru-
cial advantages for a CDSS. In detail, Heckerman [71] compared several probabilistic and
non-probabilistic reasoning methodologies. In this study, BN approaches provided the
highest accuracy and the authors concluded that BN approaches have “the most descriptive
method for managing uncertainty”. Zheng et al. [172] compared the decision qualities of
a BN and an ANN by learning the respective methods from the same test dataset. More
recently, in a large study, Seixas et al. [142] compared BNs to ANNs (specifically, a mul-
tilayer perceptron) as well as to other well-known classifiers, such as naı̈ve Bayesian net-
works, logistic regression, decision table, decision stump, and decision tree. In all studies,
the different methods received similar performance results with slightly better results for
the ANN classifiers. However, the researchers conclude the same: the performance of a
classifier mainly depends on the data quality and not on the type of classifier. Furthermore,
for clinical use, BNs’ inherent causal graph structure makes them more trustworthy being
human-readable. Jansen et al. [79] compared BNs to several “black box” approaches and
concluded further BN advantages: BNs allow for 1) converting and combining highly di-
verse types of data into a common BN framework, 2) converting without a required simpli-
fication, 3) network adjustments in case of missing data, and 4) weighting each information
source according to its reliability.
BN approaches have been applied to various clinical domains, e.g., for risk prediction
[130, 146, 5, 162], cognitive disease [168, 137, 29, 164, 142, 153], cancer diagnosis and
treatment [170, 19, 83, 143, 81], and gene expression discovery [115, 66]. However, rela-
tively few reports of application exist that specifically incorporate the use of complex BNs
in medicine. These are generally related to CDSSs for diagnosis, such as Hepar I and II
for diseases of the liver [123, 124] and the Pathfinder for pathologic diagnosis of lymph
nodes [71, 70]. Recently, the use of BNs for decision support for the diagnosis and treat-
ment of pneumonia has been suggested as well [103]. The use of a complex BN for patient
modeling and decision support for patients with hepatocellular cancer has been suggested
[11]. Only few systems are clinically integrated and actively used [92, 148]. These systems
were usually developed iteratively over decades at pioneering institutions. Examples of
clinically well-integrated BN-based CDSS are predicting hospital-acquired pressure ulcers
[25], pancreas cancer [171], multiple diseases related to abdominal pain [87], and preg-
nancy diseases [158]. All of these integrated systems are directly connected to sources of
patient data, which are either local EHR systems or other systems and devices.
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3.3 Best Practice in Developing a CDSS
This section introduces challenges in CDSS development and presents a list of recommen-
dations for a successful CDSS development.
Berner’s book on CDSS [12] describes challenges of CDSS development by review-
ing more and less successful systems. These challenges encompass: 1) the actors, such
as developers, modelers and users; 2) the system, such as decision models, model unifica-
tion, user interface design (UID), ancillary system, and application programming interfaces
(APIs); 3) the procedures, such as as modeling, validation, inference, and output; and 4)
the legal and ethical questions. A developer should be aware of these challenges before
developing an own CDSS.
The following section describes the challenges in development and, based on these
challenges, Table 3.1-3.3 summarizes recommendations for a successful CDSS develop-
ment. The topics are ordered as they are reconsidered in a concept for a BN-based therapy
decision support system, in Part II, Section 5.3.
Developers are commercial vendors and medical research centers. Usually, both differ
in their focus and their possibilities. Vendors have financial possibilities to hire clinicians
and aim to create a product. On the other hand, medical institutions often collaborate with
clinicians from allied hospitals and have a better understanding of clinicians’ desires, but
their systems often remain in the hospital. However, developers (vendors or researchers)
and their clients (clinics or founding agencies) must agree upon a problem to be solved, on
knowledge representation formats and reasoning mechanisms. Deriving from researchers’
experiences with CPOEs, the clinical implementation of a system may require a redesign
of clinicians’ workflow in order to achieve its optimal use [20, 148]. Furthermore, a system
maintenance requires technical and governance infrastructures in order to collect, evaluate
and report the system’s use and results [147, 148].
Modelers are clinicians and knowledge engineers. A clinician represents a domain ex-
pert. A knowledge engineer is a professional with a background in artificial intelligence
languages, knowledge representation techniques and tools, and software design. Specifi-
cally, modeling requires a close collaboration between both. A clinician must be involved
in order to build and maintain a medical knowledge base. A computer scientist is needed
in order to assist in the use of modeling and validation tools, ensure the model quality and
consistency, and identify major unifying concepts. The latter requires from the engineer to
familiarize herself with medical domain.
Users are considered to be clinicians or patients, both with different expectations to-
wards a CDSS. Clinicians expect a ”perfect product” when it is released, but in a devel-
oper’s practice, systems usually improve with usage, and errors will be corrected after user
feedback and error reports. Patients desire to revisit the information about their manage-
ment pathway in order to better understand decisions, but they are quickly overwhelmed
by their lack of medical expertise. Finally, users are very sensitive to obscure systems. A
system may be technically well implemented, but its successful integration into the daily
workflow depends on the user acceptance. Therefore, CDSS should be fully automatic,
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transparent and adapted to the clinician’s workflow. To inform the users about the system’s
strengths and limitations may increase its acceptance.
A decision model should be well grounded, provide the required complexity, and be ver-
ified. To generate patient-specific recommendations, the model should provide evidence-
based decisions based on national guidelines and other high-quality evidence. Links to the
source of evidence should be available for transparency. The model details should lean
on both the represented decision and the community that it is intended for. The larger the
model, the more difficult is its modeling and verification. Therefore, it is recommended to
reduce a decision complexity to limited domains, instead of ”scaling-up” to more general
systems. On the other hand, decision characteristics that are missing in the model cannot
be solved, cannot be recognized by the system as missing, and no strategies for doing so
can be developed
In general, to use standards is highly recommended in order to communicate models
between developers and users. Standards relate to the medical domain, which includes
terminologies and coding systems. Model standards will be required on a clinical, national
and international level. Particularly, an absolute necessity is the use of standardized clinical
terminologies (e.g., SNOMED CT and LOINC).
UIDs are tools for the communication between users and the system. In general, UID
includes devices, visualizations, and functionalities. Without user-friendly interfaces, the
user will miss provided knowledge and appropriate suggestions, and the system will fail
[148]. UIDs need to be adapted to the user’s level of medical expertise and experience with
computers.
Modeling, validation and maintenance is a collaborative team work between a knowl-
edge engineer and a domain expert. Before the modeling starts, it is to discover the clin-
icians’ actual problem and to provide mechanisms to obtain and extend knowledge. New
types of employees will be required who are capable of developing, implementing and
maintaining the system, as well as communicating with clinical personal [148].
A CDSS’s reasoning should provide a model output (the decisions) with a deep expla-
nation. Reasoning should be provided just at the time and location where decisions are
made. The data quality by means of completeness and accuracy is crucial for a correct
reasoning [142].
The adaption of a CDSS to ancillary systems is fundamental for clinical integration.
The integration into an existing and established EHR prevents clinicians from ”double data
entry” and enables the computerization of the decision process. Furthermore, connected to
existing knowledge bases (e.g., ontologies) the CDSS could provide more decision details.
Legal and ethical issues are not well addressed. Legal and ethical questions about
responsibilities for development, use and maintenance exist since the first CDSS. Since
the first CDSS they developed slowly, therefore, these legal and ethical questions almost
disappear. Recently, however, the U.S. department of Health Human Service released the
2015 Edition Health Information Technology Certification Criteria and an updated 2015
Edition Base EHR Definition. The department references the CDSS as an “intervention”,
with focus on a method’s outcome. Obligations for a CDSS are to be built upon an existing
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certified EHR. Therefore, the update of the EHR Definition addresses the extension of
provided patient information, which may be needed for a CDSS. Furthermore, a CDSS
should make source attributes available, including the identity of the developer (person or
organization), funding source, release and revision dates, and, if based on guidelines, also
bibliographic references.
3.4 Integrated (model-based) Patient Care with MIMMS
A CDSS’s adaption to clinically existing ancillary systems is highly recommended for a
successful integration. A CDSS’s adaption requires an appropriate IT infrastructure, like
the medical information and model management system (MIMMS) [100]. MIMMS is a
concept which describes the communication and processes of required medical information
and models between all kinds of clinically relevant functionalities. Figure 3.1 presents the
functionalities by abstracted engines and repositories, as well as permitted data exchanges
and controls in between them [101, 100]. The input information can represent various data
types, e.g., from diagnostic modalities, signals, images, and decision models. Models are
considered to be patient-specific models and clinical process models. Patient-specific mod-
els encode decisions in multiple dimensions ”regarding an individual from the microscopic
level to the macroscopic level; from genomics and proteomics, through organ structure
and functions, to functional physiology in both, health and disease” [10]. Clinical process
models describe clinical workflows, also in multi-dimensions, from a general patient care
to detailed treatment interventions. Both model types combined would build the basis for
model-guided medicine; a new, more accurate methodology for patient-specific diagnosis,
prognosis and treatment, providing the right decision support at the right time [10]. Fi-
nally, model-guided medicine would expand the established cancer treatment approach of
image-guided therapy to an integrated (model-based) patient care (IPC) [10, 99].
A MIMMS is locally adaptable to various clinical domains and environments and is
thought to communicate with other MIMMS globally. Interconnected MIMMSs allow for
sharing models and, therefore, enable a new type of evidence-based medicine, in particu-
lar a model-based medical evidence (MBME) [10]. An MBME has the potential to sub-
stantially transform the individual patient care by improving reproducibility, effectiveness,
economics and patient outcome of medical procedures [99].
The architecture is intended to be further explored, specified and adjusted at an appro-
priate level of detail, in order to obtain an overview of required systems, communications
and standards [101]. An exploration of MIMMS’s components requires collaborations be-
tween disciplines such as medicine, informatics, engineering and mathematical modeling
as well as with industry and other stakeholders [100].
At ICCAS, a MIMMS-like architecture is partially implemented in an operating room,
providing a fully interconnected environment [14, 15]. Furthermore, the EHR system on-
coflow is considered to build the basis for a MIMMS-like implementation of a hospital
information system [15, 107].
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Figure 3.1: MIMMS: ICT architecture and functionalities for model-guided medicine [100]
To conclude, for CDSS development, it is highly recommended to be aware of the
targets (e.g., the decision support and the users) and challenges (e.g., a system’s clinical
implementation and maintenance) before starting the development. MIMMS in general,
and ICCAS’s implementations in particular, provide an optimal environment for building a
CDSS. BNs are an appropriate system that provides a transparent, flexible and reproducible
decision support. Therefore, based on the MIMMS concept, a BN foundation and the CDSS
development recommendations, this thesis explores MIMMS’s ”Kernel for knowledge and
decision management” and ”validation” in order to provide the strategic intelligence for
executing decision models (see Chapter 5).
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Recommendation from best practice 1/3
3.3-R1.1 Developer
1. Involve local clinicians to avoid an inappropriate CDSS for the local situation
2. Define roles of vendor and client in development and maintenance
3. Find agreements with clients upon a problem to be solved, knowledge representation
formats, and reasoning mechanisms
3.3-R1.2 Modeler
1. Collaborate with or hire clinicians in order to develop and maintain the medical
knowledge base
2. As a computer scientist, familiarize with the domain in order to identify major unify-
ing concepts
3.3-R1.3 User
1. The system should be adapted to clinical culture and process of care
2. Inform the clinicians using the CDSS about its strengths and limitations
3. Do not worse the clinical workflow
4. Do not intrude on the sanctity of the patient-physician relationship
5. Avoid forcing the user to “double data entry”
6. Provide transparent reasoning
7. Provide advises only if questioned or in exceptional situations
8. Inform patients adequately about possible medical outcomes and quality of life
9. Enable the assessment of patients’ preferences and risk attitudes for clinical outcomes
10. Allow patients to override criticism or suggestions with required justification
11. Consider physicians’ high regard for their own capabilities
12. Consider fear of computer competition
Table 3.1: First table with recommendations and best practice of developing and im-
plementing CDSS summarized from positive and negative experiences and results from
Berner’s book on CDSS [12].
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Recommendation from best practice 2/3
3.3-R1.4 Model
1. The system should address the problems that clinicians actually face
2. Provide causal, temporal and spatial knowledge
3. Provide high degree of (causal) knowledge of the domain
4. Completeness of a specific decision
5. Support decision support for more limited domains (do not “scale up” to more general
systems)
6. Ensure consistency of represented knowledge
7. Use available standards of clinical terminology
8. Provide a mechanism for handling time-dependent data when clinical data is fre-
quently changing
9. Create an effective set of rules
10. Provide guideline-based decision combined with expertise
11. Ensure verification
12. System should be robust and flexible
3.3-R1.5 UID
1. Setting an appropriate expectation of the way the system will be used
2. Provide user-friendly interface
3. Ensure that the user will recognize appropriate suggestions
4. Develop notification mechanisms
5. Provide actionable recommendations
6. Provide alerts/reminders automatically as part of the workflow
7. Tailor information to patients’ preferences and for providing decision support
8. Consider peripheral devices
9. Consider user experiences with computers
Table 3.2: Second table with recommendations and best practice of developing and im-
plementing CDSS summarized from positive and negative experiences and results from
Berner’s book on CDSS [12].
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Recommendation from best practice 3/3
3.3-R1.6 Modeling, validation and maintenance
1. Discover clinicians’ actual problems before modeling
2. Provide a mechanism to obtain knowledge
3. Update knowledge bases regularly
4. New knowledge must be reconciled with those already present in the knowledge base
5. System should learn from experiences
3.3-R1.7 Reasoning
1. Provide the suggestions at a time and location where the decisions were made
2. Provide output with deep explanation
3.3-R1.8 Ancillary System
1. CDSS integration into an electronic medical record and APIs
2. Use technical standards assuring integration of ancillary systems
3. Use adequate databases
4. Use ontologies as resource for communication, computational inferences and reuse,
and knowledge management
5. Computerize the entire process
6. Integrate data automatically
7. Consider clinical computers
3.3-R1.9 Legal and ethical issues
1. Vendor should inform client about required technical support and/or clinician training,
for appropriate system use and understanding of recommendations
2. Assign a vendor’s obligation of providing regular knowledge
3. Assign responsibilities for decision-making by end users based on outdated know-
ledge
Table 3.3: Third table with recommendations and best practice of developing and im-
plementing CDSS summarized from positive and negative experiences and results from
Berner’s book on CDSS [12].
Chapter 4
Clinical Decision Model using Bayesian
Networks
The following section introduces ordinary BN and BN extensions as well as modeling,
validation and visualization techniques and tools. These principles are described in a depth
that is necessary to follow methodologies in Part II. Finally, BN applications are described
that were studied as a basis for this thesis.
4.1 Bayesian Network
In 1988, Pearl [133] introduced BN to model problems implying uncertainty and inferring
diagnostic recommendations.
However, complex BN may become difficult to model, validate and maintain, or even
incomputable.
Figure 4.1: Example of a ordinary BN.
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4.1.1 Bayesian Network Model
A BN describes a joint probability distribution over a set of conditionally independent ran-
dom variables. The variables and their conditional independencies are usually represented
by a directed acyclic graph (DAG) and influences between the variables are quantified by
conditional probability distributions (see Figure 4.1).
In detail, a DAG consists of nodes with states and directed edges. A node represents
random variables with a set of at least two discrete states. A variable’s identifier must be
unique for the entire network, while a state must be unique for its variable only. A directed
edge linking two nodes represents the nodes’ direct causal dependency. The edge direc-
tion describes the causal relation from a parent node to its child node. In one network,
not directly linked nodes are indirectly dependent. To complete a BN based on the DAG,
each node requires probabilistic parameters that quantify the influences from all its par-
ents. A node’s parameters are usually represented by a conditional probability table (CPT).
Specifically, a node requires a probability distribution over its states depending on every
combination of its parent states. In case of a variable without parents, the variable requires
an a priori probability distribution.
Figure 4.1 shows an example of a BN consisting of six Boolean-valued nodes; two diseases
LarynxCa (laryngeal cancer) and Laryngitis, their common cause, Smoking, and their com-
mon effect, the symptom Hoarseness. Furthermore, laryngeal cancer has a cause and an
effect that Laryngitis does not have; the cause, Alcohol abuse, and an examination method
as effect, Neck CT (computer tomography of the neck area). The directed edges represent
the variables’ cause-effect relations as described. The variables’ CPTs are presented in
boxes around the graph.
A BN reduces a joint probability distribution over all variables to a model-specific one
by it independencies. In general, a joint probability distribution for a set of n variables
(V1, V2, . . . , Vn) is described by:
P (V1, V2, . . . , Vn) =
∏
i
P (Vi | Π(Vi)), (4.1)
where Π(Vi) represents the parents of Vi. The joint probability distribution of the BN
model in Figure 4.1 is:
P (S,A, L, C,H,N) = P (S) · P (A) · P (L | S) · P (C | S,A) · P (H | L,C) · P (N | C),
(4.2)
where S stays for Smoking, A for Alcohol abuse, L for Laryngitis, C for LarynxCa, H
for Hoarseness, and N for Neck CT.
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4.1.2 Inferencing
From a network’s joint probability distribution one can directly obtain inferences based on
a set of evidences. However, more efficient by means of memory usage and computation
time is the use of Bayesian inference.
A Bayesian inference algorithm propagates the messages of observations through the
network respecting conditional independencies to calculate for each state of unobserved
variables a probability of occurrence.
Under specific conditions, two indirectly dependent variables can become d-separated
(conditionally independent). Figure 4.2 presents three characteristics of d-separation be-
tween two variables X and Y given a variable Z. The first two characteristics present X and
Y d-connected through an unobserved Z, and d-separated with an observed Z. In the last
case, X and Y are d-connected only with an observed Z. The last case effect is an intercausal
reasoning known as ”explaining away”; observing Z and one of the other, X or Y, may ex-
plain the remaining unobserved variable. Based on the d-separation characteristics, a node
Figure 4.2: Characteristics of a d-separation between indirect dependencies.
can become independent of the remaining network given the node’s observed Markov blan-
ket [133]. A node’s Markov blanket considers a set of neighboring variables including the
node’s parents, children and children’s parents.
In this model, Hoarseness and Neck CT are only indirectly dependent on Tobacco and
Alcohol abuse. While an observed LarynxCa would d-separate Neck CT from the remain-
ing network, Tobacco would only be d-separated from Alcohol abuse.
Observations can be discrete with 100% for one of a variable’s values, or fuzzy-valued
with 100% distributed through more than one value. From our example, a radiologist may
assess a neck CT examination result as uncertain given artifacts (e.g., blurred images). In
this case, the variable’s observation could be distributed through the variable states true and
false, with a higher percentage portion to the more probable answer.
Propagation of reasoning is performed in both directions, along an edge direction which
describes causal reasoning or prediction, and against the edge direction which describes an
evidential reasoning or explanation. For evidential reasoning, Bayes’ theorem is essential,
which enables the inverse propagation of conditionally dependent events. Bayes’ theorem
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is presented in Equation 4.3:
P (A | B) = P (B | A)P (A)
P (B)
(4.3)
The initial approach for message-passing through all single nodes has been developed
by Pearl [134]. Further on, more efficient inference algorithms arose for both exact and
approximate reasoning. For each type of reasoning, several methods exist. Other exact
algorithms build a (junction) tree out of the BN graph by clustering subnetworks to single
tree nodes, and perform the inferences on the tree [96, 80, 44]. Approximate algorithms
are based on stochastic sampling [73, 144, 60, 61, 23, 167]. Dependent on the model
complexity, as well as desired computation time and accurate reasoning, the one or the
other inferring type may be most suitable.
4.1.3 Methods for Model Analysis
Once a model is created and inferred, model analysis can be supported by methods high-
lighting strength of connections, sensitivity analysis, and value of information. In general,
all three functions measure a variable’s mutual influences. In detail, the strength of con-
nections measures the strength of dependencies between variables given a model’s joint
probability distribution, independent of observations. The sensitivity analysis measures the
influence of observations on target nodes based on the inference. The value of information
computation is based on cross-entropy; this method measures the influence of observations
to a specific node’s state.
4.1.4 Complexity
Theoretically, exact and approximate inferring algorithms are NP-hard, which means that
model inferring requires exponential time in worst case [28, 42]. In detail, a BN’s com-
plexity increases exponentially with respect to the number of parental variables and states.
Therefore, worst case describes a network of one child node with all remaining nodes as
its parents. However, because practical networks are sparse, through independencies be-
tween variables, a BN reduces the number of parameters necessary to represent the joint
probability distribution from exponential to usually polynomial in the number of variables
[52]. Therefore, a BN becomes suitable for modeling, comprehending and calculating. For
example, Hepar II, a BN model for the diagnosis of liver disorders [121] consists of 70
variables. The joint probability distribution represented by Hepar II is described by merely
2,139 numerical parameters instead of more than 270 needed theoretically (based on 70
variables and Boolean-valued states).
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4.2 Model Design
Comprehensive decision models may become too extensive for an adequate modeling and
validation, or even incomputable. Therefore, a model should be sparse in the number of
parental nodes but must fulfill the domain’s desires [49, 104, 121]. Otherwise, independent
of a network’s correct reasoning, the system will loose the users’ confidence.
As a quick reminder, in case of laryngeal cancer, tumor boards take into account a
large number of patient characteristics, each usually examined by multiple complementary
clinical tests. Also, treatment options may range over multiple disciplines. Each treat-
ment option has its advantages and disadvantages regarding the outcome, which includes
treatment risks to be avoided and patients’ quality of life to be kept.
Specifically focused on extensive models, this section presents techniques to reduce the
model and modeling complexity without a necessary loss of domain-specific information.
4.2.1 Selection of Variables, States and their Identifiers
The selection of variables and states is mainly predetermined by the represented domain.
However, their selection can be affected by the attempt to keep the model sparse. Identi-
fiers obtained from experts may vary due to their language culture, even if they work in the
same environments. From the rare literature that describes the process of expert modeling,
this section presents recommendations regarding the selection of variables, states, and their
identifiers.
Theoretically, modeling can start from and be continued with any variable. Practically,
modelers start from variables that represent the desired decisions (e.g., disease for diag-
nostic models, and therapy options for therapy decision models) and continue with directly
related variables [123, 51, 104, 157]. This proceeding ensures to accomplish the desired
decision support and reduces the model extent by focusing the modeler on the decision-
relevant influences and effects. With every new variable, a modeler should ensure that
variables are self-contained [91]. For this purpose, if two variables represent the same con-
text and their states are mutually exclusive, the variables should be merged. On the other
hand, if a variable’s states can potentially occur at the same time, the variable should be
disjoint into separate variables.
Variable identifiers should be constructed readable, distinctive and organized. When
creating a variable, it is highly recommended to construct an identifier from a standardized
nomenclature, e.g., SNOMED CT [12, 26, 150]. Otherwise, experts are likely to describe
the same information entity by different terms, which will hamper the understanding and
communication of shared models. In case that a BN model represents decisions over multi-
ple body areas or organs, variables that represent similar information at different locations
need to be specified by one or more location-specific terms [32].
In detail, SNOMED CT1 is a multilingual ontology that consists of medical terms. Each
1http://www.ihtsdo.org/snomed-ct
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term provides an identification number (or SNOMED CT code), synonyms and definitions.
Terms are classified as, e.g., body structures, findings, morphologic abnormalities, disor-
ders, qualifier values, staging scales, environments, and procedures. Within a class, terms
are organized into and connected through a taxonomic (is-a) hierarchy, e.g., the Glottis
structure is a Laryngeal structure. Clinical terms exist as a single unit but are also addi-
tionally registered regarding specific body regions and specific values. For example, the
Tumor stage finding also exists more specific as, e.g., Subglottis TNM finding or even pT3:
Tumor limited to larynx with vocal cord fixation (larynx, subglottis). Each of the repre-
sentative terms has a code that is unique in a specific language. Synonyms are connected
to the representative term without an own code. Representative terms between supported
languages are connected using the same code.
To increase the variables’ overview and quick search in models with a large number
of variables, their identifier terms should be ordered categorically, such as in a postcode
system, i.e., from the most general to the most specific body structure, and ending with the
information of interest (e.g., a disorder or procedure) [32]. For example, a variable that
represents a CT result of a glottis infiltration could have the identifier ”Larynx glottis CT”.
It is to emphasize that this ordering is less readable by means of reading flow compared to
reader-friendly SNOMED CT terms.
The construction of identifiers obviously depends on the desired grade of details of
represented decisions. The level of model detail is often heterogeneous, which may be
affected by technical limitations, a modeler’s desires to reduce the modeling and validation
effort, or available knowledge [72, 124, 32]. To minimize the model extent, the modeler
follows similar principles (1) grouping variables that represent similar examinations, (2)
considering only observable variables, and (3) removing variables with a low impact [7,
104, 121]. Less relevant variables and states can be identified using statistical analysis
[74, 166]. It is to stress that these methods lead to a loss of information and, therefore,
should be applied carefully. However, such methods might be required when a variable
becomes incomputable by too many parents.
On the other hand, parents can be preserved by a structural divorcing technique or a
parameter-based noisy gate technique. The divorcing technique [120] summarizes subset’s
of a variable’s parents by adding new representative parents. A variable’s dependencies to
a subset of parents are removed, and a fictitious variable becomes the subsets new common
child and the variable’s new parent. The technique of noisy gates [72] decreases the number
of required conditional parameters, which also influences the selection of variables and
states. This technique is described in the following section.
Finally, the selection of states is rarely described by researchers because of their limited
variability; first, they require to be unique only within a variable and second, they are
Boolean-valued or with multiple values that are strongly related to their variable’s identifier
[91]. Also, the number of states is usually kept small to reduce the extent of CPT tables,
but should be distinctive enough to represent the desired information, self-explanatory in
context for the variable’s identifier, and meaningful for its child nodes [32].
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4.2.2 Building Dependencies and Causalities
In BN, modelers can represent both causal and associational knowledge [135]. Causal
knowledge represents progresses, e.g., a disease is pointing to an examination: first, a
disease must exist and then an examination becomes positive. In contrast, associational
knowledge represents conclusions, e.g., an examination is pointing to a disease: first, an
examination must be positive to conclude a disease. The knowledge representation is with-
out a necessary effect on the reasoning results, but can have negative consequences for
modeling, model understanding and model modifications [135, 69].
Imagine two networks, each with two directly dependent nodes but with reversed causal-
ities. Mathematically, both networks represent the same knowledge if the nodes’ proba-
bilistic parameters are adjusted (mathematically transformed) to their specific causal rep-
resentation [53]. In case of the two nodes A and B, the causality from A to B with the
probabilistic parameters presented in Equation 4.4 can be reversed by transforming the pa-
rameters to the one presented in Equation 4.5. BN’s reasoning is bidirectional, and there-
fore, given the same evidences both networks would reason the same.
A→ B

P (A) = a
P (B | A) = b




P (B) = ab + (1− a)c
P (A | B) = ab
(ab+(1−a)c
P (A | ¬B) = a(1−b)
1−ab−(1−a)c
(4.5)
Also, this flexibility enables, theoretically, to represent a combination of causal and as-
sociational knowledge. Inconsistencies in the knowledge representation will hamper model
modification by means of adding new nodes or deleting an existing one [69].
BN models are supposed to represent consistent causal knowledge [121, 49]. To max-
imize the representation of information and minimize model inconsistencies, Diez et al.
[49] introduce a methodology for clinical BN decision graphs to integrate all clinically
necessary examination methods while reducing the model and modeling complexity. The
methodology separates variables into three types with restricted causalities. The variable
types are: personal data, anomalies and medical findings.
1) Personal data are root nodes (without direct causes) that represent a patient’s known
facts (e.g., age, sex and smoking status) and medical history.
2) Anomaly nodes represent pathologies, which are not directly observable. An anomaly
node can have parents and children of the same type as well as parent nodes of the type
personal data representing causes of the anomaly, e.g., smoking causing lung cancer, and a
child node of type medical finding, e.g., small lesions revealed by a lung CT.
3) A medical finding results from the examination of an anomaly, and is therefore al-
ways a leaf - a child of an anomaly without own children.
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On the one hand, this structure allows inferring (backwards) a characteristic by a num-
ber of findings from different examination methods. Furthermore, the examination meth-
ods’ degree of accuracy can be respected. On the other hand, independent of specific
observations, all nodes are always directly or indirectly dependent on each other through
the unobservable anomalies (no d-separations).
4.2.3 Reducing the Effort in Modeling Parameters with Noisy-OR gates
An increasing model complexity often results in a larger number of node parents, and thus
in a large number of conditional probabilities that are difficult to elicit, analyze, and may
be incomputable. Noisy-OR gates reduce the complexity of a node’s CPTs without a loss
of information [72, 49, 125]. Therefore, modelers use Noisy-OR gates when conditional
states make it possible. The assumption is that a node’s parents effect the node indepen-
dent of each other. In this case, the node’s CPT size is reduced to the number of parents by
describing its parents’ influences separate. For example, the M state for laryngeal cancer
may have several parent nodes representing metastases in other organs. For a positive M
state (M1), a metastasis of only one parent needs to exist independent of other metastases
occurring.
To summarize, rules and recommendations for a decision model without loss of domain-
desired information are:
4.2-R1: Identifier must be unique, readable and distinctive
4.2-R2: Identifier should be from standardized nomenclature
4.2-R3: A variable’s states must be mutually exclusive
4.2-R4: Contextual similar variables with mutually exclusive states should be merged
4.2-R5: Divorcing multiple parents
4.2-R6: Representation of causal knowledge
4.2-R7: Distinguishing data types
4.2-R8: Using Noisy-OR whenever possible
4.3 Model Development
Modeling a BN structure and parameters is possible using machine learning methods, do-
main experts, or a combination of both. From the previous literature review of CDSSs,
models are usually fully learned for knowledge discovery or built in combination of ex-
pert knowledge and learning for alerting systems and decision support. In the former case,
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prior knowledge does not or only partially exist. Knowledge discovery from the data is
desired and a further use of the model for decision support is, theoretically, possible. In
the latter case, a model structure is built by experts while the parameters are learned from
data. An expert model structure has the advantage of being human-understandable and de-
creases the variability of (incorrect) learning parameters. Fully modeled systems are rare
in the literature because of a usually large number of required parameters. However, expert
models may be necessary for rare or new diseases when appropriate data is temporarily
unavailable.
4.3.1 Machine Learning
Various machine learning algorithms exist that can create and validate BN models auto-
matically [68, 30, 58, 4, 62]. They apply statistical methods to learn the model structure
and the probabilistic parameters from data. The data is acquired from clinical guidelines,
large randomized controlled trials and other reliable medical sources. The available data is
usually unstructured and, therefore, requires a preprocessing by text mining methods that
extract the relevant information. Among the large amount of data that is required for an
appropriate learning, the most crucial is the data quality [89]. The quality relates to the
data correctness and completeness.
In the medical domain, and especially for rare diseases, the required adequate data is usu-
ally unavailable [52, 124, 102, 157].
4.3.2 Expert Modeling
A team of domain experts and knowledge engineers is able to built expert models in a valu-
able quality. The models can then be further improved by data-based adoptions.
Clinical experts are capable to provide the necessary information, although they might
initially disagree [104, 124, 157, 51]. While models represent a modeler’s individual un-
derstanding of how the world works, they likely yield disagreement [113].
Furthermore, acquiring both structure and joint probability distributions from domain ex-
perts outperforms learning of models; experts achieve better classifiers and more robust
networks [102].
However, for extensive models with hundreds of variables, expert modeling is cumbersome
by requiring both time and the collaboration between domain experts and knowledge engi-
neers. For example, authors report that the elicitation of a BN structure with 94 variables
takes the experts approximately 40 hours [123]. Therefore, expert models are usually built
in combination of both: the structure is created by experts, while parameters are learned
from data. On the other hand, various modeling techniques enable the modeling of an
extensive decision while decreasing the model’s complexity, presented in the following
section.
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4.4 Bayesian Network Extensions
A multi-entity decision graph (MEDG) [163, 31] extends the modeling framework of or-
dinary BNs to a highly expressive language. Its framework enables 1) the expression of
ontologies, 2) automated creation of situation-specific model structures, and 3) including
user-specific decision preferences. An MEDG combines a multi-entity BN (MEBN) that
enables the first two extensions, and an influence diagram (ID) for the last extension. Fig-
ure 4.3 presents an exemplary MEDG model, and Figure 4.4 a resulting situation-specific
BN (SSBN). Figure 4.3 highlights the MEBN extensions in green and the ID extensions
in orange, the gray nodes represent an ordinary BN. The following section describes the
concepts of a MEBN and an ID with examples regarding these two figures.
Figure 4.3: Examples of two BN extensions combined in one network; a generic BN with
additional green nodes, edges and node arguments, and an ID with additional orange nodes
and edges.
4.4.1 Multi-Entity Bayesian Network
A MEBN [163, 31, 94] combines Bayesian theory with First-Order Logic (FOL). Sowa
states that FOL ”has enough expressive power to define all of mathematics, every digital
computer that has ever been built, and the semantics of every version of logic including
itself” [151]. In combination with BN, FOL enables both, creating generic BN models
and expressing probabilistic ontologies. A MEBN can be considered as a generic BN with
instantiation constraints regarding a set of valid domains; given a set of observations, the
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Figure 4.4: A situation-specific Bayesian network automatically constructed from the net-
work in Figure 4.3.
MEBN can automatically construct a highly complex SSBN. Instantiation constraints can
be specified for single nodes, subnetworks, or the entire network. Therefore, a MEBN can
represent a joint probability distribution over an unbounded, possibly infinite number of
instances of its variables. Probabilistic ontologies [132, 163, 94] are a synergy between BN
and the ontology web language. The probabilistic ontology open research work2 aims to
extend the BN by the ontology web language, in the same way as BN extends the ontology
Web language to a probabilistic ontologies.
In detail, the network of a MEBN, called MTheory (from MEBN theory), consists of
a set of domain variables and a collection of interconnected MFrags (from MEBN frag-
ments). Domain variables are generally defined in the MTheory representing its domain
of discourse. If knowledge of a domain is represented in an MFrag, the domain variable
requires local specifications using arguments. The affiliation of arguments to domain vari-
able is defined by the context constraints. Finally, for each domain variable consists of a
set of domain entities. An MFrag represents the domain knowledge and consists of a set
of nodes, edges and its context constraints. Nodes are resident nodes or input nodes. Each
resident node has a set of arguments and a CPT. In an MTheory a resident node exists in
exactly one MFrag. If a resident node has a parent node in another MFrag, their causal
relation is represented through an input node. An input node references an existing resi-
dent node from the same or another MFrag. It also references the domain variables, but
may have other MFrag-specific arguments. An input node can also be in the MFrag of its
resident node but with different arguments. In this case, instantiations of one variable can
directly influence themselves, e.g., to represent a situation changing over time, or genetic
influences from relatives. If a MEBN is created, a dataset can be added to construct an
2http://www.pr-owl.org/
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SSBN. Specifically, each observations in the dataset requires an observed value with a set
of conditions (domain entities). Based on the the observations an SSBN algorithm instan-
tiates an SSBN. Finally, an SSBN is an ordinary BN, therefore, reasoning on an SSBN is
performed using the standard BN inference algorithms.
Figure 4.3 represents a MEBN with five resident nodes and two input nodes. The pre-
sented shape of nodes is negligible for a MEBN and will be described in the following
subsection of influence diagrams. The network consist of the resident nodes LarynxCa
staging, Therapy, Time in treatment, Health condition, 5-years survival, and Costs as well
as on the input nodes Time in treatment, Health condition. The domain variables are Patient
and TimeStep. Patient has one argument p, while Time has two arguments prevT and t. The
nodes LarynxCa staging and Therapy have the argument p and will be instantiated only if
the dataset consists of multiple patients. The remaining resident nodes have the arguments
p and t. The input nodes differ from their resident nodes by the argument prevT. Figure 4.4
presents an instantiation of the network given a domain entity !P0 of the domain variable
Patient and three domain entities !T0, !T1 and !T2 of the domain variable TimeStep.
4.4.2 Influence Diagrams
In general, IDs [76], also called relevant diagrams, extend BNs to user-specific preferences
(user’s expected utility). These preferences are described by decisions and utilities. Given
the probabilities from the ordinary BN part and utilities from the extended network part,
the aim of an ID is to find the optimal strategy. In detail, IDs extend a BN’s type of
uncertainty node and conditional edge to two additional types of nodes, decision node
and utility node, and one more type of directed edge, informational edge. A decision
node is drawn as a rectangle representing a decision to be made by the user. A set of
discrete states describes a decision’s possible alternatives (in the example in Figure 4.3, the
node Therapy with the states surgery, chemoradiation, and none). Nodes are connected
by conditional edges, except for edges that point to decision nodes, which can only be
informational edges (the link from LarynxCa to Therapy). An information edge passes
information from a decision’s parents only along its direction. All parents are required to
be observed before the decision can be made (in the example, to make a therapy decision
a cancer staging is required beforehand). A utility node is drawn as octagon (or diamond)
and represents a user-specific value for each possible outcome of its parents (uncertainty
and decision nodes). Therefore, utilities are continuous variables that measure preferences
(in the example, the node Cost).
In an ordinary ID the example presented in the Figure 4.3 would exclude the arguments
and input nodes.
A BN is a probabilistic graphical model that can support transparent and comprehen-
sible decision-making. Therefore, BNs became accepted and used in context of CDSS
[12]. Many study groups already approached the issue of clinical applications of BNs. The
TREAT study group explored the feasibility and applicability of BNs in clinical settings,
mainly in the field of antibiotic treatment of patients with bacterial infections [3, 97].
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Both approaches, MEBNs and IDs, can be merged to a MEDG, as presented by Figure
4.3. It is possible and usually recommended to first create a BN model, and later extend the
model to a MEBN, ID, or MEDG [104, 105].
4.5 Validation methods
The quality of a model advice depends on the model quality. Therefore, it is vital to validate
the model before it is applied in practice. Validation can be performed both quantitatively
by machine learning techniques using a large data set compared to the model size, or qual-
itatively by a domain expert by simply valuing the model’s predictions. In case of too
little data and when data is difficult to gather, an expert validation is necessary. An expert
validation is subjective compared to data-based validation, but qualitatively higher because
the expert can study a relation between two variables, subnetworks and the model behavior.
However, in the BN community only a few reports on expert validation are available, which
are conceptual or only generally described [121, 138].
With the quantitative evaluation, an algorithm calculates the model validity automati-
cally. For this, patient records are mandatory. Results express the model quality numer-
ically by means of accuracy, sensitivity, specificity, etc. The number of patient records
should be sufficiently large compared to the model size. In practice, usually fewer cases
are available, which decreases the reliability of the evaluation results. Among the num-
ber of records, also the number of patient information per record has to be considered. A
model’s uncertainty is a natural occurrence in cases of sparse or insufficient information.
In these cases, the uncertainty is a desired feedback for clinicians. With the qualitative
approach, each patient record is studied individually and interactively with a domain ex-
pert. This qualitative study is time-consuming for the expert, but it provides an opportunity
to check patient information in case of the model’s incorrect behavior and to modify the
model directly [121].
4.5.1 Quantitative Validation
Quantitative methods calculate a model’s ability to predict values. More specific, a subset
of target variables, which represents ”the answer”, is to be selected from a model. Then,
a validation method excludes these target variables from the test data, and compares the
model’s predicted values to the target values. For example, in a diagnostic setting, target
nodes are typically the disease nodes. The individual quantitative methods give statements
about accuracy, sensitivity, specificity etc. While some methods present the model quality
numbers, others may indicate it by plotted functions. This section briefly introduces five
methods: (1) accuracy, (2) confusion matrix, (3) Receiver Operating Characteristic (ROC)
curves, (4) Area under the ROC curve (AUC), and (5) calibration curve. These five methods
were studied and partially applied to a model validation cycle, presented in Part II of this
thesis.
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Accuracy
Accuracy [111] counts a model’s correct predictions. For each target variable, an accuracy
is expressed by a ratio of the number of correct predictions to the number of all records.
Typically, only the state with the highest probability counts as a prediction. However,
for some decisions, it might be valuable to count a prediction as correct if it is within
the second, third, or fourth most probable states, or if its probability reaches at least a
predefined minimum probability threshold [49, 105, 121]. In any case, incorrect predictions
are unspecified by this method.
Confusion matrix
Confusion matrix [111] counts a model’s correct and incorrect predictions. Incorrect pre-
dictions are counted separate for each possible value. The predictions are presented in a 2D
matrix, usually with rows representing the target variables against columns representing the
predicted values. This matrix enables studying the predictions’ distributions; the distance
between mismatches and the correct answer. It is to note that counts are presented without
the specific probabilities, which could be desired to identify critically wrong predictions.
For instance, wrong predictions with a large distance to the correct answer but small prob-
abilities may be less critical than a close prediction with a high probability. In diagnostics,
small probabilities demonstrate typical uncertainties of the model, which would motivate
to perform more examinations. A high probability may exclude other options.
ROC curve
ROC curve [161] visualizes the model’s ability to distinguish between correct and incorrect
predictions. For each target value, ROC calculates a function of a true-positive rate against
a false-positive rate. The true-positive rate, known as sensitivity, describes a model’s ability
to predict correctly. The false-positive rate, known as specificity, describes a model’s ability
to not predict this value, in case that another value is the correct answer. A ROC curve is
plotted in a Cartesian coordinate system, typically with sensitivity at the vertical axis and
1-specificity at the horizontal axis. A curve with high specificity and high sensitivity runs
close to the coordinate [0,1]. In the worst case, a curve is diagonal from [0,0] to [1,1], which
means a 50-50 chance for correct prediction. A curve under the diagonal line indicates a
system’s wrong interpretation of the values and can be flipped over.
AUC
AUC [161] represents a ROC curve by one number. The AUC goes from 0.5 (worst case)
to 1.0 (best case) and describes a plot’s area size between a ROC curve and the diagonal
line. The machine learning community criticizes the AUC for being too unspecific about
the ROC curve; an AUC between 0.5 and 1 can always represent more than one ROC curve.
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Calibration curve
Calibration curve [46] expresses a model’s diagnostic accuracy; the ability to predict with
correct probabilities. Therefore, and in contrast to the previous methods, calibration curve
utilizes the predictions’ probabilities. Specifically for each of the targets’ states, calibra-
tion curve calculates a function of probability estimates against expected probabilities. A
resulting curve provides two information: first, about over- or underestimated predictions,
and second, a probability threshold when a state’s prediction becomes more reliable. At
best, the curve is a straight diagonal line from (0,0) to (1,1). The area below this line indi-
cates an underestimation, above this line an overestimation. In clinical practice, both could
have a serious impact on treatment decisions. An under- and overestimation of a patient
situation could result in an under- or overtreatment. For example, an underestimated TNM
staging may misleadingly propose a respectable tumor which would turn out to be a unre-
sectable situation under surgery. In a well calibrated model, with an increasing probability,
a variable’s curve would run towards a diagonal line indicating the model’s confident of
predictions with higher probabilities. In clinical practice, minimum probability thresholds
could increase the trust in predictions.
4.5.2 Qualitative Validation
To analyze the model qualitatively, experts may study the model behavior from both the
patient records and the direct model interaction. These studies require a software with a
suitable graphical user interface (GUI) and real time inferencing.
Studying the patient records gives an understanding of future model behavior in practice
as a CDSS. In an early phases of validation and refinement, an incorrect prediction often
indicates the need for some model adjustments. However, a clash between model output
and an expert’s intuition gives the expert an opportunity for important insights.
Direct model interaction focuses on subnetworks, which allow for finding model-related
issues. By directly interacting with an interconnected subnetwork of two or more variables
an expert may study direct influences. For these studies, an expert simulates combinations
of possible observations based on own knowledge and experiences. A subnetwork analysis
usually covers the range of a variable’s Markov blanket. In other words, if every node in
a model responses correctly, given all possible observations in the node’s Markov blanket,
then the network should response correct.
Structural analysis may lead to both expanding and simplifying the model. An incor-
rect model requires modifications of the model structure and its parameters. Parameters
are strongly related to the structure; if the structure is correct, only parameters need to be
changed. However, modifying the structure usually requires an adjustment of the parame-
ters. Therefore, a graph should be reconsidered before parameter correction.
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4.6 Visualization of Probabilistic Graphical Models
Statistical information is difficult to understand, discuss and explain and, therefore, the
user requires assistance by appropriate visual aids [109, 128]. Visualization tools for in-
teraction with BN should provide a deep understanding of the available information and
reasoning [155]. At the same time, tools should be adjusted to the user’s needs and under-
standing.
BNs are commonly visualized by their inherent graph structure, specifically, their nodes
and directed edges to represent the direct causal influences between variables. Visual tech-
niques can provide additional information on a network’s probability distributions and rea-
soning as well as support in the organization and exploration of sizable graphs. Zapata-
Rivera et al. [169] and Kadaba et al. [82] studied the informative impact of nodes and
edges by applying temporal orders, sizes, colors, proximities and animations. Especially
for sizable graphs, Zapata-Rivera proposes using colors instead of sizes and positions, and
explored an intuitive understanding of the causal strength and the visual proximity between
two directly connected nodes. Both see a great potential in the animation representing
causal influences. Koiter [90] applied thicknesses and colors to edges in order to represent
strengths and directions of influences between directly connected nodes. Dang et al. [43]
applied analyzed causalities in complex networks of biochemical pathways. They represent
causalities by color shifts of the edges. Wang and Mueller [160] propose a graph-based tool
for studying causal structures given a set of learned dependencies. Chiang et al. [24] visu-
alized CPTs by heatmaps in order to overview, compare and analyze them. A widespread
framework for BN development and interaction is the software GeNIe [50]. Similar to
other BN software, GeNIe represents nodes by bar charts with probability distributions,
and dependencies by edges. It supports modeling, validation, and reasoning. Finally, the
software provides various functionalities for model and reasoning analyses.
4.7 Tools and Methods for Modeling, Validation and Vi-
sualization
Open accessible modeling packages and frameworks exist that enable domain-independent
modeling [114, 50, 21]. Using these packages or frameworks for clinical domains requires
from a modeling expert either to acquire knowledge regarding the specific modeling tool
and advanced BN modeling principles, or being reliant on collaborative work with BN
experts [12]. In other words, the available frameworks may be intuitive for a computer
scientist, but difficult to use by clinicians. Specifically for probabilistic modeling, van the
Gaag [157] developed a technique to acquire clinical knowledge more efficiently.
This section describes GeNIe’s framework and van the Gaag’s method for parameter
assessment. GeNIe was used to create and validate the model in Part II of this thesis, while
the parameter method was the basis for an expert modeling techniques in Chapter 8.
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4.7.1 GeNIe and SMILE
GeNIe3 is a free access software from the University of Pittsburg, which allows for model-
ing, validating and reasoning over various Bayesian approaches, e.g., ordinary BNs, fuzzy
BNs and IDs. GeNIe consists of a GUI for user-model interaction, and SMILE, an engine
for reasoning and advanced BN functions. For computer scientists, GeNIe’s framework is
intuitive to understand and simple to use. A screen shot of GeNIe’s GUI is presented in
Figure 4.5.
In detail, GeNIe supports an alphabetically ordered list of variables for a quick search, to
Figure 4.5: Exemplary screenshot of the GeNIe software. The center window shows the
model, zoomed-in on the T-state variable with its direct causes. The software offers a list
of all variables (left window) and functionalities to study and modify the model (tool bar).
In between the center window and tool bar is the case manager (list with added patient
records).
zoom in and out the graph, and move across the graph structure. The user models a BN’s
nodes and dependencies trough GeNIe’s center window via drag and drop. A node’s states
and CPT are added in a node property window, see Figure 4.6. For patient records, a case
management allows to open csv-file based patient records, and to select, modify and save
observations using discrete values. Fuzzy values for a node’s states are to enter through the
GUI using bar charts or pie charts. Furthermore, to study the model behavior, the model
inference is updated in real-time while interactively changing observations.
3GeNIe software for Bayesian networks. Available free of charge for academic research and teaching use
at http://bayesfusion.com. c© BayesFusion, 2016.
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Figure 4.6: A table may be unsuitable to visualize a large CPT for both modeling and
maintaining. This exemplary screenshot of the GeNIe software presents the T-state node
with seven multi-valued parents. In total, this table presents more than 59,000 parameters.
The slider at the bottom indicates the full size of the table.
Extended BN functions support model analysis and quantitative validation. GeNIe sup-
ports three BN features for model analyses: strength of connections, sensitivity analysis,
and value of information. The dependencies’ strength is displayed through the edges’ thick-
ness (the thicker an edge, the stronger a connection). The strength of influence is visualized
by a node’s color, using a white to red color scale; with white representing a low and red
a high influence, and gray for no influence. For each state of a selected target node, obser-
vations are presented in a list and ranked by their diagnostic values, starting with the most
influencing observation at the top. Model validation is support by five methods: accuracy,
confusion matrix, ROC, AUC, and calibration curve. These validations are executed at
once, and are presented separate by lists or method-specific Cartesian coordinate systems.
4.7.2 Domain-specific Modeling Tools
BN modeling methods should allow a domain expert to focus on the main intend, to trans-
late domain knowledge into a model. Graph modeling includes the selection of random
variables, arguments, and direct causal dependencies. Modeling probabilities require quan-
tifying the impacts of causal influences.
From BN modeling, probability modeling is the most time-consuming and error-prone
part [121, 157]. It is well known that probability estimates by domain experts are likely
to be biased and not properly calibrated [84]. Usually, experts apply heuristic methods,
which often result in over- and underestimated probabilities. Additionally to these prob-
lems, expert estimates may be positively or negatively influenced by the selected modeling
method.
CPT assessment by domain experts requires appropriate tools to improve the parameter
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Figure 4.7: An example of the approach of van the Gaag et al. [157] for assessing proba-
bilistic parameters.
quality. In case that BN modeling tools present CPTs in tables, parameter assessments
and analyses become difficult for large CPTs. Figure 4.6 presents GeNIe’s representation
of CPTs with an example of a multi-valued node with seven multi-valued parents (the
T-state node from the Larynx model presented in Part II of this thesis). This exemplary
node requires more than 59,000 parameters. In the presented model, it is an individual
extreme case, but it demonstrates that parameter assessment may become both difficult in
identifying causal relations as well as time-consuming simply by the number of desired
parameters.
Researchers studied various methods to achieve unbiased probability estimates, e.g.,
probability scales, frequency formats, and standard reference gamble [54, 63, 117]. Van
the Gaag et al. [157] used probability scales and combined them with an own text fragment
method to provide clinicians with a more intuitive understanding of requested probabilities,
see Figure 4.7. Particularly to assess probabilities, a probability scale is used that is divided
into six unequally spaced segments with numerical and verbal anchors: 0% (almost) im-
possible, 15% improbable, 25% uncertain, 50% fifty-fifty, 75% expected, 85% probable,
and 100% (almost) certain. To provide self-explaining CPT equations, mathematical no-
tations are transcribed to text fragments stated in terms of likelihood. All text fragments
are similarly constructed, for example: “Consider a patient with no tobacco consumption;
no alcohol abuse. How likely is it that laryngeal cancer occurs?” This method is tested
successfully on a subnetwork for patient-specific therapy selection for oesophageal carci-
noma. The subnetwork consists of 40 variables with approximately 1000 parameters. The
variable with the largest CPT required 144 parameters. Finally, the experts were able to
assess about 150 probabilities per hour.
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For graph modeling, only domain-independent methods and tools exist, as presented by
the GeNIe software. Applications demand that a domain expert acquires knowledge about
variables, arguments, indirect dependencies, as well as application-specific functionalities.
Otherwise, the domain expert needs support from a knowledge engineer.
Part II





Patient-specific Bayesian Network in a
Clinical Environment
5.1 Introduction
”If used properly, clinical decision support systems have the potential to change the way
medicine has been taught and practiced.” Berner, 2007.
The ICCAS DP2M project aims to develop a TDSS. A TDSS should assist clinicians,
staff and patients in finding the optimal patient-specific treatment decision. It should be
(1) based on the best available knowledge, (2) highly adopted to a clinic’s situation and
population for a most effective use, and (3) continuously improved with new knowledge
and decision-supporting methods [127]. Probabilistic graphical models, specifically BNs
have the potential for building the basis of a TDSS [12]. A BN-based system can represent
a highly complex decision including all relevant variables, their direct causal dependencies
and influential weights (see Chapter 6) [94, 38]. A BN’s inherent graph structure enables a
transparent and reproducible decision support and allows for expert modeling, model mod-
ification and validation [123, 38].
It is highly recommended to consider the challenges related to a CDSS development and
implementation in advance (see Chapter 3). This section presents, firstly, a therapy decision
workflow in head and neck oncology that considers several workflow steps which could
benefit from a TDSS, secondly, a concepts of a TDSS using generic BNs as an exploration
of MIMMS’s Kernel of Workflow and Knowledge and Decision Management, and thirdly,
a concepts for multi-institutional quality management as an exploration of MIMMS’s Val-
idation.
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5.2 Decisions in an Oncological Therapy Workflow
In oncology, a therapy decision is primarily determined at a tumor board, but during the
treatment workflow a patient situation is discussed multiple times, which also has impacts
on the tumor board’s decision. For example, if a patient disagrees with a tumor board de-
cision, then another potentially sub-optimal therapy must be conducted. Therefore, when-
ever diagnoses or therapies are discussed, determined or conducted, a TDSS should be
utilized. Relevant recommendations from Section 3.3 relate to users (R3.3.3), decision
models (R3.3.4), UIDs (R3.3.5), reasoning (R3.3.7), and ancillary systems (R3.3.8).
Based on Meier’s oncoflow patient treatment workflow (see Subsection 2.3.2), six work-
flow steps are identified that could be supported by a TDSS. The six workflow steps are
presented in Figure 5.1. Considerable recommendations for the specific TDSSs are listed
as well.
At the first step, part of (A) the consultation and examination is the cTNM. A correct
TNM staging must be ensured due to its significant impact on the treatment selection. In
other words, an incorrect TNM staging would result in a sub-optimal treatment with an
impact on a patient’s post-therapeutic quality of life or even survival.
In preparation of the following tumor board, the clinician needs to (B) prepare a tumor
board document with a summary of the patient situation, the cTNM and recommends for
one or more therapy options. The recommendations are based on the patient data and
cTNM, and can include questions due to outstanding issues.
At the tumor board, the multidisciplinary expert team reviews and discusses both the
patient situation and the clinician’s assessment to (C) determine a therapy which is sup-
posed to be the best option. Is the available patient information insufficient for a sound
decision, (1) an additional examination may be required by repeating the workflow from
(A).
Next, determined therapy options are (D) offered and explained to the patient. If the
patient agrees on a recommended therapy option, the treatment is initiated. Otherwise,
(3) the case may be presented again at a tumor board with the updated information of the
patient will. In single cases, a follow-up (2) without a therapy is possible.
For (D) a treatment, the attending clinician determines a patient-specific treatment pro-
cedure, which is based on the tumor board decision and patient data. In some cases, also
an ongoing treatment (e.g.,reevaluation of treatment response after induction chemo, or in
long-term palliative systemic treatment) can require (4) an early tumor board review for
adjustments. Also, at a surgical treatment, the patient situation may have changed since the
tumor board decision, which can either require, in situ treatment adjustments or discarding
the procedure with a tumor board review. From surgical procedure, usually a biopsy is ob-
tained for a pTNM. The pTNM is considered to approve the cTNM or correct it for further
treatment decisions.
After a treatment, (4) a treatment review at the tumor board is mandatory to continue
with a follow-up or an adjuvant treatment. At the follow-up of most head and neck cancers,
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the patient is regularly examined for five years. In case of tumor recurrence or malignan-
cies, (5) the case is presented at the tumor board for further therapies.
In the presented workflow, a TDSS could support each step:
firstly, (A) the diagnosis to determine or verify TNM stagings, see Chapter 9;
secondly, (B) the initial treatment assessment to ensure that the available patient infor-
mation are adequate for sound treatment decisions as well as to represent the recommenda-
tions;
thirdly, (C) the tumor board to interactively and jointly study a patient situation and the
therapy options. Once the best therapy options are determined at the tumor board, a TDSS
could be applied, again, to verify the decisions;
fourthly, (D) the doctor-patient communication by presenting the therapy-relevant infor-
mation in a patient-understandable abstraction in order to study, discuss and adjust therapy
options and their potential outcomes (e.g., avoiding treatment risks or preserving specific
qualities of life);
finally, at (E) the therapy and (F) follow-up by alerting the clinician in dangerous or
changing situation.
At each workflow step, the users and the requested decision scope may vary. The systems
and regulations of a TDSS must be adjusted to each workflow step in order to guarantee an
undisturbed or even facilitated workflow, doctor-patient communication, and advice only
on request or in exceptional situations, at the right time and place for the right persons.
In particular, recommendations to fulfill are 2.3-A3, 2.3-A4, and 2.3-R3 from Subsection
2.3.1; and 3.2-R1.3.3, 3.2-R1.3.4, 3.2-R1.3.7, 3.2-R1.6.4, 3.2-R1.8.1, and 3.2-R1.8.2 from
Section 3.3.
Figure 5.1: Treatment decisions workflow
5.3 Concept of a BN-based TDSS
This section presents a concept for a BN-based TDSS, see Figure 5.2. This concept is con-
sidered to be an exploration of the MIMMS’s Kernel for Knowledge and Decision Man-
agement (see Section 3.4). The concept describes interactions between involved actors and
systems. Actors and systems are based on the recommendations from Section 3.3 Best
Practice in Developing a CDSS. The concept can be adjusted to specific workflow steps
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and, therefore, serve as a basis for a BN-based TDSS development. In fact, based on this
concept we developed modeling and visualizations systems which are presented in the fol-
lowing chapters. The content of this section has been published in [37].
Figure 5.2: Concept of a Bayesian network-based therapy decision support system [37].
This section first describes the concept’s actors and systems and their relation to the
topics of Section 3.3, and second, the interaction.
In this concept, the developers (3.2-R1.1) are described as (a) engineers. Part of the
engineering team are, e.g., the system administrators and knowledge engineers. The mod-
elers (3.2-R1.2) in charge are (b) domain experts only. The model (3.2-R1.4) is specified
to a (c) generic BN therapy model, regardless of an individual BN extension. The reason-
ing (3.2-R1.8) is separated into an instantiation and reasoning mechanism, the (d) engine,
and outputs, the (e) patient-specific Bayesian networks (PSBNs). The BN engine includes
algorithms for instantiation of various BN extensions, and the final BN reasoning. Respon-
sible for engine maintenance are the engineers. A PSBNs is an ordinary BN, similar to a
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MEBN’s SSBN but, again, independent of a specific BN extension. The ancillary systems
(3.2-R1.9), the model unifications (3.2-R1.5), and the legal and ethical issues (3.2-R1.10)
are considered to be provided through and regulated by a (f) MIMMS architecture. How-
ever, in this concept in particular an (g) EHR database is considered, which provides the
required patient data for the BN engine’s PSBN computation. The (h) users (3.2-R1.3)
and the (i) UID (3.2-R1.6) remain the same. Based on the recommendations regarding
the user (3.2-R1.3.11), UID (3.2-R1.6.1-3/7), and reasoning (3.2-R1.8.1), additionally, a (j)
viewpoint method is added. A viewpoint describes a subset of a PSBN’s information.
The engineers (1) integrate and maintain the BN engine and (2) support the domain
experts with the decision models if needed (e.g., when integrating a new BN extension).
Contrary to the engineers, the domain experts (3) model, validate and maintain therapy
decisions, and (4) support the engineers in integrating and maintaining the engine. In this
concept, the domain experts are able to work autonomously using appropriate modeling
tools (see Chapter 8). A user is allowed to (5) select a decision model and patient data to
compute a PSBN. Technically, the user selects the model and data through the (6) inter-
action with a UID. Specifically, the UID (7) forwards the user’s request to the engine by
a program called “Down compiler” [98]. Next, the engine (8+9) requests the repositories
for the user’s desired model and patient data. Then, the model and the patient data are (10)
pushed to the BN engine. From both, the engine (11) instantiates and computes a PSBN.
The PSBN will then be (12) mapped one-to-one to the UID by another special computer
program called “Up compiler” [98]. A UID’s GUI (13) offers different focuses that allow
to (14) adapt the visualization in order to focus on a user’s information of interest. The
underlying PSBN remains the same. A specific UID may vary dependent on the users and
their environment. For interaction in the operating room, a voice interface might be the
best choice, while in a meeting room or tumor board, a GUI may be more appropriate. The
focus varies dependent on a specific user group. For example, a clinician’s focus might
present the patient with regard to the expert’s field of specialization, while a patient’s fo-
cus might highlight different treatment options and their possible consequences related to
risks and quality of life. A set of initial focuses is (15) defined by experts. They can be
(16) adapted by the users according to their preferences. Software agents are integrated in
UIDs being assigned to interpret user queries according to legal restraints (distinguishing
between doctors and patients), and to suggest options for using, editing and extending the
PSBN. For example, the user may wish to change the decision model or modify patient
data to study potential treatment outcomes. For this purpose, the UID is connected to the
MIMMS architecture to (17) request and (18) receive further information regarding, e.g.,
nomenclatures, ontologies and user-specific restraints. A user’s requested PSBN modifi-
cations are, again, transferred to the engine, and based on the modifications, the engine
requests the repositories for new data or directly recomputes the PSBN.
Finally, through the UID, the user is able to save and reload the PSBN.
Based on this concept, the following chapters focuses on (1) the decision models; (2)
their development, validation and maintenance; and (3) the User interfaces with viewpoints.
This thesis takes the required ancillary systems and BN engine for granted. At the DP2M
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project we use oncoflow as the primary EHR (see Subsection 2.3.2), and GeNIe’s SMILE
as the BN engine (see Subsection 4.7.1).
5.4 Concept for Semi-automatic Quality Management of
BN based TDSS
Aiming for a full clinical integration of a BN-based TDSS, a MIMMS-like communication
architecture is required that connects BN-based decision models to the necessary engines
and repositories (e.g., for validation, computing, and visualization) [100]. However, for a
clinical adoption of a TDSS and its long-term maintenance, a model validation and mod-
ification management is essential [12, 59, 100] (3.3-R1.4.11). This section presents and
discusses requirements and a concept of model quality management for adopting and main-
taining clinical BN-based decision models over multiple institutional levels. The content
of this section has been published in [35].
Figure 5.3: Concept for semi-automatic quality management of BN-based TDSS.
A clinical integration of a BN-based TDSS requires an infrastructure and standards
for data communication, model validation and modification, and error and update han-
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dling (3.3-R1.6.2 and 3.3-R1.8.1/5). In detail, frequent model modifications based on new
guideline recommendations as well as adjustments to clinic-specific populations must be
supported (3.3-R1.6.3-4/6 and 3.3-R1.8.3/5). To avoid redundant model updates as well as
uncontrolled strong deviations from guidelines, this approach needs multiple levels of con-
trolling authorities (national and international institutions). The model and data commu-
nication at one institution and between institutions requires a MIMMS-like infrastructure
with model cross-sharing standards (see Sections 3.4 and 11.4; 3.3-R1.8.2). Furthermore,
for modelers, independent model adjustments, standardized formats and procedures need
to be established for patient data and for model development and validation (see Chapter 8).
Finally, a validation and modification report system with modeler notification is essential
for a transparent and reproducible error and update handling.
This section describes a concept for quality management based on the requirements.
The concept is built on 1) the MIMMS architecture and describes 2) the model valida-
tion management over three institutional levels, see Figure 5.3. The lowest institutional
level performs decision support and is responsible for a regular local quality management
(private practice, hospital, etc.). The institutions above are representing superior authori-
ties (e.g., by national and international governmental bodies) with a commission for data
collection and quality control of lower level institutions. In detail, at the lowest level in-
stitution, for a validation and modification, 1) MIMMS provides 3) the decision models as
well as a set of 4) modeling, 5) computing and 6) validation tools and engines. Regularly,
7) a quantitative validation is automatically performed for each BN-based model that is
in 3) the decision model repository using patient cases from 8) a patient dataset reposi-
tory. If the validation results are acceptable, a model’s validation ends with a) a positive
report that is sent to 9) a validation and modification report repository. Otherwise, a) a
negative report including the validation results is sent to the report repository and a task
request is b) pushed further to 10) an expert team. The team consists of domain experts
and knowledge engineers. They c) request the results of the quantitative validation and d)
conduct 11) a validation and modification workflow for identifying model deficiencies and
developing solutions. After a successful modification, e) the corrected model is returned to
3) the model repository. Furthermore, f) a validation and modification report is sent to 9)
the local report repository and to 12) a report repository of B) the next higher institution.
Similar to the previous validation, the 13) expert team of the next higher institution g) re-
quests the information about the validation and modification tasks of the lower institution,
and h) conducts 14) a validation and modification workflow. This validation aims, firstly,
to proof if modifications of the lower institution are acceptable, and secondly, to identify
if modifications are relevant for all of its lower institutions. Therefore, the validation is
performed using, firstly, 8) the dataset and 3) the model from the lower institution, and sec-
ondly, 15) an own patient dataset collected from all of its lower institutions and 16) a more
general model that is based on the larger population. Models of lower institutions are avail-
able through i) interconnected MIMMS architectures, while patient datasets are j) pushed
separately and unidirectionally. After the higher level validation, a report is k) sent to the
own repository, and l) a response is sent to the lower intuition, which informs about correct
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modifications or requires model corrections. Furthermore, if modifications are relevant for
the other institutions, the model modifications are added to the more general model and
forwarded to all lower institutions through the MIMMS connections. Finally, in case that
model modifications are required due to new guideline recommendations (usually released
by B) and C) superior authorities), first, a 17) quantitative validation is performed, and af-
terwards, only if the validation is successful, 13) the expert team 14) modifies the model
and m) and i) forwards the model modifications to lower institutions as described before.
This procedure of next level quality proof and model updating is analogously repeated with
C) higher levels of institutions.
Besides the highly relevant quality management of decision models, this interconnected
MIMMS architectures of low level institutions through the higher level institutions would
improve an overall patient care. A current weakness of this concept are the required inter-
institutional data exchange policies. Taking into account that these boundaries will mainly
disappear, this architecture allows lower level institutions for patient-specific decision sup-
port by requesting models from the patient population. Furthermore, higher level institu-
tions will be able to study and develop model-based medical evidence [100].
Chapter 6
TreLynCa: A Tumor Board Decision
Model for Laryngeal Cancer
6.1 Introduction
To support tumor board decisions, a BN model should consist of all decision-relevant in-
formation (3.3-R1.3.3 and 3.3-R1.4.1/2/3/4). Otherwise, clinicians may loose confidence
in the network’s inferences. Also, a BN model should be easily comprehensible to keep the
decision workflow efficient (3.3-R1.3.1/3 and 3.3-R1.4.6/7).
At the DP2M project, we developed the TreLynCa model, an expert BN model to sup-
port treatment decisions of laryngeal cancer. The University Hospital Leipzig supported
this project by providing domain experts for a teamwork BN modeling (3.3-R1.1.1/2/3 and
3.3-R1.2.1). The teamwork required from both modelers, the clinician and the knowledge
engineer, to acquire a basic understanding of the other’s area of expertise (3.3-R1.2.2).
After three years, TreLynCa consisted of about 1000 variables and more than 1300 depen-
dencies.
This section describes the modelers, the modeling software and tools, the model and
modeling methodologies, and finally the scope of TreLynCa. Applied methodologies re-
garding the model structure and modeling are introduced in Section 4.2 and were extended
to the specific needs of developing multidisciplinary treatment decisions.
6.2 Teamwork and Knowledge Acquisition
Within three years, mainly in teamwork with Dr. med. Matthaeus Stoehr, we constructed
the BN model TreLynCa. He provided the expert knowledge for modeling, while I sup-
ported the clinician in interacting with the modeling software and ensured both a suitable
graph structure and model consistency. Clinicians and medical students from the same
hospital supported the modeling.
Prior to this project, I had a basic understanding of the diagnosis of laryngeal cancer
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from my diploma project. At the beginning of our teamwork, Dr. Stoehr started his spe-
cialist training as an otorhinolaryngologist. The first year, we worked together in full-time
at the project sharing the same office. In this close teamwork, we instructed each other
with basic knowledge about the treatment of laryngeal cancer and Bayesian networks. At-
tending weekly head and neck tumor boards at our university hospital, we both acquired
an advanced understanding of important information and treatment options as well as the
decision-making process by a multidisciplinary expert team. The second year, Dr. Stoehr
started his full-time work at the hospital, therefore, our teamwork decreased to meetings
twice a week for four hours. At the same time, medical students started working at the
project in total for ten hours a week. Finally, in the third year, our teamwork decreased
again to meetings once in two weeks for four hours but the students’ support increased to a
total of 20 hours a week.
To collect the required domain knowledge, Dr. Stoehr studied and collected information
from biomedical literature, domain-specific guidelines and studies as well as retrospective
patient data of the tumor board decisions at our university hospital from 2012 to 2014.
Additionally, we both attended head and neck tumor boards, and met with experienced
clinicians (i.a., clinical oncologists, surgeons, radiotherapists, and immunotherapists) for
discussions and model reviews.
Modeling a graph in teamwork, at each modeling step, I addressed three questions to the
domain expert. First, I asked a question about a desired element to be modeled (identifier,
state and dependencies), second, about a specific information entity. Finally, to ensure the
correct knowledge representation, I converted previous questions and the expert’s answers
into two contrary statements from which she was supposed to select the correct one. Dur-
ing the three years of development, I evaluated the most suitable questions and statements,
from which I developed a modeling technique that enables domain experts to model BN
graphs autonomously (see Section 8.3).
6.3 Software and Tools for Modeling and Validation
For BN graph modeling, we chose the two most extended open access softwares UnBBayes
[21] and GeNIe [50]. We started using UnBBayes, because this software allows modeling
MEBN, which we expected to be necessary for our project. However, for two reasons we
changed the software after the first year. Firstly, for the treatment decision we considered
patient findings over a time period, but the final tumor board decision represents a snapshot
of the specific patient situation. Secondly, UnBBayes became difficult to use with the in-
creasing model extent because of missing basic functionalities (e.g., missing zoom-in/-out,
undo/redo, and a narrow exception handling) and terminated model reasoning when nodes
reached more than 16 parents (using a standard 16 GB RAM computer). In the second
year, we changed to GeNIe, which was more stable in the modeling process and reasoning,
includes most of the necessary functionalities as well as advanced model validation and
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decision analysis tools.
However, since both softwares did not support the function undo/redo, we drafted a graph
using the graph editor software yEd1. Once we were satisfied with a subnetwork in yEd,
we remodeled it in GeNIe. Compared to the difficulties in modeling without a possibility
for undo/redo this ”double modeling” was considerably faster.
For probabilistic modeling, GeNIe was unsuitable for models with large CPTs. GeNIe
displays the CPT as a table, whose size quickly increased and was difficult to read (see
Figure 4.6). For these purposes, we developed a web-tool that simplifies the parameter
elicitation and enables an autonomous expert modeling (see Section 8.4).
Finally, for constructing variable identifiers, we used a SNOMED CT browser2 that
provides a hierarchically-ordered drop-down list of medical terms as well as a search field.
6.4 Model Development
From the teamwork with Dr. Stoehr, I explored a model structure and identifiers that suite
the modeling of large multidisciplinary treatment decisions (3.3-R1.4.9). Furthermore, we
determined the handling of a priori probabilities. Finally, I specified a modeling workflow
based on the model structure, which I applied to a method for guided graph modeling
(presented in more detail in Section 8.3).
6.4.1 Model Structure
To support tumor board decisions, it is necessary to structure a BN graph in a suitable
way that enables the integration of all decision-relevant information (3.3-R1.4.1/2/3/4/10).
Furthermore, the model should be human-readable and consistent to enable a collaborative
modeling (3.3-R1.4.6/7/10). Model consistency relates to the selection of variables and
their uniform labeling as well as dependencies and causalities. Finally, in the future, the
structure should also allow for model extensions and modifications (e.g., for new knowl-
edge based on updated guidelines) with a reasonable effort (3.3-R1.4.12 and 3.3-R1.6.4).
This section presents a graph structure that fulfills the requirements for building a tumor
board decision model. We applied this meta-structure to the TreLnyCa graph, which will
be presented in the following section.
The presented graph structure extends the approach of Diez et al. [49] (see Subsection
4.2.2) by an additional node type describing deterministic decisions. In detail, the structure
consists of four variable types and a set of permitted dependencies. The variables are: per-
sonal data (PD), anomalies (A), examination data (ED), and deterministic decision (DD),
see Figure 6.1. Specifically, variable type DD is observable and is supposed to represent
deterministic decisions, staging systems or activities required [38, 40]. Furthermore, the
1yEd graph editor. Freely available at https://www.yworks.com/products/yed. c© yWorks, 2017.
2SNOMED CT Browser. Free to use at http://browser.ihtsdotools.org. c© SNOMED International, 2017
v1.33.2.
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node type DD reduces the inference effort once the node is observed (d-separation). In
comparison, in Diez’s approach a network’s d-separation is not possible, because indirect
dependencies between any two nodes are always through nodes of the type anomaly, which
are not observable. The dependencies in between Diez’s three node types remain the same,
but directed edges are added pointing to or from the node type DD. Valid parents and chil-
dren of a DD are nodes of the same type and of type A. Nodes of type PD can only be
parents of DDs. Finally, nodes of types A and DD can be root nodes or have parents, while
ED nodes have at least one parent, and PD nodes are always root nodes.
Figure 6.1: Direct dependencies between four variable types: personal data (PD), anoma-
lies (A), examination data (ED), and deterministic decisions (DD).
6.4.2 Modeling Variables and States
Variable identifiers need an organized and standardized style to be intuitively understand-
able and applicable to model extensions with a minimum effort (3.3-R1.4.6/7/9/12 and
3.3-R1.5.3.). Cancer therapy decisions range over multiple domains because metastases
can occur, theoretically, at any body region. Therefore, we decided that variable identifiers
must be unique over all clinical domains and understandable independent of a clinician’s
specialization. Variable states are categorically arranged from low to high risk or grade.
If decision characteristics were clinically described by continuous values, we decided to
itemize these values into discrete ranges. We derived the ranges from clinical practice as
well as statistics where discrete ranges are used for simplification. States’ namings were
usually defined short and in context to their variable identifier they are supposed to be self-
explanatory. Finally, each variable of type ED has always an additional state ”unknown”
for the purpose that an examination result may be qualitatively insufficient. Furthermore,
each variable of type DD has always an additional state absurd for the purpose that combi-
nations of parental states cannot occur in the real world (e.g., if the count of tumor cells is
nonzero, also the size of the largest cell must be nonzero).
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Following the recommendations to use standardized terminology, we started modeling Tre-
LynCa using SNOMED CT for both the variable identifiers and states. However, with an
increasing extent of the model, for practical reasons, we decided to use the terminology
from the clinician’s clinical practice and literature. For an organized identifier composi-
tion and to avoid redundancies I defined rules based on my previous experiences [32] but
specified to our model structure.
However, during the modeling SNOMED CT became unsuitable, since applying SNOMED
CT terms was difficult because of their heterogeneous grade of detail, and by using the
SNOMED CT browser the search for meaningful terms and their combination was time-
consuming. In detail, some terms were not represented at all (e.g., pre-epiglottic tissues)
and others were represented only as a unit or only in combination with more general body
structures (e.g., no finding is combined with examination methods). In the first case, the
clinician defined terms, while in the second case, he was supposed to combine existing
SNOMED CT terms in order to represent them by codes. Combinations of SNOMED CT
terms became unsuitably extensive, which decreased an identifier’s readability. For ex-
ample, a variable that represents a CT examination for identifying a vocal fold infiltration
would have an identifier out of the terms Computed tomography of soft tissues of neck
without contrast and Malignant tumor of vocal cord.
In detail, each identifier is constructed by one or a composition of medical terms. For
each variable type different term classes are allowed. A PD has an identifier that describes
the patient generally (e.g., age and sex). An A has an identifier with information about the
localization, structure and condition. A condition may describe a structure-specific condi-
tion or quantity (e.g., anomaly, size and count). An ED’s identifier is a combination of its
parental A identifier and the representing examination method. Finally, a DD’s identifier
describes locations and procedures.
Therefore, in context of a tumor board decision, for the four variable types, I define the
following rules for identifier composition:
PD: <general information entity>
A: <localization(1)>...<localization(r)><structure(1)>...
<structure(s)><condition(1)>...<condition(t)>
ED: <related A identifier><examination method>
DD: <localization(1)>...<localization(r)><procedure(1)>...<procedure(u)>
with r, s, t and u ≥ 1,∈ N; localization(1) > localization(r), structure(1) > struc-
ture(s), condition(1) > condition(t), and procedure(1) > procedure(u).
A general information entity describes short human-specific and domain-independent in-
formation as, e.g., age and gender. Localization describes body regions from the most
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general to the most specific region. The structures, conditions and procedures are arranged
equivalent to the localization. Examination methods are described short (e.g., by their ac-
cepted abbreviation as CT or MRI). For example, in the TreLynCa model, every variable
identifier that describes a larynx-related characteristic starts with the term Larynx. The
variable representing the CT examination for identifying a vocal fold infiltration has the
identifier Larynx sub-glottis vocal fold infiltration CT.
6.4.3 Modeling Probabilistic Parameters
Once a (sub-)graph is constructed, the model requires probabilistic parameters. In the best
case, the parameters are automatically learned from a large number of patient records. In
case of the TreLynCa model, the appropriate data for learning was not available. Further-
more, even with available patient records, the parameters could not be directly learned
because of the generally missing information for the unobservable node type A as well as
the inappropriate information for the node type ED and DD. Therefore, expert knowledge
was necessary for assessing the parameters.
In detail, the variables of the types A and DD may require either a priori or conditional
parameters. The variables of the type PD can have only a priori parameters, while vari-
ables of the type ED can have only conditional parameters. In case of a priori probabilities,
parameters could reflect specific various populations (e.g., patients, local inhabitants or
humans in general). However, in the first place, the system is supposed to support our clin-
icians in treatment decisions for patients with laryngeal cancer. Therefore, we decided to
reflect the common population of laryngeal cancer patients at our hospital. In case of con-
ditional probabilities, a variable of type A requires probabilities that reflect its occurrence
independent of every real-world inaccuracy. A variable of type ED requires probabilities
that reflect its inaccuracy of the represented examination method, which depends in partic-
ular on the method’s technical inaccuracy regarding the examined body area or structure.
Finally, a variable of type DD requires probabilities that reflect decisions based on exactly
known conditions.
The TreLynCa model consists of a few PDs and DDs, a large number of As, and EDs the
most. Obviously, these conditional parameters could not be directly acquired from patient
records or medical literature. However, we experienced that our clinicians felt comfortable
with assessing the conditional probabilities. In fact, discussing decisions with our clini-
cians, they always argued about explaining patient characteristics independent of specific
examination methods. Discussing patient characteristics in context to examination meth-
ods, they argued about the methods’ reliabilities. Finally, Dr. Stoehr assessed necessary
parameters for a subnetwork using a tool for expert modeling (see Section 8.4). The sub-
network consists of more than 78,000 parameters and is described in the following section.
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6.5 Scope of the TreLynCa Model
The TreLynCa model encodes the tumor board-relevant variables derived from medical
guidelines, biomedical literature, and recommendations from expert meetings. It is an
ordinary BN representing a decision snapshot in the moment of a tumor board.
In the first year, the model was mainly based on the NCCN head and neck guidelines.
From these guidelines, Dr. Stoehr listed decision-relevant information about the disease,
symptoms, examination methods, findings, rankings, classifications, treatment procedures,
and outcomes. The list represented TreLynCa’s initial grade of granularity. Values from the
list were either modeled as states of variables or as variables with Boolean-valued states.
Using the guidelines, clinically acquired continuous values from examinations were de-
scribed in discrete groups and could be simply adopted to the model. Generally, we avoided
modeling fictitious variables and states because the graph was supposed to serve for expert
discussions and be self-explanatory in clinical use. In the second and third year, Dr. Stoehr
and colleagues derived knowledge from additional clinical literature and expert meetings,
and directly integrated this knowledge into the model. In the first year, the model consisted
of about 600 nodes, in the second year the model was extended to about 800 nodes and
after the third year to about 1 000 nodes.
The current stage of the TreLynCa model is presented in Figure 6.2. In the figure,
variables are manually arranged according to clinically related topics and highlighted by
colored rectangles for illustrative purpose only. Variables describe the tumor extension ac-
cording to TNM staging (red, purple, green, and yellow), comorbidities (magenta), genetic
and molecular factors (cyan), therapy options (orange), risk factors (blue), complications
(grey), and quality of life (lime green). In total, the graph consists of 1 020 variables with
1 362 dependencies and 13 parents at most. The CPTs enumerated about 1 380 000 proba-
bilistic parameters, which were only partially assessed. The model varies in its granularity
based on the current medical knowledge. For instance, TNM staging is the most detailed
subnetwork, compared to the genetic and molecular factors being integrated mainly as
placeholders for both expert discussions and future extensions due to research develop-
ments. Furthermore, to each node we attached at least one information source of medical
literature (e.g., references and web links to guidelines or PubMed3 articles).
Furthermore, we selected the TNM model to be the first subnetwork completed by the
necessary parameters and the SNOMED CT terms (described in the following section), val-
idated (see Chapter 7), and evaluated (see Chapter 9). The TNM staging is the most suitable
subnetwork for validation and evaluation because 1) it heavily impacts the patient-specific
treatment decision, 2) is well-defined by medical guidelines making 3) computer modeling
easier and 4) verifiable, and 5) has a sufficient complexity to discover causes for wrong
predictions. The TNM model is presented in Figure 6.3. Again, for illustration purposes
only, in this figure, groups of variables are highlighted by colored rectangles. Groups relate
to one of four topics: describing the primary tumor (purple) with its T-stage (red), N-stage
3PubMed Database. Free to access at https://www.ncbi.nlm.nih.gov/pubmed. c© US National Library of
Medicine, National Institutes of Health, 2013.
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Figure 6.2: TreLynCa: A BN model for treatment decision support of laryngeal cancer.
Variables are manually arranged according to clinically related topics and highlighted by
colored rectangles for illustrative purpose only.
(orange), M-stage (green), and the final T, N, and M staging decisions (pink). In total,
this subnetwork consist of 303 variables with 334 dependencies and 78,875 probabilistic
parameters. The parameters were assessed by Dr. Stoehr in about six hours using our CPT
web-tool (see Section 8.4).
To decrease the number of probabilistic parameters we applied the method noisy OR
gates whenever possible. Obviously, a suitable subnetwork for a noisy OR gate was the M-
state. An M-state is only false (M0) or true (M1) and becomes true by at least one metastasis
independent of specifically affected body regions or organs. The M-state has ten Boolean-
valued parents and its CPT required 2,048 parameters. A less suitable but most efficient
subnetwork for noisy OR gates was the T-state. The T-state has seven parents, but required
58,321 parameters. The T-state’s parents effected it dependent on each other, however,
single parent states and combinations of a parent’s states effected it independently. There-
fore, we applied noisy OR gates partially for specific combinations of parental states (see
Section 8.4). A different approach for decreasing the required parameters is the divorcing
of parents. However, we avoided fictitious variables and, therefore, we accepted divorcing
6.6. Discussion 65
Figure 6.3: The TNM staging subnetwork from the treatment decision model of laryngeal
cancer.
only if it was given inherently. An example of inherently given divorcing are the T-state’s
parents. A T-state is obtained from information about the primary tumor, the vocal fold
function and 24 infiltrations. The variables of the primary tumor and vocal fold function
were parents of the T-state node, while the effects of the 24 infiltrations were summarized
in five representative nodes. The five nodes represent a T staging system’s classification
criteria, which are also applied clinically.
6.6 Discussion
This section summarizes the advantages and disadvantages of the presented BN structure,
identifiers, parameters as well as TreLynCa’s current stage and future intentions.
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6.6.1 TreLynCa’s Development
Modeling effort
Over the course of time, the TryLynCa model became more complex and the distances be-
tween modeling tasks increased. Therefore, one may assume that modeling became more
difficult. However, in comparison to the experts’ decreased available time, the modeling
productivity increased. The increased productivity can be associated with a, finally, con-
sistent modeling.
Model structure
In general, the clinicians and students who participated in TreLynCa’s modeling under-
stood the BN structure, TreLynCa’s composition and the CPTs after a short introduction.
Furthermore, they acknowledged the possibility to distinguish the reliability of examination
methods, and felt comfortable in assessing the required probabilistic parameters.
In detail, applying the BN structure on therapy decision models, Bayesian’s powerful d-
separation is more rare compared to a model where observed examinations can d-separate
the model. On the other hand, a DD’s number of parents is reduced to representative As,
an ED can be added, modified or removed independent of the remaining network, and the
model is human-readable and clinically oriented.
Identifiers
The identifier rules fulfilled both the desired purpose of avoiding redundancies and the
model understanding at expert meetings. Nevertheless, we recognized SNOMED CT’s
high impact for the purpose of sharing models and, especially, when developing a system
for collaborative modeling. The intention was to 1) connect the system with a SNOMED
CT database, 2) use only the codes in the system’s background, but 3) display the terms to
the user. This approach would enable displaying a model in all supported languages.
Parameters
The parameter modeling of the TNM model was promising and will be extended to the
remaining subnetworks (see Chapter 7). Currently, the model’s parameters were mainly
assessed by Dr. Stoehr and a few medical students. To study the quality of expert parame-
ters regarding the specific model structure, larger studies will be needed involving multiple
experts from various disciplines. In the future, with an increasing data collection, Tre-
LynCa’s parameters could be partially learned, but appropriate formulas will be required to
obtain probabilities regarding the specific model structure.
Finally, TreLynCa’s increasing size of the graph and the CPTs required appropriate mod-
eling tools. From my experiences of supporting expert modeling as a knowledge engineer,
I derived a novel method for guided graph modeling and extended an existing method for
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probabilistic parameters. Both methods are presented in the following chapter. During my
thesis, only the method for modeling parameters could be fully implemented as a web tool
and applied to the TNM staging subnetwork. However, currently we are implementing a
graph modeling system and, therefore, we started to rename TreLynCa’s subnetworks by
using the SNOMED CT terminology.
6.6.2 TreLynCa’s Applicability
Impact of the TreLynCa graph and the TNM model
The graph of the TreLynCa model itself has the potential to support clinician training as
well as treatment decisions. Once medical students or clinician trainees understood the
specific graph structure (see Subsection 6.4.1) they were able to ”read” and explain the
TreLynCa graph. From one medical student at the DP2M project, we received a promis-
ing feedback of an easy laryngeal cancer exam having in mind a general overview of
TreLynCa’s graph. Therefore, the web platform for graph modeling (see Section 8.3) is
supposed to serve as learning platform as well. Furthermore, the TreLynCa graph could
support treatment decisions by highlighting observed nodes. Hence, the graph could be
displayed at tumor boards in order to 1) give clinicians an overview of available patient
information, which would 2) give them more certainty in uncertain patient cases, and 3)
detect incomplete or missing patient data of required examination procedures.
In the near future, when large and qualitatively appropriate dataset will be available,
human-readable decision models with the presented graph structure could be learned au-
tomatically. For this purpose, the validated TNM model may suite as a gold-standard to
study machine learning algorithms. For instance, from this TNM model large datasets can
be automatically generated, in different degrees of quality. Based on the datasets machine
algorithms will learn models, which should achieve the TNM model.
Applicability to other domains
A cancer treatment decisions should be fully represented by all treatment decision relevant
patient and treatment characteristics. The TreLynCa model is limited to a treatment de-
cision of laryngeal cancer. Other cancer decisions will require new modeling. From the
TreLynCa model, only single nodes can be reused for another decisions. Specifically, Tre-
LynCa provides deep explanations about laryngeal primary tumors, the tumor extensions,
laryngeal treatment options, and potential outcomes of laryngeal cancer treatment. Char-
acteristics regarding other organs (e.g., comorbidities and metastasis) are represented more
abstract (without structural details and only Boolean valued). Therefore, a cancer treatment
model of another organ would require more details about the specific organ and only gen-
eral, Boolean valued information about the laryngeal condition.
Obviously, an expert model can only be the same precise as the modeling experts. There-
fore, often the question occurs: ”Why would the modelers TDSS need the system?” In
68 Chapter 6. TreLynCa: A Tumor Board Decision Model for Laryngeal Cancer
fact, if the model is created by the best experts, these experts would not necessarily need
the TDSS for their domain specific decisions. However, 1) multiple disciplines can be in-
tegrated into one model, 2) these experts are not always available, 3) decision condition
at research are more relaxed compared to clinical practice, and 4) clinics exist that treat
patient cases of the same complexity but less frequent with less experiences.
Adjustability
Applying the graph structure, nodes of the type examination data require fewer modifi-
cation effort compared to the remaining node types. Clinically, it could be expected that
examination methods will change more frequent than fundamental knowledge of patient
data, anomalies, and deterministic decisions. However, the TNM staging system for head
and neck cancer is annually updated to reflect new evidence. The most recent update com-
prises some major changes of the lymph node staging including new states as well as ad-
ditional influences [2]. Still, such an update can easily be implemented. It requires only
small adaptations of the BN TNM model, e.g., adding, modifying and removing variables,





A reliable model validation is crucial for the model’s corrections and, finally, clinical accep-
tance (3.3-R1.4.11). Similar to modeling, the appropriate data is often limited or unavail-
able. For an extensive model with only a small dataset, a reliable quantitative validation is
impossible, and a complete qualitative validation is time-consuming and can effect an over-
fitting. However, the quantitative validation, even for small datasets, allows both providing
an overall understanding of the model behavior as well as identifying severe predictions.
To interpret the issues of wrong prediction a qualitative validation is required.
Supported by Dr. Stoehr, I developed a validation and modification workflow. At the work-
flow, experts iteratively apply a quantitative validation to support a subsequent qualitative
validation. To decrease the risk of overfitting, qualitative validations and modifications are
limited to severe predictions from a quantitative validation. The validation and modifica-
tion workflow was applied to TreLynCa’s TNM model.
This chapter is divided into seven sections: first, describing severe levels of incorrect pre-
dictions; second, presenting the validation and modification workflow; third, introducing a
study set-up using the TNM model; in the following three sections, describing three steps
of the workflow that were applied on the TNM model; and finally, a discussion. The content
of this chapter has been published in [38].
7.2 Prediction in a Clinical Treatment Decision Context
A prediction’s acceptance depends on the decision context. For example, a diagnostic pre-
diction of cancer could rise an alarm if its probability reaches as little as 0.1. However,
at the end, one diagnosis with high confidence would be desired. For therapy decision
support, high confidence distributed through the second or third most probable predictions
would be acceptable, since usually more than one therapy option is applicable.
For the validation, I consider accepting a node’s w most probable state (with w ∈ {second;
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third}), as well as setting a probability threshold. I applied a probability threshold to value
if a prediction is acceptable being the w most probable state. The threshold specifies an
acceptable maximum distance d of a prediction’s probability to the probability of the cur-
rently most probable state (with d ∈ R).
The following list describes terms of high confidence, uncertainty, acceptable, unaccept-
able, and critical as these terms are used in the next sections:
• high confidence: a state has a high probability compared to the remaining
states.
• uncertain: a state has a probability close to another state.
• acceptable prediction: a predicted state is one of the w most probable states,
and the distance of its probability compared to the probability of the most
probable state is maximum d.
• unacceptable prediction: a predicted state is not one of the w most probable
states, or the distance of its probability compared to the probability of the
most probable state is more than d.
• misguiding state: an incorrect value is the most probable state with a high
confidence. In clinical practice, this high confidence would exclude the con-
sideration of other options.
7.3 Validation and Modification Workflow
The process of model validation and modification, consists of three steps, presented in
Figure 7.1: from the (1) quantitative validation through the (2) qualitative validation to
the (3) modification, and back through the (2) qualitative validation to the (1) quantitative
validation.
The quantitative validation is based on all available patient cases to quickly overview
the model quality, and directly identify model deficiencies. One ranks identified model
deficiencies from misguiding to acceptable predictions. Beginning with the misguiding
predictions, a subset is selected from the patient cases that relates to exactly one of the
identified model deficiencies. Based on the patient case subset, the qualitative validation is
applied to study the model behavior and identify sources for the model’s incorrect predic-
tions. Sources of errors can occur in both the model and the data. Given identified error
sources, modifications are performed to solve the problem with minimum required effort
to avoid bias influences. Modifications are reviewed by repeating the qualitative validation.
With a positive model behavior for the specific patient case subset, next, the quantitative
validation is repeated with all patient cases to test if the modifications develop other in-
correct predictions. If also the quantitative validation is successful and our modifications
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are not developing new avoidable deficiencies, the validation is continued for the remain-
ing model deficiencies discovered earlier. Otherwise, in case of wrong model behavior at
the qualitative validation or identified new avoidable deficiencies at the quantitative vali-
dation, previous validation steps in order of the workflow cycle must be repeated until the
problem is solved. Unavoidable deficiencies may appear after modifications, which existed
before but could not be recognized given previous model deficiencies. In case of a new
unavoidable deficiency, the new deficiency will be processed in a separate validation and
modification cycle, and the current validation cycle is continued.
For validating and modifying a model, a selection of applied methods is necessary. The
methods used for the TNM staging are presented in Figure 7.1. Quantitative validation
required three of five methods: accuracy, ROC, and the confusion matrix. Qualitative
validation included testing the model behavior on patient records, followed by studying
a single node or a sub-network in more detail. First modified are patient data, then the
graph structure and finally, the CPT parameters. More details about specific intentions of
selecting and ordering methods are described in the following sections.
Figure 7.1: Validation and modification cycle.
7.4 TNM Model and Study Set-up
The validation and modification workflow has been applied to the TNM staging subnetwork
(see Section 6.5), with a set of 66 patient records.
Retrospectively from 2013, we acquired a complete dataset of 66 patient records describing
the patients’ TNM stagings. Each patient record provides from 36 to 154 information
entities, with an average of 78 information entities.
72 Chapter 7. Model Validation
The TNM model validation was preformed with Dr. Stoehr. For quantitative and qualitative
validation, we used the GeNIe software. To decrease the required validation time, we
focused mainly on the decision nodes’ T, N, M stage. The domain expert valued the model
behavior and validation results, and recommended modifications. I operated with GeNIe,
interpreted results from quantitative validation and ensured the correct model structure with
modifications. In total, the presented validation required two intensive weeks of team work.
7.5 Quantitative Validation
For the quantitative validation, initially, we used all five validation methods, and experi-
enced the need of only three during the validation. I present the workflow using all five
methods, and explain why two of them are dispensable. All methods were executed auto-
matically using the GeNIe software. We used the collected 66 patient records and selected
the three target nodes: T, N, M stage. It is to note that the number of records for individual
states was unequally distributed. For only one state per target node, we had more than 25
records, see M0, N0 and T4a. For the other states, we had on average seven records, for
the states T0, Tis and N2a we had no records.
7.5.1 Accuracy
State Probabilities Ratio State Probabilities Ratio
T+N+M 0.7626 151/196
T-state 0.4697 31/66 N-state 0.8182 54/66
T0 — 0/0 N0 0.9231 36/39
Tis — 0/0 N1 0.625 5/8
T1 0 0/3 N2a — 0/9
T1a 0.2857 2/7 N2b 0.6667 6/9
T1b — 0/0 N2c 0.875 7/8
T2 0.5 6/12 N3 0 0/2
T3 0.3529 6/17
T4a 0.6154 16/26 M-state 1 66/66
T4b 1 1/1 M0 1 60/60
absurd — 0/0 M1 1 6/6
Table 7.1: The accuracy of the TNM model based on 66 patient cases.
The TNM model accuracy was measured in three variants, firstly, considering only cor-
rect answers with highest probabilities, secondly, considering also correct answers in the
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second and third best predictions, and thirdly, accepting these second and third best predic-
tions only with a maximum distance threshold. Using the GeNIe software, we calculated
the accuracy for each state of the three target nodes, T, N and M-state, see Table 7.1. From
the states’ accuracy, the software added up a total accuracy for each target node, and one
accuracy for all target nodes. Ratios were denoted in both a percentage and a number.
However, only the most probable state predictions counted; therefore, the second and third
best predictions as well as the distance were calculated separately. The total accuracy of
the three nodes was 76.26% (151/198). In more detail, we see from the 66 records, each
with an T, N, and M-state, that the M-state always responded correct, the N-state responded
with 81.82% (54/66) and the T-state responded worst with 46.97% (31/66).
Additionally, we recalculated the accuracies accepting also the second and third best an-
swers. At first, we focused on the T-state, since its accuracy was the worse. Considering
the second best answers, the accuracy increased to 60.61% (40/66); considering also the
third best answer, the accuracy increased again to 71.21 (47/66), with 16 more accepted
records compared to the initial accuracy.
At the first validation step, we studied the 16 records in more detail by interacting
directly with GeNIe’s GUI. We aimed for identifying acceptable thresholds. We valued the
predictions as acceptable and unacceptable in context of a clinical application. From this
study, we determined a prediction as acceptable 1) being at least the second best answer
with 2) a probability distance of maximum 32% compared to the probability of the best
answer. Therefore, all seven third best answers were at least unacceptable. Three of the
nine second best answers were misguiding. Based on the new thresholds for acceptable
predictions, the accuracy was 56.06% (37/66). The maximum distance threshold of 32%
was determined from the arithmetic mean of two probabilities: one probability was from
the best unaccepted prediction and the other one was from the worst accepted prediction.
The same thresholds were used for the following workflow cycles.
7.5.2 ROC
From the accuracy, we focused on studying the ROC curves of the T-states. For each state,
the curve is calculated and plotted separately. Figure 7.2 presents the resulting ROC curves
of the T-states, except for the states without records. For illustrative reasons, this figure
summarizes the curves in one image. Searching for the worst ROC curves, they intuitively
pointed us at the states in the order of T1, T3, T2, T4a, T1a, and T4b.
However, studying the curves in detail, all curves have a very similar pattern. T3 has the
lowest AUC and is the only curve starting with a horizontal line, which indicates a worse
specificity. T1 looks worse because of the low number of available records. Surprisingly,
T1a has a strong curve but the second worst accuracy with 0.29.
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Figure 7.2: The ROC and AUC of the T states T1, T1a, T2, T3, T4a, and T4b at the first
validation cycle. Screenshot from GeNIe is modified to display the curves at once.
7.5.3 Confusion Matrix
Typically, we started studying the confusion matrix from the worst ROC curve, which was
T3 state. However, the confusion matrix gave us an opportunity to expose ROC curve pro-
gressions. Studying T1a and T3 at the confusion matrix explained the initially unexpected
curve progressions. Incorrect predictions of T3 were distributed through T2, T4a, and T4b.
In contrast, an incorrect T1a was always predicted as T2. Similar extensive distribution of
incorrect predictions could be exposed at the states T2 and T4a. Therefore, we assumed
correcting that first the T2 state’s issues would also correct the incorrect predictions of T1a.
Finally, the T1 state had a similar AUC to T2 and T3, however, with a different pattern of
predictions; it was never predicted correctly, but incorrect predictions were distributed to
only two other states.
Therefore, in spite of the accuracies, further studies were focused in order of the T3, T2,
T1, T4a, and T1a state.
Additionally to the accuracy and ROC curves, the confusion matrix led to a better un-
derstanding of the incorrect predictions. In fact, one could start the quantitative validation
directly from the confusion matrix. However, from our experiences, using also the other
two methods accelerated the validation workflow by pointing the expert at the relevant
nodes and states.
The three ordinary methods were used to identify unacceptable predictions. However,
because the methods do not consider probabilities, only the extended accuracy method with
the combined thresholds of considering the second best answer and a maximum probability
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Figure 7.3: The confusion matrix presents correct and incorrect predictions of particular
T-states. The Vertical axis represents the state from patient data against the most probable
state in the horizontal axis.
distance could indicate states with misguiding predictions.
7.5.4 Calibration Curve
Initially, we used the calibration curve, but it could not reasonably support the validation.
At all, this method was working well for the states T3 and T4a, which have a comparatively
large number of records.
However, we selected two exemplary calibration curves aggregated in Figure 7.4 to present
and discuss a calibration increase and its impact on clinical use. The red curve represents
the T4a based on the first TNM model and initial patient data sets. This curve exhibits
many ups and downs. The green curve also represents T4a, but with updated patient data
and modified TNM model (see Section 7.6.1). In general, the comparison of both curves
indicates an increased calibration after modifications, which the green curve reflected be-
ing more smooth and straight. In detail, for the small probabilities, the overestimation
increased, but the underestimations disappeared. The higher the probability the more pre-
cise the model became. Furthermore, from the green curve (T4a), we derived a probability
threshold of 70%.
7.6 Qualitative Validation
While a quantitative validation points at states with unacceptable and misguiding predic-
tions, the qualitative validation allows for identifying the specific incorrect predictions and
their causes. One should start the qualitative validation from the misguiding predictions,
because model modifications may also influence the classification of the remaining TNM
states.
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Figure 7.4: The calibration curve of the state T4a from T-state based on first TNM model
with initial patient data.
7.6.1 Patient Record-based Model Validation
For the study of patient records, we first selected a subset of the records with an equal
value. Following the order determined at the confusion matrix, we started with all T3
stage records. Then, we loaded each record one by one into the model and analyzed the
predictions and influences. In cases of incorrect model predictions, the domain expert
studied the graph for finding the relevant issues. Specifically, the domain expert first studied
the results of GeNIe’s advanced BN features, and secondly, based on these results, he
went through the graph structure and studied the model predictions and observations. We
repeated this study for every patient record. Finally, the study of patient records enabled
identifying deficiencies in the patient records.
7.6.2 Subnetwork Validation
In the subnetwork study, we interacted with a node simulating observations in the node’s
Markov blankets. Specifically, we started studying the network with the T-state node by
simulating observations in its Markov blanket, and extended the study to Markov blankets
of the neighboring nodes with incorrect influences. Finally, we also studied the states
without representative patient records, e.g., T0, Tis and T1b from T-state. This subnetwork
study allowed identifying deficiencies regarding the model structure and CPTs.
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7.7 Results and Modifications
From the validation, we observed four problems of incorrect model predictions: (P1) in-
correct data, (P2) incomplete patient data, (P3) outvoting relevant observations, and (P4)
incorrect model. We decided to solve one problem at the time and test a problem’s influence
on the model predictions. Therefore, we solved the four problems by four modifications:
(M1) re-staging the patients, (M2) including negative findings, (M3) adding fuzzy values,
and (M4) modifying the model. Table 7.2 shows the accuracies of the T, N, and M states
and the total accuracy before and after the modifications. Finally, we present probabilities
from T-states predictions for analyzing the predictions’ certainty, see Figure 7.5.
Initially, the model accuracy based on the 66 patient cases was 76%. The patient record-
based model study enabled to identify the first three problems for incorrect predictions.
First, the expert (P1) identified 28 incorrect T, N or M stagings in the patient data. Using
retrospective data, the reasons for the mismatches were incomprehensible. The experts as-
sumed that information may have been lost, was not updated after new examinations, or
possibly of a wrong TNM staging. Finally, the clinician confirmed, after (M1) re-staging
given the available findings, that the model inferred the TNM stages in all 28 cases cor-











tion (M1 to M4)
T-state 0.47 0.74 0.77 0.91 1.0
N-state 0.82 0.94 0.94 1.0 1.0
M-state 1.0 1.0 1.0 1.0 1.0
Total 0.76 0.89 0.9 0.97 1.0
Table 7.2: Accuracies of the T, N and M states and in total, before and after the modifica-
tions of M1 to M4.
Problem P2 was caused by the fact that, in general, records consist only of positive
findings and unexpected negative findings. Knowing the performed examination methods
and examined body areas, the clinician derived, as it is typically done in practice, the ad-
ditional negative findings. Without these negative findings, the inference is performed on
the CPTs, which may not fit to the specific patient. We (M2) added the derived informa-
tion to the patient records, which corrected 8% of the patient cases. However, the overall
accuracy increased only by 1% (see Table 7.2), because the modification M2 also lead to
problem P3 which impaired previously correct predictions. Problem P3 was an outvoting
of results from reliable examination methods by a larger number of incorrect results from
less reliable examination methods. Using GeNIe, the clinician was able to (M3) decrease
the influence of some observations by fuzzy values, which increased the accuracy by 7%
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to a total of 97%.
Additionally to the patient record study, the sub-network study discovered problem P4:
a problem with the model detail. A variable was missing, therefore, we (M4) added one
node and adjusted dependencies as well as edited affected CPT parameters of the new node
and its children. In Figure 6.2, the added node is highlighted with a circle. Finally, the total
accuracy increased to 100%, the AUC of each state was at least 98%.
Figure 7.5: A plot of the T-states: probabilities inferred by the TNM model against the
number of patient information.
For a TDSS, besides the high model accuracy, also a high prediction confidence is
desired.
The T-state required the most modification effort, therefore, we selected this variable to
present the predictions’ probability values after the last modification. Figure 7.5 shows
a plot of T-state predictions from each patient record. In this 3-dimensional graph, T-
states are plotted against the amount of patient information and calculated probability. The
probabilities reached from 36% to 97%, with an average of 71%. In general, the model
predicted higher T-states with more confidence. The amount of patient information was
not decisive compared to the prediction confidence and T-state.
7.8. Discussion and Conclusion 79
7.8 Discussion and Conclusion
This chapter describes several critically important methodologies for validating the design
and structure of a TDSS based on a comprehensive BN. The utilized validation methods
are well known in the machine learning community for validating models and supporting
their adjustment. For both, validation and adjustment, enough test data should be made
available. However, in the quantitative validation, it could be shown that even with a small
set of patient records issues can be discovered that would be faced in clinical practice, e.g.,
the problem of unmentioned negative findings.
In general, for expert treatment models, the workflow described in Section 7.3 is a valu-
able procedure to identify issues and find solutions. Quantitative validation provides both
an overview of model quality and details about wrongly predicted states. In turn, a qual-
itative validation enables to find causes of incorrect predictions as well as corresponding
solutions. The presented validation effort is related to the model complexity. Multidisci-
plinary decision models of a similarly large grade of detail will need the same validation
effort independent of the represented domain. For less complex models, the validation cy-
cle is the same, but may be simplified by using fewer methods at the qualitative validation,
and correcting more issues in the same cycle. The validation workflow based on patient
records and on sub-networks is always needed, but may be differently focused. Simpler
models may have more patient records available and need fewer sub-network studies.
The validation of multidisciplinary treatment models poses new challenges in data col-
lection, modeling and validation. These challenges should be tackled first with a clear
decision as, e.g., the TNM staging, which is accurately defined and well-founded. The se-
lection of variables, setting dependencies between these variables, and also the CPT were
comparatively simple, and therefore, the model was achieved with a high accuracy. This
simpler sub-network helped to identify some basic problems with modeling and validation
(M1 to M4), and should precede the validation of the more comprehensive laryngeal cancer
model.
The results are promising for the clinical integration of the TNM sub-network, and for
further validations of the remaining model. In case of correct model and patient data, the
uncertainty in predictions is an important feedback for clinicians. The model’s uncertainty
may be caused by missing relevant examinations and unusual patient cases. In treatment
decisions, it is common that more than one treatment option is possible. While complete
certainty is often unachievable in clinical decision-making, a BN provides the clinician
with more certainty about the remaining uncertainty. We encourage expert validation but
also point out the need of collaborative work between clinician and computer scientist to
overcome the intensive validation time. The computer scientist was required for activities
which, in principle, could be completely replaced by a modeling tool that is more adapted
to clinicians’ understanding. These activities include: 1) managing the software, 2) inter-
preting the quantitative validation results, and 3) ensuring the correct model structure with
modifications.
Future developments should be on tools to support both BN modeling and validation
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[36]. A first successfully developed tool is for the assessment of conditional probabilities
[33]. It is important that a validation tool follows the presented validation workflow and
includes the validation methods in an abstract way that is adapted to clinicians’ intuitive
understanding.
Chapter 8
Tools for Guided BN Modeling
8.1 Introduction
Tools are required that guide experts in autonomous BN modeling and validation (M&V).
They could safe modelers’ time and costs, allow for uniform models, and improve team-
work between domain experts.
BN graph modeling is challenging regarding 1) the variability of knowledge representation
and 2) the required interaction with complex modeling tools. Clinical domain experts need
either training in BN knowledge representation and tool usage, or assistance by a knowl-
edge engineer (see Sections 4.2 and 4.7.1). However, the resulting models represent the
modelers’ understanding and, therefore, are usually incompatible with other’s models. For
modeling CPTs, Van der Gaag et al. [157] developed a paper-based method that allows
domain experts to assess the required parameters autonomously (see Section 4.3.2). How-
ever, due to sizable CPTs, this method may become practically exhausting, because one
parameter’s elicitation takes about 2.5 minutes. For example, the TNM model has over
77,000 parameters and with this method an expert would require more than 3,200 hours,
i.e., almost one year of work with eight hours a day.
Nevertheless supporting tools, such as Van der Gaag’s approach, should transform the
necessary M&V tasks to a domain-specific design (3.3-R1.6.2) [98]. They could provide
experts’ understanding and enable graph theoretic and autonomous modeling. Furthermore,
to enable compatible models (3.3-R1.6.4), modeling tools should guide experts through
the procedures in a standardized manner regarding the model structure, representation and
granularity. Finally, tools implemented on an open platform could be a breakthrough for
collaborative modeling.
Based on Van der Gaag’s approach, I present a web tool concept for guided graph and
probabilistic modeling as well as model validation. From this concept, I developed a guided
graph modeling method, and extended Van der Gaag’s method for more sizable models.
We evaluated both methods in user studies. For the studies, we selected two exemplary
diagnoses. Finally, the method for probabilistic modeling has been implemented and was
also applied at the TNM model (see Section 6.5). The method for graph modeling is in
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development and the method for autonomous validation is described only conceptually.
8.2 Concept for Guided Modeling and Validation
This Section presents requirements and a resulting concept for a system to support guided
M&V in the clinical domain. Requirements were collected from my teamwork experiences
with clinicians presented in Section 6.2, as well as modeling recommendations from the
Sections 3.3, 4.2 and 4.7.2. The content of this section has been published in [36].
8.2.1 Requirements for an Autonomous Expert Modeling and Valida-
tion
M&V are complex tasks, which should be adapted to the domain experts’ understanding
as well as to their lifestyle. Domain experts should be enabled autonomous M&V at any
workplace and any time, with the possibility for interruptions. The decision modeling,
model content and model validation need to be comprehensible and verifiable.
In detail, a major goal of the guiding tools is an autonomous, regulated and verifiable
expert M&V.
Autonomous modeling by domain experts is supposed to make the usually required
knowledge engineers dispensable in order to 1) save costs, 2) reduce non-expert influences
and 3) enable M&V at any time. Costs can be saved of at least one engineer by means
of the time for domain-specific training as well as M&V (3.3-R1.2.2). Knowledge en-
gineers transform domain experts’ knowledge into a BN-conform structure which can be
influenced by the knowledge engineers’ personal understanding and, therefore, should be
inhibited. Furthermore, teamwork tasks are difficult to schedule with full-time clinicians.
Obviously, after long and busy working hours, an expert will have a low concentration.
Meetings during the working hours are often interrupted by clinical requests or emergen-
cies. Modeling interruptions require an expert’s repeated modeling orientation, which is
unfavorable right before finishing a modeling step.
Regulated model and validation procedures are supposed to guarantee that BN models
are 1) Bayesian theory conform, 2) mutually compatible, 3) human-readable, and 4) repre-
senting the modelers’ desires. For an autonomous M&V, tools need to support every task
that is usually required from the knowledge engineer. The tasks span from approving a
model’s correctness (regarding the model structure and variable selection, see Chapter 6)
to the interpretation of validation results (regarding the quantitative validation, see Chapter
7). Tools provide information about the expected time for completing a modeling step,
which may motivate the expert to finish it before interruption.
Finally, to support collaborative modeling, modification and validation, tools will re-
quire a comprehensible and verifiable documentation. Therefore, modeling decisions and
utilized medical evidences should be accessible through individual nodes or subnetworks.
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To summarize, recommendations for the development of guided M&V tools are:
Requirements for modeling tools
8.2-MR1: Ensure a model structure according to the definitions in Chapter 6.
8.2-VR2: Ensure model modifications that reconcile with the remaining model.
8.2-MR3: Transform M&V tasks into a domain-specific design.
8.2-MR4: Enable modeling without a required BN understanding.
8.2-MR5: Enable attaching of utilized evidences.
8.2-MR6: Enable notes about modeling decisions.
8.2-MR7: Enable documentation about modeling decisions and procedures.
8.2-MR8: Enable location-independent modeling.
8.2-MR9: Enable time-independent modeling.
8.2-MR10: Enable modeling interruption.
8.2-MR11: Provide an overview of the actual modeling status with information about
the expected modeling time.
8.2-MR12: Provide a simple user interface.
Requirements for validation tools
8.2-VR1: Provide a validation process due to the validation cycle in Chapter 7.
8.2-VR2: Enable notes for validation and modification details.
8.2-VR3: Enable model modifications that reconcile with the remaining model.
8.2-VR4: Provide an overview of the network to be validated.
8.2-VR5: Provide information of modeling decisions.
8.2.2 Concept of a Web-based Expert Modeling System
A concept for guided M&V, presented in Figure 8.1, proposes an expert system, which aims
at guiding experts through the individual M&V procedures in an intuitive and regulated
manner. The basic idea for the guided M&V is to transform BN M&V tasks into natural
language forms. The system combines three tools: 1) a graph modeling tool (GMT), 2) a
CPT modeling tool (CMT), and 3) a model validation tool (MVT). The tools can be used
separate, but are interconnected to be used together in one workflow.
The GMT supports building and modifying decision graphs. Based on a decision graph,
the CMT supports the assessment and modification of CPTs. Finally, the MVT supports
validating and maintenance of both the graphical and probabilistic model. The system is
meant to be a web platform, which enables collaborative M&V. M&V tasks require access
to repositories and an inference engine. Repositories should provide the decision models
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Figure 8.1: Concept of an expert modeling system consisting of three tools for autonomous
M&V [36]. The system is connected to ancillary systems and engines through a MIMMS-
like architecture.
and PSBNs as well as medical literature, standards, patient data, and test data. Medical
literature (e.g., with treatment guidelines and studies) and standards (e.g., medical termi-
nologies) are necessary in order to provide consistent and comprehensible models as well
as inhibit redundancies. To tests models during the M&V procedures, the inference engine
interactively infers and updates PSBNs using the patient and test database. According to
this architecture (except the PSBN), all system components communicate bidirectionally
through a MIMMS.
8.3 Graph Modeling Tool
A GMT is supposed to enable domain experts autonomous graph modeling. For this pur-
pose, I developed a novel modeling technique, which comprises three main features: a
conditional form, an information pool, and a graph representation. The conditional form is
the key modeling component and facilitates a structured knowledge acquisition. The infor-
mation pool provides necessary information entities for the modeling (e.g., from nomencla-
tures and ontologies). The graph is automatically built as a background task and represents
a current stage of the model development. This modeling technique addresses the model
structure, the modeling rules and recommendations, and the teamwork experiences pre-
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sented in Chapter 6. This section presents, first, a conceptual framework of a GMT based
on the modeling technique, and second, the technique in detail with an example of model-
ing the diagnose middle ear infection (MEI). With the same example of MEI, the technique
was tested by two domain experts. The content of this section has been published in [39].
8.3.1 Conceptual Framework of a Graph Modeling Tool
A conceptual framework of a GMT is presented in Figure 8.2. The tool is structured in six
fields presenting 1) a conditional form, 2) supplementary information, 3) an information
pool, 4) a modeling-specific graph view, 5) a graph overall view, 6) and a list of modeled
variables.
Figure 8.2: Conceptual framework of a graph modeling tool [36].
1) The conditional form consists of predefined questions and statements, which were
evaluated in the course of the teamwork presented in Section 6.2. Answering a question
or selecting a statement, the system automatically creates a new or adjusts an existing BN
model.
2) The field for supplementary information provides information (e.g., about the user
interface, the modeling and the model) and allows for attaching notes to selected graph
elements (e.g., references to guidelines and modeling decisions).
3) Questions about identifiers may require a searching, selecting or creating of med-
ical terms. Therefore, the information pool is connected to the SNOMED CT database.
SNOMED CT provides an ontology of medical terms and synonyms, which supports the
user in finding the correct terms in a desired grade of detail. In case a desired term does
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not exist in the nomenclature, the user is able to define a new term. The new term is saved
separate from the SNOMED CT database, but also with a unique identification code. The
GMT saves SNOMED CT codes in the model, but displays the specific terms at the graph.
This enables displaying a graph in all SNOMED CT-supported languages. In case an iden-
tifier is too long to be fully displayed, the GMT displays the terms’ acronyms or shorter
synonyms.
4) The graph is represented at the modeling-specific graph view and the overall graph
view. The modeling-specific graph view displays only a section of the graph, which is
focused on the currently modeled nodes or dependencies. This graph view displays the
nodes with their identifiers and states, and allows selecting single nodes to provide node-
specific details in the field for supplementary information.
5) The overall graph view displays less details but provides an overview of the entire
graph. Furthermore, it highlights the focused graph section of the modeling-specific graph
view by a frame. The user can move this frame to change the focused graph section and
select another node or dependency to be modeled next.
6) Finally, the list of modeled variables gives an overview of its content and allows
selecting a variable to focus it at the modeling-specific graph view.
8.3.2 Guided Graph Modeling
The model creation usually starts from a desired decision and extends to the decision’s
causes and effects. This section first introduces the modeling workflow steps and then
illustrates the workflow with an example of MEI. Compared to a treatment decision of
laryngeal cancer, the diagnosis of MEI is less complex and requires only basic medical
knowledge. I tested this method with one clinician and one student using the same exam-
ple of MEI. At this development stage, the approach is paper-based. Therefore, I supported
both tests by imitating the guiding system.
The modeling technique is described by the clinical example of diagnosing acute left otitis
media (lat. for acute left middle ear infection). The structured input of clinical know-
ledge into the conditional form comprises the five main steps 1) Data type, 2) Identifiers,
3) States, 4) Parents, and 5) Examination methods, see Figure 8.3. Each step is associated
with a maximum of two out of the three general tasks select, create (and modify), and ver-
ify. Select refers to a multiple choice selection from a list of values, create (and modify)
involves a search for SNOMED CT terms, and verify requires picking the correct answer
from two contrary statements. In the first three input steps, nodes representing clinical
variables of the four types introduced above as well as the nodes’ states are defined. In the
fourth input step, parent nodes are either created or previously created nodes are selected
as parents, and then, the resulting causalities are verified. In the fifth input step, the mod-
eler primarily selects examination methods from a predefined list (based on SNOMED CT
terms), but also a new method can be created using the search for terms. Dependent on
the modeler’s selections and answers, the form can deviate from the order by both skipping
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Figure 8.3: Modeling workflow steps of the guided modeling method. Modeling steps
include the 1) data type, 2) identifier, 3) states, 4) parents, and 5) examination methods.
Solid lines represent regular flow while dashed lines represent valid jumps.
steps and loops. For instance, after creating a parent node in 4a), the form jumps to an
adjusted 2a) for creating the parent’s identifier.
Starting with task 1a), the domain expert selects one of the three data types: patient data,
anomalies, and determinable decisions. Examination data is later added in step 5. The
expert is then guided by the conditional form which adheres to the valid inter-node depen-
dencies, see Figure 6.1: selecting “patient data” lets the form terminate at task 3b), since
patient data must not have parent nodes; selecting “anomalies” may include all 5 steps;
selecting “determinable decisions” includes all steps up to 4b).
Here, we exemplary describe all possible steps of anomaly node definition. Once the
data type has been selected 1a), the node’s identifier is defined 2a). It may consist of multi-
ple terms connected through underscores. SNOMED CT contains predefined single as well
as connected terms. We recommend the use of predefined terms, e.g., Acute otitis media.
If a suitable connected term does not exist, it should be created from single terms con-
nected in an orderly way from very general body structures via substructures to morpho-
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logic abnormalities. At the verification task 2b), the modeler chooses between two contrary
statements that contain the constructed identifier:
1. The identifier Acute otitis media describes the variable in your desired detail AND
Acute otitis media cannot be mixed-up with a similar identifier (e.g., in another body re-
gion).
2. The identifier Acute otitis media is still too general and should be more specific OR
Acute otitis media cannot be associated with the desired body region. I would like to add
another term to make the identifier more specific.
Here, Acute otitis media should be refined by incorporating the lateral half of the body,
e.g., Acute left otitis media. Hence, the modeler would select statement 2, search for
“acute otitis media left”, find Acute left otitis media, repeat 2b) with the new term, and
at this time, select statement 1. This completes the first step and creates a node, see Figure
8.4-a.
Figure 8.4: Middle ear infection example using the modeling steps in Figure 8.3.
At the next step 3a), the modeler creates all states of the previously created node. The
states must be unique and ordered from the most positive to the most negative state, in a
clinical sense. Compared to a variable’s identifier, states can be less specific being related to
the variable’s context. For example, acute left otitis media may be simply Boolean-valued
from no (positive) to yes (negative), see Figure 8.4-b. At 3b), the modeler verifies that a
variable’s states are mutually exclusive by selecting one of the two statements:
1. No and yes of Acute left otitis media cannot arise at the same time.
2. At least two of Acute left otitis media’s no and yes can arise at the same time.
If statement two is selected, the conditional form returns to 3a) for modifications and
from 3a) even to 2b) in case the variable’s identifier needs to be more specific.
To create a parent in 4a) is optional. Here, we construct another anomaly node and
make it the parent. Bacterial infection being the anomaly may be present or absent in a
patient and is a direct cause of middle ear infection. Hence, the modeler creates an iden-
tifier by jumping to task 2a), follows the form path to the end of 3b), and finally jumps
to 4b). More specific, the identifier Middle ear structure bacterial infection by site is cre-
ated (out of the two SNOMED CT term concatenations “Middle ear structure” and “Bac-
terial infection by site”), and the Boolean states no and yes are defined, see Figure 8.4-c.
The verification task 4b) aims to inquire the right causality between the newly created par-
ent and its child node:
1. A no or yes of Middle ear structure bacterial infection by site leads to a no or yes
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of Acute left otitis media.
2. A no or yes of Acute left otitis media leads to a no or yes of Middle ear structure
bacterial infection by site.
In case of selecting statement 1, the cause is confirmed and the modeler can return to
4a) for creating another cause, or proceed to the next step 5a). Selecting statement 2 would
inform the modeler of the wrong causality and return the modeler to 4a) for modifications.
In 5a), the modeler is allowed to select multiple examination methods from a prede-
fined list. In case an examination method is missing, a new method can be created in 5b)
based on SNOMED CT terms and can be added to the list. By selecting an examination
method, a child node is created automatically. Its identifier is a construction of its parent’s
identifier and the examination method. The node’s states are the same as its parent’s states
but with an additional state for “unknown” to indicate diagnostic uncertainty. In our exam-
ple, an examination method is magnifying otoscopy. The associated node has the identifier
Acute left otitis media magnifying otoscopy and the states no, unknown, and yes, see Fig-
ure 8.4-d.
8.3.3 Study Set-up
For this initial study, the conditional form was on three paper sheets. A web browser was
used for SNOMED CT searches, and the modeling software GeNIe to represent the mod-
eling status. Both participants were asked to model the same decision. As a knowledge
engineer, I imitated the guided modeling system with three tasks. Firstly, I read the con-
ditional form and filled the form’s blank boxes with terms given the modeling situation.
Secondly, I interacted with the SNOMED CT browser by searching for terms that were
requested by the domain expert. Finally, I modeled the graph in GeNIe given the domain
expert’s answers. Afterwards, both models were compared, and each of the participants
was asked to review the other’s model. At the modeling I had no background knowledge
about the disease of middle ear infection.
8.3.4 Study Results
In general, with some exceptions, both participants followed the modeling instruction of
the conditional form, resulting in comparative models, and with a similar time of one hour.
In detail, the medical student followed the instruction step by step, while the modeling-
experienced clinician wished to skip descriptions and repetitive statement selections. Ini-
tially, we allowed skipping both, but skipping statement selections resulted in mistakes:
too general identifiers, wrong causalities, and examination nodes with improper identifiers
and states. Finally, from the participants, we received similar decision models with a few
differences in selected variables, but the same model structures. Figure 8.5 presents the
model of the clinician. Compared to this model, in the same time of one hour, the student
created the sub-network that is represented in Figure 5 with dashed lines. The identifier
had only differences of single terms, which related to the level of the desired detail. For
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example, the presented node “Middle ear structure Bacterial infection by site” was in the
student’s model “Left middle ear structure Bacterial infection”. The participants were able
to “read” the model of the other, and to understand the other’s variable selection.
Figure 8.5: The graph model of the clinician with manually integrated dashed lines to
represent the student’s model.
8.3.5 Discussion
The following section discusses the modeling technique and results, presents future inten-
tions, and general limitations.
Generally, this evaluation was small in the number of participants and small in the
model size. Given the available modeling time, the example of middle ear infection could
only be represented by two of four data types. However, the paper-based evaluation gave
the opportunity for correcting the conditional form based on ambiguous tasks and unclear
descriptions. Finally, the expert’s understanding of the other modeler’s graph enables
discussions between domain experts, to focus on the relevant modeling aspects: desired
model detail and clinical understanding. Using SNOMED CT’s existing groups, it is not
always possible to keep our recommended order of terms, e.g., SNOMED CT’s group
“Acute otitis media” would be “Otitis media acute” in our suggested order. Our topology
is less readable compared to SNOMED CT, but it is more consistent and easier to find
in a large model where alphabetically ordered lists are required. On the other hand, it is
valuable to use SNOMED CT’s existing groups of terms, because 1) SNOMED CT sup-
ports multiple languages, and 2) each term and group of terms has an identification number,
which is unique in one language but the same for other translations. These multi-lingual
relations between terms would allow software to represent the graph in different languages
based on the IDs. Using our method, the knowledge engineer was still required in the
evaluation but could be fully replaced by a future computer-assisted system. For the eval-
uation of our paper-based method, we still require the knowledge engineer to imitate the
system, which includes guiding the expert through the conditional form, as well as answer-
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based graph modeling in GeNIe. However, the knowledge engineer did not require any
domain knowledge or even advanced BN experiences; only basic understanding of graphs
and experiences with the modeling tool. For autonomous and collaborative modeling and
collaborative model validation further development is needed.
In the future, this method will be extended to a web-based modeling tool that:
• provides automatic form construction,
• allows parsing modeling results into established free modeling tools,
• is multilingual by using SNOMED CT, and
• enables collaborative modeling, validation and maintenance by supporting
discussions.
8.3.6 Conclusion
This method has the potential to enable autonomous expert modeling. Resulting models
comply with recommended BN model formalities. Further usability studies with more
complex diseases are necessary. Finally, with an appropriate web-based modeling frame-
work, collaborative modeling between domain experts is possible, would expedite the
model development of other diagnoses and therapies, and allow for discussing domain-
specific decisions. Based on this concept, a web tool is currently in development.
8.4 CPT Modeling Tool
Previous work from van der Gaag et al. [157] showed that medical experts are able to
assign probabilistic parameters to BN by formulating BN equations into natural language
questions and providing a scale for assessing parameters. Using this approach, experts
provide probabilities at a rate of about 150 probabilities per hour, which are 2.5 minutes
per question.
To decrease the modeling effort for extensive CPTs, I extended van der Gaag’s method
to a web-based system with an additional question form. A user study that we conducted
(presented in the following sections) resulted in an considerable decrease of required mod-
eling time to about 10 seconds per question. However, with exponentially increasing CPTs,
their assessment would still require too much time. Therefore, I developed a question form
that allows the modeler to summarize groups of parent variables with equal probabilistic
influences, which can be considered as dominant noisy OR gates. This question form can
decrease the expectational increasing CPTs to a linear modeling effort.
This section introduces a CMT that is based on the extended CPT modeling approach.
The CMT was tested in two usability studies and evaluated on the basis of the TNM model.
The following subsections presents 1) the additional question form, 2) the CMT framework,
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3) the two usability studies, 4) the results, and ends with 5) a discussion including the
evaluation.
The content of this section has been published in [33].
8.4.1 Questionnaire to Find Dominant Parent States
From the teamwork with Dr. Stoehr, the tumor board attendances and expert meetings, I
observed clinicians simplifying decisions to subsets of influences. Specifically, the com-
plexity of a decision with several influences is usually decreased to single or small groups
of influences. Once their influence is estimated, other single or groups of influences are
taken into account.
Inspired by these experiences, I specified a natural language question to identify single
or groups of parent states that have a dominant influence on their common child, indepen-
dent of the remaining parent states. From this, the hypotheses are:
• For a variable, a subset of parent states effects the variable independent of any
of the remaining parents.
• Given the subset, probabilistic parameters for the variable are equal for every
state combination of the remaining parents.
• A parent state can be in different subsets.
• From all of the determined parent subsets, the state combination of the re-
maining parents increases exponentially to the number of parents, which de-
creases the CPT’s modeling effort to a linear time.
• To minimize the modeling effort, assessing probabilistic parameters should
start from the smallest subsets to cover the most combinations of the remain-
ing parents.
Figure 8.6 presents an exemplary CPT with subsets of parent states. In this example,
the probability for V given the observation C = true is independent of any observation of
the remaining parents A, B and D. If C = false, the subset B = false and D = true as well
as B = false and D = false are different, but both are independent on an observation of A.
The remaining combination of parent states need to be considered individually.
The question form is added to van der Gaag’s approach. Specifically, the form is pre-
sented to each variable at first. After assessing parameters for all desired state sets, the
assessment continues for the remaining combinations, as described by van der Gaag’s ap-
proach.
8.4.2 Web-based Framework for CPT Assessment
A CMT has been implemented as a web tool in the DP2M project and is introduced in the
following section [33]. In general, the tool 1) allows the user to upload a graph model,
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Figure 8.6: Exemplary representation of dominant subsets of parent states. Each dominant
subset is represented by a color.
2) automatically creates a questionnaire from the model, 3) allows the user to assess the
probabilistic parameters, and 4) provides the model with the probabilities for download.
In detail, the tool runs as a server application on the Node.js1 architecture and uses
MongoDB2 as a persistence layer. Being a web application, the tool is independent of a
specific system and can be used from common browsers. The tool requires a user authen-
tication to prevent misuse by unauthorized parties, enables parallel modeling and records
user-specific metadata. Specifically, it records 1) the order of selected nodes as well as 2)
the time to set a probability and 3) to complete a node. For uploading and downloading
probabilistic models, it supports file-formats from GeNIe (xdsl), UnBBayes (ubf), and a
self-developed Json format. The Json format is similar to GeNIe’s format but more general
to be system-independent. The tool automatically extracts the variables, their states and
dependencies from an uploaded model. From this graph information, it generates a) an
overview table and the two types of questionnaires, b) the questionnaires for finding dom-
inant subsets of parent states and c) the questionnaire for the remaining combinations of
parent states.
a) The overview table lists all nodes and each with additional information about the
number of question pages (i.e., the total number of combinations of parent states) and the
number of parents, see Figure 8.7. Each each node also contains a button to start the elicita-
tion process for the specific node. A user is allowed to freely select any node. Furthermore,
she can start and stop the probability assessment at any time and from anywhere. The tool
saves a current state after every probability assessment.
b) In case a node has at least two parents, a question form is presented to find com-
binable influences, see Figure 8.8. From top to bottom, this form displays: 1) a progress
bar 2) the variable identifier, 3) information of the requested task, 4) selection boxes for
each parent with their states, 5) a slider to assess a probabilistic parameter, and 6) selection
boxes to indicate the personal certainty of the probability assessment.
1Node.js is a JavaScript runtime. Available free of charge at https://nodejs.org. c© Node.js Foundation,
2017.
2MongoDB is a cross-platform document-oriented database program. Available free of charge under the
GNU Affero General Public License (v. 3) at https://www.mongodb.com/. c©MongoDB, Inc., 2017.
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Figure 8.7: Overview table from CPT tool.
In detail, at the top of the page, the user is presented with a progress bar for guidance
and motivational reasons receiving direct feedback on a parameter assessment. The vari-
able’s identifier is emphasized in large letters. The user can select a subset of states. The
selected states are highlighted by a dark blue color, while the remaining affected parent
states are highlighted by a light blue color. Unaffected from this are states that already re-
ceived the required probabilities for all combinations of the remaining states. This coloring
is supposed to indicate the user that the assessed probability parameter will be applied to
all combinations of the colored states. Assessed subsets of parent states are emphasized
by a blue dot with a number. The numbers start with one and increase with every new
combination. States of the same subset receive the same numbers. For example, in Figure
8.8, state no of the variable larynx infiltration Nvagus has a blue dot being the only one
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Figure 8.8: Question form to assess probabilities for dominant subsets of parent states.
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Figure 8.9: Question form for probability assessment for single combinations of parent
states.
with the number 1. This indicates that the state outvotes all remaining states and, therefore,
the probabilities for larynx T resectability given this state in combination with all remain-
ing states can be assessed at once. To assess a probability, the tool provides a slider. A
probability scale according to van der Gaag’s approach surrounds the slider bar, while the
selected probability is displayed at the slider. However, the user has the possibility to set
exact percentages in 1% increments.
In the exceptional case of Boolean-valued variables, only the state true requires a prob-
ability. Otherwise, the tool displays a slider bar for each state (e.g., the T-states). Further-
more, with more than one state, the user is supposed to set the probabilities to a total of
100%. However, once the user continues, in the background, the system interpolates all
probabilities to 100%, dividing each of these probabilities by their quotient. Their quotient
is the sum of the probabilities divided by 100. For example, the probabilities for the states
n1, n2, n3 of the node N are set to 35%, 30%, 60%. Then, the system divides each of the
probabilities by 125%, because of (35 + 30 + 60) / 100 = 125%. In this example, the inter-
polated values would be 28% + 24% + 48% = 100%. After submitting the probabilities, a
next subset of parent states can be selected.
Finally, at the end of the form is a multiple choice selection for evaluating the assess-
ments’ confidence level. The options are: unsure, rather unsure, rather sure and sure. If
unsure is selected, an additional input field is presented to the user asking for more details
about their uncertainty.
3) Once probabilities for all desired combinations of states are assessed, the user can
continue with the second question form, see Figure 8.9. In this form, the probabilities are
requested for all remaining state combinations, one after the other. The layout of this form
8.4. CPT Modeling Tool 97
is similar to the previous form, but without the parents’ selection boxes and in return a list
of automatically composed parent states. Therefore, the user is not required anymore to
select any parent state.
Finally, after completing all of the node’s probabilities, the tool returns to the overview
page and displays the node’s selection button in a green color indicating its completeness.
After completing all nodes, the user can export the network.
8.4.3 Study Designs
For testing the CMT, we performed two studies, one evaluation study with three clinical
experts, and a usability study with 20 non-medical participants at the usability center of
the University of Applied Sciences in Merseburg, Germany. In the usability community, it
is established to conduct usability studies with five participants to find 85% of a system’s
issues, and 20 participants to find all issues [119, 118].
The presented studies have two limitations: first, the question form for dominant subsets
was implemented after the evaluation with two of the three experts as a result of it. Second,
the blue coloring for highlighting subsets of parent states was implemented after all these
studies, being again a result of them. However, the complete tool, as described in the
previous subsection and illustrated in the figures, was applied on the TNM model and will
be discussed at the end of this section.
Evaluation study
For this study, in oder to evaluate the CMT in a reasonable time with a more intuitive
decision model, we developed a BN graph model representing the treatment decision of
rhinosinusitis (nasal sinusitis) including acute and chronic rhinosinusitis. The model con-
sisted of 75 nodes, 100 dependencies, and required 1,526 probabilistic parameters. Ini-
tially, the graph was built by non-medical experts based only on guidelines. Afterwards,
three medical experts validated the graph together in a time of two hours with only minor
modifications. The one physician was Dr. Stoehr and the other two ear, nose and throat
(ENT) doctors in private practice. At this stage, Dr. Stoehr was in his second clinical
year with considerable experiences in rhinosinusitis treatment as well as experiences in
modeling BN. The other two doctors had seven and ten years of rhinosinusitis treatment
experience, each with approximately 1100 treatments a year. From these treatments, about
520 and 780 are surgical treatments and the remaining are conservative therapies.
The study was conducted using two versions of the CMT. The first version was without
the new question form that allows defining dominant subsets, and the second version was
with this form. The two more experienced experts assessed the probabilistic parameters
with the first version. From this experience, we developed the second version, which was
then used by Dr. Stoehr. For each expert, the duration of the study was scheduled for
two weeks. In this time, the experts assessed the probabilistic parameters independently,
and were free to choose the time and location to use the CMT. To enable direct result
98 Chapter 8. Tools for Guided BN Modeling
comparisons, one requirement I gave was to finish a node once it was started.
Usability study
The usability study was conducted with 20 participants of different gender and ages be-
tween 25 and 44 years. The study focused on identifying potential sources for incorrect
assessments, which may be caused by the tool’s construction, design and usability. For
this purpose, again we created a new model with a more intuitive example representing
the accident rate of traffic. In this study, we combined different usability methods to gain
qualitative and quantitative results. Methods include screen capturing, voice recording, eye
tracking, recorded interviews and questionnaires. Participants were supposed to think out
loud and describe their actions. Furthermore, they were supposed to use the CMT indepen-
dently, but with the possibility for questions to an attending engineer.
8.4.4 Results
Evaluation results
For the assessment of the 1,526 probabilistic parameters the two experts with the first ver-
sion of the CMT required on average seven and twelve seconds per question (ranging from
two to 20 seconds), with a rate of 300 to 500 probabilities per hour. In total, to complete the
elicitation process, they required 3.5 and five hours. With the second version of the CMT,
Dr. Stoehr was able to eliminate 47.97% of all probabilities (732 parameters) using less
than 50 assessments. Finally, he assessed all probability parameters in less than two hours.
From the three experts, only Dr. Stoehr reported uncertainties using the provided input
field. All experts started from the nodes with the least number of questions and continued
with the remaining nodes in chronological order.
Comparing the results between the three experts, out of the 1,526 probabilities 501
parameters (32.83%) had a deviation of less than 15% and 148 parameters (9.7%) had a
deviation of more than 50%. To directly compare the experts’ assessments, we applied
intraclass-correlation kappa, which describes how closely the elicited values resembled
each other in six categories: no agreement, slight, fair, moderate, substantial, and almost
perfect agreement [93]. Figure 8.10 presents the kappa on a scale of -1 to 1, only for the
nodes with at least one parent. We excluded all twelve nodes with a priori probabilities,
because the experts assessed the probabilities with a different understanding of the rep-
resented population. In average the kappa was 0.16, indicating a “moderate agreement”.
Twelve of the 30 nodes depicted in the graph were categorized “substantial agreement”.
The three nodes fell into the “fair agreement” category.
Usability results
From the usability study, we identified 28 negative aspects and classified them in three
levels of severity: 1) critical – system crash or misleading to wrong probabilities (six of
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Figure 8.10: Kappa for each node with at least one parental node from the rhinosinusitis
model.
28), 2) user-unfriendly – demotivating or loss of attention (six of 28), and 3) nice-to-have
– is not affecting the rating (16 of 28). Table 8.1 presents the issues and the number of
affected testers from the severity level 1 and 2. One of the main misleading problems was
the additional question form for dominant subsets. Problems with the severity level 2 lead
to a longer answering time. For the most participants, the study was discouraging after 15
to 30 minutes, and after 30 minutes they usually lost attention. The third level is not listed
due to reflected subjective feelings without an affect on the assessment quality or time.
8.4.5 Discussion
After the evaluation, we conducted a follow-up meeting with the experts to discuss prob-
lems during the elicitation as well as specific assessments with high divergences in the
results. Incorrect answers due to the divergences appear in the assessments of all experts
and in the most cases without a specific cause. From this, I can only assume usability is-
sues. However, in single cases divergences in the diagnostic understanding appeared but
in the end they were able to agree on specific parameters. One major issue of the evalua-
tion with the two experts was the missing possibility of combining common influences and
hence the exhausting assessment of single nodes with large CPTs.
They all emphasized the tool’s flexibility being a web application. Two of the experts
assessed the parameters at home in the late evenings, while one assessed them at work in
the early mornings.
Especially the question form for dominant subsets of parent states is a necessary ap-
proach to minimize the high modeling effort of complex treatment decision models. In
comparison of both studies, Dr. Stoehr was able to properly apply the question form for




Level of severity 1:
- Unclear understanding of applying dominant subsets 12
- Group of direct causes not recognized 7
- Duration of the questionnaire for one node too long 7
- Only the first probability bar taken seriously 5
- Relation between all bars unclear 4
- Unclear how to interpret the input field for uncertainty 4
- Some web browsers allow to stop pop-ups, which prohibits functions of the
tool
3
Level of severity 2:
- Comment feature hinders the assessment process 4
- Node terms or subject unclear – missing instructions 3
- Duration of ”pages” and ”questions” unclear 1
- Information on lost data when closing the application 1
- Program entraps to click through the questionnaire 1
- Not enough application feedback, ”unable to tell what’s happening in the
background”
1
Table 8.1: Table of negative aspects from the CMT usability study [33].
dominant subsets because of an initial introduction. However, also with an introduction,
subsets were difficult to recognize. Therefore, we implemented the blue coloring for sub-
sets, as presented in Figure 8.8. Furthermore, we will provide a tutorial with the tool to
provide the required information.
Finally, based on the results from both studies, all problems with severity level 1 were
corrected and also some of level 2 that affected a larger number of testers. For example, a
problem is that the time for setting a CPT without interruptions may become exhausting,
which led to fast, impatient, inattentive, and, finally, undesired assessments in the usability
study. Knowing from the studies that an answer required about ten seconds, this prob-
lem could be solved by presenting an expected remaining time for each modeling step an
expected remaining time. Also, interruptions during a node’s CPT assessment could be
allowed by providing a history that the user can study before continuing the assessment.
In case of the TNM model, the CMT was complete as presented in the Figures, includ-
ing the question form and the blue coloring of selected states. Dr. Stoehr successfully set
the 78,875 probabilistic parameters in less than six hours. From observation during his
modeling and a personal talk, I recognized a higher modeling satisfaction reasoned by the
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tool’s latest improvements. This satisfaction was mainly reasoned by the improvements of
the question form for dominant subsets, the possibility to stop modeling at any time, and
an updated information of the expected remaining time. Furthermore, we experienced that
usually the more extensive a CPT is, the more dominant subsets exists. In other words, the
largest CPTs could be assessed faster than comparatively smaller CPTs.
8.5 Conclusion
The CMT was successfully applied on the rhinosinusitis model and the TNM model. Fur-
thermore, the question form for specifying dominant subsets of parent states enabled the
modeling of highly extensive CPTs in a linear time, with a reasonable effort for the user.
Other complex decision models from a clinical domain have the same decisions-making
culture and, therefore, the question form could be applied as successful as to the TNM
model.
At the moment, the CMT supports GeNIe and UnBBayes, but can be extended to other
tools with reasonable effort.

Chapter 9
GUI for PSBN-based decision
verification
9.1 Introduction
This chapter presents a visualization tool for the verification of TNM stagings.
Various tools are available for modeling and inference analyses of BN models, as well as
approaches for model visualization and interaction (see Section 4.6). However, the avail-
able tools are application-independent with a framework that requires experiences with
modeling tools and BNs, which medical personnel usually does not have and would have
difficulties to acquire (3.3-R1.5.2/3/7/9).
The concept for TDSS in Section 5.3 considers various UIDs to interact with PSBNs,
aiming for an uninterrupted workflow (3.3-R1.3.1/3/4/5/7) or even an improved workflow
(3.3-R1.3.6/8/9/10, 3.3-R1.5.5/6 and 3.3-R1.7.1/2). Therefore, UIDs should be adjusted to
the specific clinical decisions regarding 1) the users’ domain-specific expertise (e.g., clin-
icians and their specialization as well as patients with and without medical background,
3.3-R1.3.3 and 3.3-R1.7.2), 2) information on users’ interests (e.g., treatment options, main
or unexpected influences for specific decisions, and missing examination methods with a
diagnostic value; 3.3-R1.5.7), 3) the environments for decision-making (e.g., patient room,
doctor’s room, tumor board room or operating room; 3.3-R1.7.1), and 4) available devices
in the specific environments (e.g., working station in the doctor’s room, tablets and moni-
tors in the tumor board room; 3.3-R1.5.8), see Section 5.2.
Verifications of initial diagnostic and treatment decisions are clinically not applied, but
could indirectly improve the decision quality and patient safety, and directly improve the
costly time of tumor board attendees. For instance, verifications could be applied before the
tumor boards in order to identify suboptimal decisions as well as unconsidered or missing
patient information (see Section 5.2). Considering the current situation in highly special-
ized hospitals, patients are well examined by multiple disciplines and, therefore, a verifi-
cation would usually require studying extensive patient records from various paper-based
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and electronic sources of different clinical domains.
For this purpose, we developed an exploration tool for PSBNs. As an initial use case
we selected the TNM model. The implementation was realized in collaboration with the
Gesellschaft für Technische Visualistic mbH (GTV), Dresden, Germany. My contribution
to this development was the specification of 1) a BN-based solution, 2) visualization and
functionality requirements, 3) back-end requirements, and 4) the evaluation of the system.
The following sections describe the clinical motivation for TNM verification, requirements
for a PSBN exploration tool, a requirement-based framework, basically introduces imple-
mentation, and finally presents the tool’s evaluation by a user study with five clinicians and
20 patient cases.
The content of this chapter has been published in [41].
9.2 Motivation for TNM Verification
Between 2013 and 2015, Dr. Stoehr conducted a prospective internal study of the decisions
of head and neck tumor boards at the University Hospital Leipzig. The study has shown that
more than 10% of the patients required a renewed invitation. From our clinical experiences,
TNM staging may be incorrect at the initial staging because of, e.g., an unusual patient
case, overlooked or ignored patient information, or qualitatively inadequate or missing
examination for sound staging. In such cases, TNMs remain unnoticed until the tumor
board, which is costly and can delay the treatment. Specifically, costs relate to the time
of multiple experts, which requires a restaging based on discussions and lengthy search
in paper-based medical records. In the worst case, the tumor board postpones a treatment
decision because of unavailable, inadequate or unexamined patient information.
A verification of the TNM staging prior to the tumor board is usually not conducted, but
could increase the patient safety and at the same time decrease costs. In general, decision
verifications could be conducted at each workflow step (see Section 5.2). Decision verifica-
tions will require additional labor and, therefore, one must balance between 1) the required
costs for verifications, 2) the frequency of suboptimal decisions that could be avoided in
beforehand, and 3) the costs of correcting decisions in the following steps.
In case of TNM staging, the verification could be conducted in between the workflow
step of (A) consultation and examinations and the step of (B) initial treatment assessments.
However, conducting TNM verification in the current clinical situation would be time-
consuming and is prone to overlooking information. Traditional verification methods do
not exist, except for studying the patient records.
To compare the verification tool that is presented in the following section, we tested a
verification time on ten patient cases using two software-independent methods and con-
sidered the long-term experiences in using GeNIe. The two methods are based on, first,
ordinary paper-based and electronic patient records and, second, results from the network,
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such as a paper-based list.
During the test, the patient records provided on average 78 information items (ranging
between 36 and 154 items). Specifically, the information usually described examination
results through multiple pages of running text. A network’s list consisted of all 303 vari-
ables providing the available patient information and probabilistic parameters. For each
case, the list of variables was printed on twelve pages with about 25 variables per page.
The clinician was supposed to verify the first five TNM stagings using the patient records,
and the second five using the network list. The document-based verification required on
average ten minutes per patient case (ranging between six and 15 minutes). Studying the
TNM stagings was exhausting due to the extensive documents. Using the lists, the clinician
stopped the verification after the first case being overwhelmed by too many list items. He
continued and finished the verification using the first method. In all cases, the clinician
verified correctly. However, this method is unsuitable to be applied in a clinical workflow.
For instance, in the University Hospital Leipzig, at one tumor board, approximately ten to
15 patients cases are reviewed, which would require about one to 1.5 hours. Also, due to
the required verification time, the extensive documents of running text and the clinicians’
busy schedules, the probability is higher to overlook information.
Using GeNIe for verification required only basic functionalities, such as zoom in and
out and moving across the graph structure. The real-time updating was turned on for both
to compare a clinical information to the network’s inference and, in case of a difference, to
explore its issues. While comparing stagings could be simply done by setting or taking out
a node’s information (which updated the network inferences immediately), the exploration
of issues was more difficult. Specifically, the exploration required a frequent setting and
taking out of patient information in order to identify causes of different influences and
follow them through the graph structure. However, from our experiences, the graph and the
patient information are difficult to overview, which makes a verification unsuitable.
9.3 Requirements on TNM Verification
Requirements are based on clinically applied systems, interaction experiences with GeNIe,
and clinical expert meetings. Furthermore, to evaluate the following requirements, a visual-
ization scientist, Dr. Stoehr and I extracted the requirements to craft and refine paper-based
prototypes incorporating BN’s inherent graph structure.
Clinically applied oncoflow-like systems have a similar framework. To make the user
aware of considering the right patient case, for a double-checking the systems (R1) display
a patient ID on every page with patient-specific information (e.g., name, age and gender).
Furthermore, the systems’ layout is well-structured by (R2) readable and self-explanatory
information. Specifically, in case of oncoflow, the layout is independent of display sizes and
underlying systems being implemented as a web application (R3). Finally, their function-
alities allow for (R4) focusing on desired information and (R5) a quick search for changing
the focus.
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From our experiences with GeNIe, a visual verification requires only a subset of the
provided PSBN information, visual representation and supported functionalities. Required
(R6) BN information are the direct dependencies and the probabilities. Using our specific
graph structure (see Section 6.4.1), the graph exploration was performed with and against
the causal directions and, therefore, they can be ignored.
Two basic functionalities were required (R7) to explore the graph, the zoom in and out
and the possibility to move across the graph structure. Zooming allows to focus on single
nodes with their relatives as well as to overview larger subnetworks. Another necessary
functionality was the real-time updating in combination with interactively changing pa-
tient information in order to (R8) distinguish observed from computed information. Based
on divergences in compared observed and computed information, the probability bars can
visually (R9) guide the user to the examination methods that are the source of incorrect
staging.
Finally, to integrate a system into the clinical workflow, the clinician should be able to
verify the TNM stagings (R10) autonomously in (R11) a reasonable time.
R1 Display of patient ID for double-checking patient case
R2 Readable and self-explanatory variable identifiers and states
R3 Web application for system independence
R4 Focus on relevant variables
R5 Quick access to desired variables
R6 Provide details of the BN
R7 Enable exploring the graph structure
R8 Distinguish observed from computed information
R9 Guide the user through the network
R10 Enable autonomous model exploration
R11 Verification in a reasonable time
9.4 Verification Framework
A verification tool is integrated into a therapy decision support system as a UID (see Section
5.3). Specifically, the tool consists of a GUI that is motivated by the requirements. This
section presents the tool in Figure 9.1 and summarizes the framework’s compliance with
the requirements.
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Figure 9.1: The graphical interface of the visualization approach is separated into four
areas: 1) a graph view (center), 2) a basic patient information summary (top-right), 3) a
variable selector (right), and 4) a tool set (bottom-left). Additionally, the variable selector
consists of two fields: check boxes and a slider and a variable list; and the tool set consists
of two fields: a set of four tools and a time line.
In general, the graphical interface is separated into four areas: 1) a graph view (center),
2) a basic patient information summary (top-right), 3) a variable selector (right), and 4)
a tool set (bottom-left). Furthermore, the interface is implemented as a web application
to be independent of specific clinical computers (R3). The basic information summary
includes a patient’s name, birthday and id number, and is always displayed on the screen
for double-checking the correct patient case at any time (R1). The graph view focuses on
relevant variables by displaying only a subset of the model, which includes the relevant
variables and their directly related variables (R4). Other variables of the network can be
explored by changing the focus to the directly related variables (R4+R7), as well as a
variable list and a search bar at the variable selector (R5). Variables’ identifiers must be
unique and are supposed to be self-explanatory (R2). This information is provided in the
graph view by clear fonts in readable size. To avoid an overwhelming graph view by too
many details, the graph visually indicates variables’ probabilistic values with the possibility
to display desired details (R2+R6). Using the graph view, a user can freely explore the
network. However, additional tools and modes allow to highlight separate computations
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and observations (R8) in order to visually guide the user to sources of discrepancies (R9).
9.5 Graph View Design
The interactive visualization of the PSBNs has been implemented as a web application,
based on HTML5, SVG, CSS3 and JavaScript frameworks. In particular, AngularJS [64]
was used to implement the data structure, in combination with the data-driven library D3.js
[16] for creating the SVG elements. This section describes the design of the verification
tool, as presented in Figure 9.1.
1) In the graph view, a PSBN is visualized as a two-dimensional graph by its inherent
properties of nodes and edges. Nodes are depicted as circles, and edges as undirected and
dotted lines. In more detail, the graph view hides the nodes’ state labels and probabilistic
values, but clicking on a node opens the details, as presented in Figure 9.2. Within every
circle, a circular bar chart is visualized. The number and order of a circle’s slices relates to a
variable’s states; usually ordered clockwise, from the best to the worst value. The filling of
a slice (a dark slice) represents the states’ probabilistic values. Observed nodes have only
one slide filled and an empty inner circle, see a) in Figure 9.3. At an inferred node, the state
with the highest probability fills out its slice completely, while the remaining states fill out
their slices according to their probabilities but relative to the completely filled slice, see b
and c in Figure 9.3. If one state has a certain prediction compared to the remaining states,
visually only one slide appears filled, see b in Figure 9.3. Because of the relative fillings,
probability values within circles are neither comparable nor well recognizable. Finally,
circles can have one of two sizes to distinguish the node type examination data (the smaller
circles) from the remaining node types, see Figure 9.3 comparing the first and second row
of a, b and c.
A model subset is predefined by a user focus, which is represented by a focus ring in
the window center. A focus of a single node displays the node in the focus ring while a
focus of more than one node aligns the nodes on the ring. Beyond the focus ring, only
nodes are displayed that are directly related to the focused nodes. Furthermore, the graph
view enables selecting and deselecting nodes to or away from the focus ring by drag and
drop. An approach of a middle-out, semantic zoom technique is used that allows users to
interactively and individually explore graphs, originating from the middle of the canvas, the
focus of attention. For a specific zoom of a specific model with a set of nodes in the focus,
nodes are organized automatically, which supports an easy node recognition for frequently
uniform model explorations.
2) The basic patient information summary displays a patient’s name, birthday and id
number.
3) The variable selector contains three options to highlight nodes in the graph view:
check boxes, a search field, and a node list. Two check boxes enable the user to high-
light observed or computed values. The nodes that meet the requirement (observed or
computed) are unaffected while the others become transparent by 50%. The search field
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Figure 9.2: Displayed node detail, exemplary of the T-state variable. Nodes are represented
as a circular bar, with details about the specific states and probabilistic values. Slices
represent states, ordered clockwise, e.g., from T0 to T4b. Probabilities are displayed by
fully or partially filled slices, and by numbers. An empty inner circle highlights an observed
value. In this specific case, T2 is an observed value (staged by a clinician).
enables searching nodes using keywords and adding them directly to the focus ring. The
list represents all of the model’s nodes, and enables the user to select nodes for the focus
ring, but also to deselect nodes. All nodes that are displayed in the graph view are also
highlighted in the list by a white font color while all remaining nodes are gray. Specifi-
cally, nodes that are in the focus ring are emphasized in the list by a pulled out node name
to the left.
4) The tool set at the bottom offers two graph visualization options: an initial overview
and a model comparison. For verification, the model comparison mode compares two PS-
BNs computations of the same patient but with different patient information. One PSBN
is based on patient examination results and a predefined TNM staging. According to the
results and stagings, all the remaining nodes in between are computed. The second PSBN
computation is only based on the patient examinations. If the second PSBN infers another
TNM staging compared to the first PSBN, then also the remaining unobserved nodes in
between will have different probability distributions. Comparing both PSBNs in the graph
mode, these differences are supposed to visually guide the user to the responsible exami-
nation results. This mode provides additional information in the graph view, and adds two
check boxes and a slider to the variable selector, which allow to distinguish computational
matches from mismatches by highlighting the one or the others. In detail, when compar-
ing two model computations, two colors (blue and yellow) distinguish the different node
information, see Figure 9.4. The color blue visualizes the original model computation, and
yellow the comparative computation. The node details provide the probabilistic values of
both computations, visualized in their specific colors. If at least one of the values is ob-
served, then the inner circle is filled with the value’s representative color (see blue inner
circle in all nodes of Figure 9.4). In case of a high degree of agreement of more than
90%, the filling of the glyph’s slices is set to black in order to avoid their visual emphasis
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Figure 9.3: Example glyphs for the encoding of observed (a) and computed information
(b,c). Observed nodes have one completely filled slice and an empty inner circle. Com-
puted nodes have one completely filled slice of the most probable state while the remaining
slices are filled relative to the most probable state. In the second row of a, b and c, nodes
have a smaller size representing the type of examination data.
(Fig. 9.4 (a)). This threshold has been obtained from the network modeling. BNs perform
reasonably accurate, even with a less precise model quantification [122]. Therefore, the
model’s probability parameters were assessed by seven probabilistic values from 1% to
99% in irregular 10% to 15% steps [33]. For this reason, we also accept an inaccuracy
of up to 10% in the PSBNs. For lower degrees of agreement, the slices are filled and dis-
tinctly colored according to the results of the two model runs (Fig. 9.4 (b-d)). In c) for
instance, the T-state given from the patient record was T3, resulting in a 100% blue fill-
ing of the respective slice. The computed T-state (yellow), however, is uncertain assigning
only a probability of 53.4% to T3. Please note the blue, semi-transparent center circle in all
glyphs of a) to d). It indicates that the corresponding information was set by the physician
in run (1), similar to indicating an observed medical examination by a blank circular cut-off
as explained before.
9.6 User Workflow
Based on the clinical TNM staging workflow (described in Section 5.2), the following
section describes the approach of a verification workflow in eight steps.
(1) At the initial verification step, the tool presents the nodes of T, N and M-state at the
focus ring, and their directly connected nodes surrounding them. This step is supposed to
give the clinician a quick overview indicating the variables’ states by black filled slices.
(2) For more details of an individual variable, the clinician performs two tasks. First, she
moves the courser to a node, which highlights its directly connected nodes by decreasing
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Figure 9.4: Example glyphs for the comparison of two TNM model computations (blue and
yellow) showing different degrees of agreement of the computed probability distributions:
a) high, b) acceptable, c) low, and d) no agreement. A high degree of agreement is indicated
by a black slice filling. Detailed information regarding the encoding is given in the text.
the opacity of the remaining nodes. Second, she clicks on the specific node, which displays
the variable’s states and probabilistic values.
(3) To verify the TNM staging, the clinician switches to the comparison mode. In this
mode, nodes with black colored slices indicate the system’s high degree of agreement.
Nodes consisting of two-colored slices indicate the system’s lower degree of agreement.
Especially, the M-state shows a high degree of agreement by a black filled slice representing
the state M1. The N-state shows an acceptable degree of agreement with the largest yellow
filling at the predetermined blue filled slice representing the state N2c. Finally, the T-state
shows a low degree of agreement by the largest yellow filling at the slice representing the
state T3 while the predetermined state is T2.
(4) The clinician is mainly interested in exploring issues of nodes’ low degree of agree-
ment. Therefore, she shifts the focus by dragging the T-state node into the center of the
focus region. In this case, only the T-state’s directly connected nodes remain while all the
remaining nodes disappear.
(5) She repeats step 4 to explore the network until she arrives at the examination meth-
ods. From the initial focus on the TNM staging, each examination method can be reached
within a maximum of three focus shifts.
(6) At this point, the clinician is only interested in the clinically performed examinations
(not in the computed probabilities of the remaining ones). To highlight these, she selects the
check box ”observed values” in the variable selector area. Two observed nodes remain the
same while the other nodes become more transparent. The two nodes represent a clinical
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Figure 9.5: Verification workflow of a TNM staging given in a patient record (see Sec-
tion 9.6 for details).
examination and a stroboscopic examination.
(7) She studies the examinations in more detail and takes notes. While the clinical
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examination reports a paralyzed vocal cord (step 7), the stroboscopic examination reports a
fixed vocal cord (step 8). In direct comparison between both examination methods, at this
specific body region the stroboscopic examination is most reliable. Therefore, the T-state
is at least T3, which was correctly inferred by the system. In this case, the clinician can
only assume that the predetermined TNM staging was performed prior to the stroboscopic
examination.
(8) Finally, if the clinician is interested in other variables and influences, she can shift
the focus to another node and start exploring the network again by repeating from step 4.
To quickly find a specific variable, she uses the list or search bar in the variable selector
area.
9.7 Study Set-up of TNM Verification
We conducted an evaluation to study the impact of the TNM model on supporting clin-
icians in verifying these TNM states. The following section describes the study set-up,
participants and test cases.
Prior to the study, 21 patient cases were prepared: one test case to introduce our tool
and 20 to evaluate our tool. To study the participant’s behavior in case of 1) an incorrect
clinical TNM staging or 2) a system’s wrong suggestion, nine of the 20 cases have been
manipulated by 1) changing the clinically recorded T, N and M-states, or 2) deleting single
examinations. Furthermore, we prepared a one page paper sheet explaining the visualiza-
tion of nodes, which included the Figures 9.2, 9.3, and 9.4.
Five clinicians participated in the study: three resident physicians (R1/2/3) and two
senior physicians (S1/2). The resident physicians had a clinical experience of nine months,
four years, and five years, while each senior had more than ten years of clinical experience.
All participants had no background knowledge about BNs, the TNM staging BN model,
or our tool. Each participant answered questions about self-confidence with both staging
TNM and using computers (with a possible ranking of 1 = little, 2 = ordinary and 3 =
considerable).
The study was conducted in two sessions during the clinicians’ working hours. During
the study, each participant was more or less often interrupted by clinical calls and needed
to leave the study for several minutes.
During the study, clinicians separately evaluated TNM stagings of the 20 patient cases
using only our tool. A knowledge engineer introduced our tool as described in Section 9.4,
and presented an example patient case based on the workflow as described in Section 9.6.
Each clinician was asked to 1) study the patient’s TNM states, 2) reconstruct the rationale,
and 3) confirm or correct the TNM states. Upon request, participants were allowed to use
a printed table of the TNM staging system. Finally, the participants took notes of the T,
N and M-states and their conclusions. This procedure was repeated for the remaining 20
patient cases. Clinicians were supposed to work autonomously, but in case of a question
the knowledge engineer was available.
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The study was video-and audio-recorded. From these records and notes we evaluated
the required time for each patient case, the number of guideline requests, and the partic-



































R1 0.75 1 2 5 3.8 20 20 19
R2 4 3 3 5 3.7 19 19 19
R3 5 2 1 4 4.7 19 17 16
S1 10 3 2 9 4.6 20 16 15
S2 13 3 1 2 3.6 20 20 20
Table 9.1: Personal details (self-assessments) and results from the five participants of the
verification study.
Figure 9.6: Study results of five participants (R1, R2, R3, S1 and S2) with 21 patient cases:
one to introduce our tool and 20 for the evaluation. This diagram combines a bar chart and
a table presenting the required time for each patient case and the answer quality of stagings
with conclusion.
We evaluated the TNM states and conclusions, the time, the participants’ questions, and
their comments during the study (for more details see Table 9.1 and Figure 9.6).
Initially, all participants were introduced to our tool, which took between eight and
23 minutes depending on a participant’s requests. Afterwards, each participant required
support from the knowledge engineer for the first three to four cases, and was able to work
autonomously for the remaining sixteen cases.
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During the study, all participants requested the table of the TNM staging system, either
to obtain information or to verify an assessment. Specifically, the less experienced partici-
pant R1 requested the table to conclude or verify the T, N and M-states. The experienced
participants R2 and S1 requested the table more often, but usually to approve their esti-
mates. Compared to the other participants, they were also more frequently interrupted by
clinical calls. Especially participant S1 was interrupted several times during the first three
cases and needed repeated introductions.
The verification took between 1.5 and 10.25 minutes, and included the participants’
requests and discussions as well as an explanation of the current procedure. On average,
all participants required the same time of about four minutes. From the 12th patient case,
all participants verified correctly and the average time decreased to less than three minutes.
Misunderstanding of our tool’s content included distinguishing, interpreting and arguing
observed and computed values. Initially, in the first patient cases, two participants wrongly
assumed that all nodes represent clinically available patient information. Furthermore,
two resident and one senior clinician wrongly assigned a high confidence to the clinically
available information, which are always presented in the model with 100%.
Finally, all participants felt comfortable with the space-filling arrangement of nodes.
Also, after presenting the informational paper sheet with visual node descriptions, the clin-
icians understood the node design. However, initially, one participant related the circle bar
slices to a tumor size. Therefore, he expected information about larger tumors at Boolean-
valued nodes (e.g., the M-state node) compared to nodes with more values (e.g., the T-state
node). The participant explained this initial conjunction by studies of tumors in clinical
images, which usually appear as round, black and differently sized areas.
9.9 Discussion
Our tool enables an autonomous TNM verification (R8 in Section 9.3). Furthermore, par-
ticipants were able to verify or correct a TNM staging in a reasonable time of four minutes
on average (R9). The following discusses the study results as well as issues and future work
related to our tool’s layout, functionality and applicability.
9.9.1 Study results and limitations
The study shows that a user can successfully use our tool and correctly verify a TNM stag-
ing after about ten training cases. Compared to our test of traditional verification methods,
the verification time with our tool was twice faster. Anecdotal feedback by the clinicians
indicates that the tool promotes an understanding of the represented decisions and their
influences.
However, all studies were performed in a relaxed atmosphere without consequences in
case of mistakes. This limitation should be tackled in a prospective study by letting the
clinicians present their verification results at the tumor board. It is only to assume that,
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compared to traditional methods, the probability of overlooking information is lower using
our tool.
9.9.2 Layout
Clinicians benefit from a clear overview and a simple exploration. They neither expect nor
desire a causal graph structure. On the one hand, clinicians know the direct influence be-
tween diagnostic information due to their daily practice of studying guidelines and making
complex decisions. On the other hand, we experienced a clear understanding of the variable
relations from the participants’ workflow and explanations.
After a short learning phase, the node glyphs are easy to read and understand. How-
ever, Boolean-valued nodes appear prominently in the graph view due to their large slices.
Furthermore, a Boolean-valued node that is set to True surrounded by nodes that are set to
False is difficult to distinguish.
Our hierarchical graph navigation approach impedes the user in gaining an overview
of the entire TNM classification model. The graph layouting technique does not aim at
continuity of individual node positions, which hampers the recovery of a node of interest
after layout changes.
9.9.3 Functionality
During the TNM verification process, clinicians recorded their insights by taking notes
on the tumor board sheet. Recording should be improved by adding functions to our tool
for marking and annotating relevant nodes as well as for storing intermediate views of the
graph.
The clinicians frequently used the table of the TNM staging system during verification.
In clinical practice, such tables are attached to walls of the doctor’s room or stored on
the clinical workstation. Our prototype should be extended by a table view that provides
node-specific information on request.
Finally, the study indicated potential to automatize uniform, frequently performed user
actions, for instance, highlighting the observed values when reaching examination results
during network exploration (cf. step 6 in Section 9.6).
9.9.4 Applicability
TNM staging systems are organ-specific, including different states and influences. There-
fore, applying our approach to other clinical domains requires a new TNM model. How-




This work presents a GUI for probabilistic graphical models for tumor therapy decision
support. The approach is focused on this application but may serve as a role model for
a wide variety of complex treatment decisions, e.g., related to severe vascular diseases,
where precise diagnosis is essential, as well as to select the right combination of treatment
options. Usability issues could be recognized and partially solved by a clear introduction
of the design and available tools. Misleading design issues will be addressed in further
development. Finally, our tool meets the clinical requirements, is simple to understand
with a clear introduction, and after a few patient cases also autonomous to use.
In future work, we will add a tutorial to our tool presenting the initial introduction as








This thesis presented a methodology for the development of Bayesian network-based clini-
cal treatment decision support systems. For this purpose, a concept introduced interactions
between actors and systems. The proposed concept emphasizes model development with
an exemplary use case of model interaction.
A graph model design was presented that allows integrating all relevant variables of
multidisciplinary treatment decisions. At the current stage, we developed TreLynCa: A
graph model representing the treatment decisions of laryngeal cancer. From TreLynCa,
a subnetwork that represents the TNM staging is completed by the required probabilistic
parameters, and finally validated. The model validation required the development of a
validation cycle in combination with existing data- and expert-based validation methods.
Furthermore, modeling methods were developed that enable domain experts to model
autonomously without Bayesian network expertise. Specifically, a novel graph modeling
method was developed, and an existing method for modeling probabilistic parameters was
extended. Both methods transform Bayesian network modeling tasks into a natural lan-
guage form and provide a regulated modeling environment. A method for graph modeling
is based on the presented graph model design with a regulated and restricted modeling
procedure. This modeling procedure is supposed to enable collaborative modeling of com-
patible models. The method is currently under development. A method for probabilistic
modeling is extended to reduce the modeling effort to a linear time. The method has been
implemented as a web tool and was tested and evaluated in two studies.
Finally, for clinical application of the TNM model, requirements were collected and
constructed in a visual framework. In collaboration with visual scientists, the framework




Appraisal and Future Work
11.1 Applicability of Methodologies and Tools
In general, the presented methodologies and tools are independent of this specific disease
and could be applied to decisions of other domains with a similar model and modeling
complexity. The model complexity relates to decisions 1) with uncertainties, 2) integrating
multidisciplinary domains, 3) providing deep explanations, and 4) being adjustable to local
conditions. The modeling complexity relates to 1) limited evidences that require expertise,
2) expertise that requires collaborations of multiple domain experts, and 3) experts who
can model in both environments, during their clinical work (regularly interrupted and in
changing environments) as well as after work at home.
11.2 Compliance of Requirements
Methodologies and tools comply with most of the requirements regarding the aims of tumor
boards (see Section 2.3.1), best practice in developing a CDSS (see Section 3.3), and model
design (see Section 4.2). The remaining requirements were implicitly embedded but should
have to be addressed explicitly in future work.
Obviously, the registration of patients for tumor boards (2.3-R1), attendance of a mul-
tidisciplinary team (2.3-R2) and providing medical images (2.3-R4) can neither be forced
nor influenced by a CDSS. Being a research project, requirements regarding the vendors
(3.3-R1.1.2) and legal and ethical issues (3.3-R1.9.1/2/3) were ignored. Also, represent-
ing a snapshot of a tumor board decision, temporal knowledge (3.3-R1.4.2/8) and alerts
(3.3-R1.5.4) were not considered.
Temporarily, the remaining requirements are missing, since 1) TreLynCa is incomplete
(missing probabilistic parameters; 2.3-A6/S2/R3, 2) the decision support system is used
separate from the clinical systems (3.3-R1.3.5, 3.3-R1.7.1 and 3.3-R1.8.1/2/3/5/6/7), and
3) appropriate GUIs are required to present the PSBNs at tumor boards and patient con-
sultations (3.3-R1.7.1 and 3.3-R1.3.8/9). In order to comply with these requirements, the
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following section discusses our current research.
11.3 Impact of Decision Graphs
For a complete decision support, the TreLynCa model requires the missing probabilistic
parameters. However, the graph itself could be clinically applied in order to support tumor
boards with 1) an overview of available patient data, 2) an understanding of a decision’s
complexity, 3) improving the expert communication (2.3-A1/S2/R3) and 3) information
that were used for the model construction (e.g., clinical studies and guidelines). Specifi-
cally, available patient information could be highlighted in the graph, and the graph could
be shared among clinicians
In TreLynCa, we add one or more information sources to each BN’s variable. However,
studying the network, the user is required to open a variable’s list of information sources,
from which only a subset is relevant in a specific patient case. Therefore, we suggest using
natural language programming tools in order to tailor guidelines to a specific PSBN [47].
In other words, based on a PSBN the user automatically receives the relevant guidelines
and studies to understand and verify a decision.
11.4 Storage and Cross-Sharing of BN and PSBN
The realization of a model quality management as presented in Section 5.4 including model
storage and communication between clinical systems, requires standards and regulations
[34].
In the clinical domain health data is stored and communicated using interoperability
standards. The HL7 community is active in this domain since the 1960’s, and developed
the interoperability standard HL7 version 2 in the 1970’s, which is still successfully used
in the most health systems worldwide [8]. Because patient records become more extensive,
are heterogeneous, and need to be communicated through the web, the new standard FHIR
has been developed [9]. FHIR is built upon three components: resources, references and
profiles. A resource represents the smallest complete and discrete information entity (e.g., a
patient, procedure or order). Reference resources can be linked to more complex structures
(e.g., representing clinical decisions, medication order or the entire patient record). Combi-
nations of resources are defined by profiles, which pooled can be considered as a rulebook
of services. The international HL7 community defines profiles which can be adapted to
both national conditions by national HL7 representatives as well as small local conditions
of independent organizations and project groups.
BN-based models (including PSBNs) require a standardized file format and software
exchange in order to extend their applicability (3.3-R1.8.2). Common BN software such
as, e.g., GeNIe and UnBBayes use different formats. A model created by one software
cannot be opened using another software. This hampers collaborative modeling and model
application. However, common software save BN information in an XML-like structure.
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For instance, GeNIe *.xdsl-file lists each node with its identifier, its parents, and CPT.
Through the parents, the software reconstructs the network. Therefore, the file nodes are
necessarily ordered by the number of parents, starting from nodes without parents. In case
of the CMT (see Section 8.4), the system is able to read and save both file formats from
UnBBayes and GeNIe. Specifically, from either file format the BN-relevant information
are extracted and saved in a NoSQL database, which is independent of any file format.
Finally, the CMT could be used as a parser between UnBBayes and GeNIe uploading one
file format into the tool’s NoSQL database and saving the model again in the other format.
However, the verification GUI required the PSBN that is more suitable for fast web-
based processing. In collaboration with the visualization specialist from GTV, we oriented
on GeNIe’s file format but used the file format JSON and added the children to each node.
Compared to GeNIe’s file format, JSON 1 is an established standard for web applications.
The children were added in order to speed-up our GUI’s network construction.
In the DP2M group, we study suitable formats for BN models and PSBNs that are able
to integrate both BN-relevant characteristics as well as all clinically necessary information.
For this purpose, we selected the HL7-based FHIR file format. However, in its current
version, FHIR cannot represent uncertainties. Therefore, we will study the extension of
FHIR’s recourses by probabilistic values and will define an initial profile for TreLynCa.
Finally, standards would enable establishing peer-to-peer repositories for an interna-
tional sharing of models. Such repositories would allow collaborative modeling as well as
model-based population studies by means of MBME.
11.5 Reasoned PSBN Justification
Once a model is completed and clinically integrated, a BN-based CDSS can support de-
cisions by model reasoning and analyses. However, the responsibility for decisions lies
always with the clinicians. Therefore, among the model’s recommendations and compre-
hensible representation, clinicians require a reasoned justification.
To increase the decision analysis workflow and comprehension of a patient situation
and to justify decisions, we conceptualized a TDSS work station, which is currently under
development. The work station combines three subsystems: OncoBase, OncoMind and
OncoProof. OncoBase is a GUI that uses the Oncoflow database to represent available
patient information. OncoMind combines the SMILES engine for BN analysis and the
verification GUI for PSBN exploration and model comparisons. OncoProof tailors guide-
lines to a specific PSBN. Combined in one system, the clinician starts studying a patient’s
available information using OncoBase. Based on OncoBase, the system computes the PS-
BNs, which are represented at OncoMind for further analysis of the system’s suggestions.
Based on the OncoMind analysis, the system tailors the underlying guidelines and studies
to present them at OncoProof. Using OncoProof the user can verify the system’s deci-
1JavaScript Object Notation, ECMA-404 The JSON Data Interchange Standard. For more details, see
http://json.org, May 2017.
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sion. The results of all subsystems can be prepared for a following tumor board or patient
consultation.
The work station is supposed to enable a full multidisciplinary decision analysis with
all relevant information. Therefore, a well integrated PSBN work station could eliminate
unnecessary re-invitations of patients, could ensure beforehand that all required examina-
tions are performed, and could decrease the time of experts searching for patient-relevant
information at a tumor board.
11.6 Appropriate Patient Data Quality
High data quality is crucial for a correct BN reasoning. During the TNM model validation
we identified two issues for data quality (P2+P3), which required data modification by
(M2) adding negative findings and (M3) setting fuzzy values (see Section 7.7). To acquire
data in a high quality, data acquisition could be based on BN models (3.3-R1.8.3).
For the data acquisition, I propose a model-based CPOE tool. Specifically, a user se-
lects a decision that is available in the tool as a BN model. Based on the decision model the
tool automatically constructs a CPOE form. Constructing the form, the tool extracts all ob-
servable variables with their states from the model. States represent options to be selected
by the user. Additional to the discrete states, the user is able to set fuzzy values. Variables
representing examination methods are separated into groups according to the represented
method and examined body area. Setting an examination result requests the user for more
examination results of the same methodology and applied body area in order to acquire all
positive and negative findings. The user should be able to set all decision-relevant informa-
tion otherwise the model would be incomplete.
In the DP2M group, this model-based CPOE tool is currently under development. Using
the TNM-staging model, the tool has been tested for more than 20 retrospective patient
data cases. Compared to an ordinary method using ExcelTM tables, the entry time could be
reduced to about a fourth. After the tool is be complete, we will prospectively evaluate it
with clinicians. Finally, to avoid double entry and enable an appropriate prospective data
acquisition, the model-based CPOE should be integrated into oncoflow (3.3-R1.3.5).
11.7 Extension to Multi-Entity Decision Graphs
The presented model and modeling methodologies enable the modeling of ordinary BNs.
To model user-specific utilities or complex patient-specific decisions with multiple repli-
cated subgraphs, the model and modeling methodologies need to be extended to, e.g., ID,
MEBN or MEDG.
In case of TreLynCa, the graph covers all relevant variables to support a treatment
verification, tumor board decision and patient discussion. The model is supposed to give the
decision makers (clinicians and patient) the best treatment options independent of specific
users and hospitals. The model considers a maximum of two time steps, conditions before
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and after a treatment, which can be modeled directly as a BN.
Nevertheless, the decision maker could also be interested in the treatment costs and the
patient satisfaction (see Figure 4.3), which can be enabled by extending the BN model to an
ID. Furthermore, the model extension to a MEBN would enable 1) updating examination
results in the course of decision-making (e.g., to model long-term radiation therapies or
follow-ups; 3.3-R1.4.2/8), 2) modeling multiple primary tumors and lymph node infiltra-
tions, and 3) considering information from multiple family members (e.g., in case of liver
cancer to find organ donors).
To represent and model IDs and MEBN requires an extension of the graph structure
and the modeling tool in order to restrict the additional types of nodes, dependencies and
arguments. In general, the BN-based TDSS concept in Section 5.3 considers BN exten-
sion by distinguishing it from a PSBN. Specifically, the BN-based decision models would
require the additional utility node and dependencies from the ID as well as input nodes,
node arguments and entity arguments from the MEBN. A resulting PSBN is unaffected by
a MEBN, but additionally considers an ID’s utility nodes. Therefore, distinguishing utility
nodes could also require extensions of GUIs.

Appendix A
TNM staging by the NCCN guidelines
Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor ≤ 2 cm in greatest dimension
Supraglottis: Tumor limited to one subsite of supraglottis with normal vocal cord mobility
Glottis: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure),
with normal mobility
Subglottis: Tumor limited to the subglottis
T1a Glottis: Tumor limited to one vocal cord
T1b Glottis: Tumor involves both vocal cords
T2 Tumor > 2 cm but not more than 4 cm in greatest dimension
Supraglottis: Tumor invades mucosa of more than one adjacent subsite of supraglottis or
glotis or region outside the supraglottis, without fixation of the larynx
Glottis: Tumor extends to the supraglottis and/or subglottis, and/or with impaired vocal cord
mobility
Subglottis: Tumor extends to vocal cord(s), with normal or impaired mobility
T3 Tumor > 4 cm in greatest dimension
Supraglottis: Tumor limited to the larynx, with vocal cord fixation, and/or invades any of the
following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of the
thyroid cartilage
Glottis: Tumor limited to the larynx with vocal cord fixation and/or invasion of the paraglot-
tic space and/or inner cortex of the thyroid cartilage
Subglottis: Tumor limited to the larynx, with vocal cord fixation
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T4a Moderately advanced, local disease
Lip - Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin
of face
Oral cavity - Tumor invades adjacent structures
Supraglottis, Glottis and Subglottis: Moderately advanced, local disease
Tumor invades the outer cortex of the thyroid cartilage or through the thyroid cartilage
and/or invades tissues beyond the larynx
T4b Very advanced, local disease
Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal
carotid artery
Supraglottis, Glottis and Subglottis: Very advanced, local disease
Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures
Regional lymph nodes (N)
NX Regional nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node ≤ 3 cm in greatest dimension
N2 Metastasis in a single ipsilateral lymph node > 3 cm but not more than 6 cm in greatest
dimension; or in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension; or in
bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension
N2a Metastasis in a single ipsilateral lymph node > 3 cm but not more than 6 cm in greatest
dimension
N2b Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension
N2c Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension
N3 Metastasis in a lymph node > 6 cm in greatest dimension
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
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[75] Holger Holst, Karl Åström, Andreas Järund, John Palmer, Anders Heyden, Frederik
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[122] Agnieszka Oniśko and Marek J Druzdzel. Impact of precision of Bayesian network
parameters on accuracy of medical diagnostic systems. Artificial intelligence in
medicine, 57(3):197–206, 2013.
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